var title_f36_26_37280="Anatomy of the breast";
var content_f36_26_37280=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F53212&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F53212&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Anatomy of the breast",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 381px; height: 455px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Sagittal section through the breast.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Bickley LS, Szilagyi P. Bates' Guide to Physical Examination and History Taking, 8th edition, Lippincott Williams &amp; Wilkins, Philadelphia 2003. Copyright &copy; 2003 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_26_37280=[""].join("\n");
var outline_f36_26_37280=null;
var title_f36_26_37281="Distal sugar tong splint";
var content_f36_26_37281=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F50501&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F50501&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Distal sugar tong splint",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 324px; height: 429px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Application of the distal sugar tong splint is shown in two steps. A and B demonstrate the position of the fiberglass or plaster; C shows the finished splint.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Shaw DC, Heckman JD. Principles and techniques of splinting musculocutaneous injuries. Emerg Med Clin North Am 1984; 2:391. Copyright &copy;1984 Elsevier.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_26_37281=[""].join("\n");
var outline_f36_26_37281=null;
var title_f36_26_37282="Crystals in synovial fluid";
var content_f36_26_37282=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F74417&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F74417&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Crystals in synovial fluid",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 368px; height: 264px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Crystals commonly encountered by color compensated polarized light microscopic examination of synovial fluid aspirated from inflamed joints or irrigated from tophi of patients with gout. The four panels show: needle-shaped urate crystals without inflammatory cells from a tophus (upper left); intra- and extracellular urate crystals during acute gouty arthritis (upper right); an intracellular calcium pyrophosphate crystal during an episode of pseudogout (lower left); and cholesterol crystals from a chronic joint effusion aspirated from a patient with rheumatoid arthritis (lower right). Note the characteristic needle shaped urate crystals, rhomboid shaped calcium-pyrophosphate crystal, and notched shield-shaped cholesterol crystals.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Michael A Becker, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_26_37282=[""].join("\n");
var outline_f36_26_37282=null;
var title_f36_26_37283="Echothiophate: Drug information";
var content_f36_26_37283=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Echothiophate: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?19/8/19588?source=see_link\">",
"    see \"Echothiophate: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F164017\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Phospholine Iodide&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F164026\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Acetylcholinesterase Inhibitor;",
"     </li>",
"     <li>",
"      Ophthalmic Agent, Antiglaucoma;",
"     </li>",
"     <li>",
"      Ophthalmic Agent, Miotic",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F164018\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     <b>",
"      Open-angle or secondary glaucoma:",
"     </b>",
"     Ophthalmic:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Initial: Instill 1 drop (0.03%) twice daily into eyes with 1 dose just prior to bedtime",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Maintenance: Some patients have been treated with 1 dose daily or every other day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Conversion from other ophthalmic agents: If IOP control was unsatisfactory, patients may be expected to require higher doses of echothiophate (eg,  &ge;0.06%); however, patients should be initially started on the 0.03% strength for a short period to better tolerance.",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F3017789\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     <b>",
"      Accommodative esotropia:",
"     </b>",
"     Ophthalmic:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Diagnosis: Instill 1 drop (0.125%) once daily into both eyes at bedtime for 2-3 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Treatment: Usual dose: 1 drop of 0.06% once daily or 0.125% every other day (maximum: 0.125% daily).",
"     <b>",
"      Note:",
"     </b>",
"     Use lowest concentration and frequency which gives satisfactory response; if necessary, doses &gt;0.125% daily may be used for short periods of time.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F164019\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F15822395\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer's labeling.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15822396\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer's labeling.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F164005\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Powder for reconstitution, ophthalmic:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Phospholine Iodide&reg;: 6.25 mg (5 mL) [0.125%]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F163992\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F3017790\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Proper administration technique is required for maximal benefit. The nasolacrimal duct(s) should be compressed for 1-2 minutes after instillation of the drops. Excess fluid around the eye should be blotted with tissue, and any contact of medication to the hands should be immediately washed off.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F164006\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Used as miotic in treatment of chronic, open-angle glaucoma; may be useful in specific cases of angle-closure glaucoma (postiridectomy or where surgery refused/contraindicated); postcataract surgery-related glaucoma; accommodative esotropia",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F164024\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Bradycardia, cardiac irregularities, flushing, hypotension",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Diarrhea, nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neurologic &amp; skeletal: Muscle weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Blurred vision, browache, burning eyes, ciliary redness, conjunctival redness/thickening, intraocular pressure increases (paradoxical), iris cysts, lacrimation, lid muscle twitching, miosis, myopia, latent iritis or uveitis activation, lens opacities, retinal detachment, stinging",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Dyspnea",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Diaphoresis, nasolacrimal canal obstruction",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F164010\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to echothiophate or any component of the formulation; most cases of angle-closure glaucoma; active uveal inflammation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F163996\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiac irregularities: Discontinue if cardiac irregularities occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cholinergic effects: Discontinue if symptoms of excess cholinergic activity (eg, salivation, sweating, urinary incontinence); overdosage may result in cholinergic crisis, which must be distinguished from myasthenic crisis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cholinesterase levels: May depress plasma and erythrocyte cholinesterase levels after a few weeks of therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Asthma: Not generally recommended for use in patients with asthma.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease: Not generally recommended for use in patients with bradycardia, hypotension or recent MI.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; GI disease: Not generally recommended for use in patients with GI disease, including peptic ulcer disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Ocular: Appropriate use: Baseline measurement of anterior chamber angle recommended; routine lens examinations (for opacities) should be conducted. Do not use for tonometric glaucoma, or with active or history of uveitis, or retinal detachment. Use cautiously prior to ophthalmic surgery due to risk of blood in the anterior chamber.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Parkinsonism: Not generally recommended for use in patients with parkinsonism.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Seizure disorder: Not generally recommended for use in patients with a history of seizure disorder.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Vagotonia: Not generally recommended for use in patients with vagotonia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Anticholinesterase agents: Use with caution in patients on concomitant anticholinesterase agents; warn patients of possible additive effects if chronically exposed to organophosphate/carbamate pesticides/insecticides.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Succinylcholine: If general anesthesia required, use succinylcholine with great caution due to potential for respiratory or cardiovascular collapse.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Tolerance: Patients may develop tolerance after prolonged use; a rest period restores response to the drug.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299249\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F3017787\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Succinylcholine: Echothiophate Iodide may increase the serum concentration of Succinylcholine.  Management: For patients receiving echothiophate iodide eye drops, consider using a neuromuscular-blocking agents other than succinylcholine. If succinylcholine is used, consider a reduced dose, and monitor for enhanced/prolonged effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F164001\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F3017784\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Animal reproduction studies have not been conducted. There are no adequate and well-controlled studies in pregnant women. Use only if clearly needed.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F164012\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution (reconstituted)",
"     </b>",
"     (Phospholine Iodide Ophthalmic)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.125% (5 mL): $92.52",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F6038607\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Phospholine Iodide (IL);",
"     </li>",
"     <li>",
"      Phospholine Jodide (HN);",
"     </li>",
"     <li>",
"      Phospholinjodid (AT)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F163995\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Long-acting inhibition of cholinesterase enhances activity of endogenous acetylcholine. Reduced degradation of acetylcholine leads to continuous stimulation of  the ciliary muscle producing miosis; other effects include potentiation of accommodation and facilitation of aqueous humor outflow, with attendant reduction in intraocular pressure.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F164009\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Miosis: 10-30 minutes; Intraocular pressure decrease: 4-8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Peak effect: Intraocular pressure decrease: 24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: Miosis: 1-4 weeks",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9398 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-115.25.216.6-1A240FD273-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_26_37283=[""].join("\n");
var outline_f36_26_37283=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164017\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164026\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164018\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3017789\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164019\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15822395\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15822396\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164005\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163992\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3017790\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164006\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164024\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164010\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163996\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299249\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3017787\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164001\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3017784\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164012\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6038607\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163995\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164009\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9398\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9398|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?19/8/19588?source=related_link\">",
"      Echothiophate: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f36_26_37284="Etidronate and calcium: Drug information";
var content_f36_26_37284=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Etidronate and calcium: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?5/62/6117?source=see_link\">",
"    see \"Etidronate and calcium: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block spa drugH1Div\" id=\"F10913564\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Special Alerts",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      FDA Review of Long-term Bisphosphonate Efficacy for Osteoporosis",
"     </span>",
"     <span class=\"collapsible-date\">",
"      May 2012",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       In response to serious postmarketing adverse reactions, including atypical femur fractures, osteonecrosis of the jaw, and esophageal cancer, and a paucity of long-term efficacy data, the FDA conducted a systematic review of long-term bisphosphonate therapy for osteoporosis. To date, randomized controlled trials have shown that bisphosphonate therapy is effective in preventing fractures in trials of 3- to 4-years duration. Therefore, to examine long-term efficacy, three long-term extension trials (involving postmenopausal women) ranging in a duration of treatment from 6-10 years were used in the FDA&rsquo;s analysis. Based on the available long-term clinical trial data, the FDA was unable to identify subgroups of patients who are more likely to benefit from therapy beyond 3-5 years. Continuation of treatment should be based on individual assessment of risks, benefits, and preferences of patients and their physicians.",
"      </p>",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       Until further data are available, the data suggests patients at low risk for fracture (eg, younger patients without a fracture history and bone mineral density [BMD] approaching normal) may be good candidates for discontinuation of therapy after 3-5 years. Patients at increased risk, such as older patients with a history of fracture and a BMD in the osteoporotic range, may benefit from continued therapy.",
"      </p>",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       Further investigation into the risks and benefits of long-term therapy, the usefulness of markers of bone turnover or BMD in determining duration or interruption of therapy, and surveillance or fracture risk after therapy discontinuation are needed.",
"      </p>",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       For additional information, please refer to file://www.nejm.org/doi/pdf/10.1056/NEJMp1202619.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F864486\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      CO Etidrocal;",
"     </li>",
"     <li>",
"      Didrocal&reg;;",
"     </li>",
"     <li>",
"      Mylan-Eti-Cal Carepac;",
"     </li>",
"     <li>",
"      Novo-Etidronatecal",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F864489\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Bisphosphonate Derivative;",
"     </li>",
"     <li>",
"      Calcium Salt",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F864515\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     90-day treatment regimen involves sequential administration of two products within the packaging; not to be taken concurrently. The first blister card contains white tablets containing etidronate disodium, while the remaining four blister cards contains blue, capsule-shaped tablets containing calcium carbonate.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Osteoporosis: Oral: Etidronate disodium 400 mg once daily for 14 days, followed by calcium carbonate 1250 mg (500 mg elemental calcium) once daily for 76 days",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F870068\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F864516\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Not recommended for treatment in renally-impaired patients.",
"    </p>",
"   </div>",
"   <div class=\"block foccan drugH1Div\" id=\"F10076247\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: Canada",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Combination package [each package contains 5 blister cards (90-day supply)]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Didrocal&reg;:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Tablet, etidronate disodium 400 mg (14s) [first card (white tablets)]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Tablet, calcium carbonate: 1250 mg (76s) [equivalent to elemental calcium 500 mg; remaining cards (blue tablets)]",
"    </p>",
"   </div>",
"   <div class=\"block prod-avail drugH1Div\" id=\"F11233739\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Product Availability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Not available in U.S.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F864518\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer etidronate tablets with a full glass of water on an empty stomach 2 hours before meals. The calcium carbonate tablets may be administered with food.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F864491\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment and prevention of postmenopausal osteoporosis; prevention of corticosteroid-induced osteoporosis",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F864500\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Dizziness (16%), headache (13%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Diarrhea (37%), nausea (18%), flatulence (17%), constipation (13%), dyspepsia (12%), vomiting (11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &lt;1% (Limited to important or life-threatening): Agranulocytosis, alopecia, amnesia, angioedema, arthropathies, asthma exacerbation, bone fracture, burning tongue, confusion, depression, diaphyseal femur fracture, erythema multiforme, esophageal cancer, esophagitis, follicular eruption, glossitis, hallucinations, leukopenia, leukemia (1 in 100,000 patients), musculoskeletal pain, pancytopenia, paresthesia, peptic ulcer disease (exacerbation), rash (maculopapular), Stevens-Johnson syndrome, subtrochanteric femur fracture, urticaria",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F864495\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to etidronate disodium, bisphosphonates, or any component of the formulation;  clinically-overt osteomalacia (appropriate treatment to resolve osteomalacia should be initiated before prescribing Didrocal&trade; therapy).",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F864496\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bone fractures: Atypical femur fractures have been reported in patients receiving bisphosphonates for treatment/prevention of osteoporosis. The fractures include subtrochanteric femur (bone just below the hip joint) and diaphyseal femur (long segment of the thigh bone). Some patients experience prodromal pain weeks or months before the fracture occurs. It is unclear if bisphosphonate therapy is the cause for these fractures, although the majority have been reported in patients taking bisphosphonates. Patients receiving long-term (&gt;3-5 years) therapy may be at an increased risk.  Discontinue bisphosphonate therapy in patients who develop a femoral shaft fracture.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bone/joint/muscle pain: Infrequently, severe (and occasionally debilitating) bone, joint, and/or muscle pain have been reported during bisphosphonate treatment. The onset of pain ranged from a single day to several months. Consider discontinuing therapy in patients who experience severe symptoms; symptoms usually resolve upon discontinuation. Some patients experienced recurrence when rechallenged with same drug or another bisphosphonate; avoid use in patients with a history of these symptoms in association with bisphosphonate therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Gastrointestinal mucosa irritation: May cause irritation to upper gastrointestinal mucosa. Esophagitis, dysphagia, esophageal ulcers, esophageal erosions, and esophageal stricture (rare) have been reported with oral bisphosphonates; risk increases in patients unable to comply with dosing instructions. Use with caution in patients with dysphagia, esophageal disease, gastritis, duodenitis, or ulcers (may worsen underlying condition). Discontinue use if new or worsening symptoms develop.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Osteonecrosis of the jaw: Bisphosphonate therapy has been associated with osteonecrosis, primarily of the jaw; this has been observed mostly in cancer patients, but also in patients with postmenopausal osteoporosis and other diagnoses. Risk factors include a diagnosis of cancer, with concomitant chemotherapy, radiotherapy, or corticosteroids; anemia, coagulopathy, infection, or pre-existing dental disease. Most reported cases occurred after I.V. bisphosphonate therapy; however, cases have been reported following oral therapy. Symptoms included nonhealing extraction socket or an exposed jawbone. There are no data addressing whether discontinuation of therapy reduces the risk of developing osteonecrosis; however, as a precautionary measure, dental exams and preventative dentistry should be performed prior to placing patients with risk factors on chronic bisphosphonate therapy. Invasive dental procedures should be avoided during treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypoparathyroidism: While hypercalcemia and hypercalciuria may result when therapeutic replacement amounts are given for prolonged periods, they are most likely to occur in hypoparathyroid patients receiving high doses of vitamin D.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment; I.V. form of etidronate has been noted to be nephrotoxic; therefore, this drug should be used with caution, if at all, in patients with impaired renal function or a history of kidney stones. There is no specific experience to guide cyclic therapy in patients with renal impairment or a history of renal calculi; monitor urine calcium and other relevant parameters if therapy is implemented.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Calcium/vitamin D restricted patients: Use with caution in patients with restricted calcium and vitamin D intake.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Safety and efficacy have not been established in children.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Absorption: Calcium carbonate absorption is impaired in achlorhydria (common in elderly); administer calcium component with food.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F864504\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F864505\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Food: Food decreases the absorption and bioavailability of the etidronate.",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F864493\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Etidronate: Teratogenic effects have been reported in some but not all animal studies. There are no adequate and well-controlled studies in pregnant women. Bisphosphonates are incorporated into the bone matrix and gradually released over time. Theoretically, there may be a risk of fetal harm when pregnancy follows the completion of therapy. Based on limited case reports with pamidronate, serum calcium levels in the newborn may be altered if administered during pregnancy.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F864494\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F864517\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Etidronate: Administer tablet with water on an empty stomach; avoid administering foods/supplements with calcium, iron, or magnesium within 2 hours of drug; maintain adequate intake of calcium and vitamin D.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium: As a dietary supplement, should be given with meals to increase absorption. May decrease iron absorption, so should be administered 1-2 hours before or after iron supplementation; limit intake of with bran, foods high in oxalates, or whole grain cereals which may decrease calcium absorption. Dietary calcium should be adjusted to supply at least 1500 mg/day (Didrocal&trade; supplies 500 mg/day), and dietary vitamin D intake should provide 400 units/day.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F864520\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Bone mass should be monitored; if not stabilized within 4 cycles (1 year) of therapy, consider discontinuation of treatment",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F2869448\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Didronate + Calcium (FI, NO, SE);",
"     </li>",
"     <li>",
"      Didronate/Calcium (DK);",
"     </li>",
"     <li>",
"      Didronel PMO (GB, IE)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F864510\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F864512\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Ruggiero SL, Mehrotra B, Rosenberg TJ, et al, \"Osteonecrosis of the Jaws Associated With the Use of Bisphosphonates: A Review of 63 Cases,\"",
"      <i>",
"       J Oral Maxillofac Surg",
"      </i>",
"      , 2004, 62(5):527-34.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/26/37284/abstract-text/15122554/pubmed\" id=\"15122554\" target=\"_blank\">",
"        15122554",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sellmeyer DE, &ldquo;Atypical Fractures as a Potential Complication of Long-term Bisphosphonate Therapy,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2010, 304(13):1480-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/26/37284/abstract-text/20924014/pubmed\" id=\"20924014\" target=\"_blank\">",
"        20924014",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Shane E, Burr D, Ebeling PR, et al, &ldquo;Atypical Subtrochanteric and Diaphyseal Femoral Fractures: Report of a Task Force of the American Society for Bone and Mineral Research,&rdquo;",
"      <i>",
"       J Bone Miner Res",
"      </i>",
"      , 2010, 25(11):2267-94.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/26/37284/abstract-text/20842676/pubmed\" id=\"20842676\" target=\"_blank\">",
"        20842676",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wysowski DK, &ldquo;Reports of Esophageal Cancer With Oral Bisphosphonate Use,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2009, 360(1):89-90.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/26/37284/abstract-text/19118315/pubmed\" id=\"19118315\" target=\"_blank\">",
"        19118315",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8804 Version 30.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-183.1.191.153-A58E39C754-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_26_37284=[""].join("\n");
var outline_f36_26_37284=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10913564\">",
"      Special Alerts",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F864486\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F864489\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F864515\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F870068\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F864516\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10076247\">",
"      Dosage Forms: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11233739\">",
"      Product Availability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F864518\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F864491\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F864500\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F864495\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F864496\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F864504\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F864505\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F864493\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F864494\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F864517\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F864520\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2869448\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F864510\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F864512\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8804\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8804|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?5/62/6117?source=related_link\">",
"      Etidronate and calcium: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f36_26_37285="Heavy or irregular uterine bleeding during chemotherapy";
var content_f36_26_37285=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Heavy or irregular uterine bleeding during chemotherapy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/26/37285/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/26/37285/contributors\">",
"     Andrea Milbourne, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/26/37285/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/26/37285/contributors\">",
"     Barbara Goff, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/26/37285/contributors\">",
"     Robert L Barbieri, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/26/37285/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/26/37285/contributors\">",
"     Sandy J Falk, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?36/26/37285/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 27, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chemotherapy-induced thrombocytopenia can lead to menorrhagia (ie, heavy and prolonged menses) or irregular bleeding in premenopausal women, whereas uterine bleeding is a rare complication of chemotherapy-induced thrombocytopenia in postmenopausal women. Premenopausal women treated with alkylating agents are also at risk of development of hypogonadotropic amenorrhea.",
"   </p>",
"   <p>",
"    This topic review will address management of menorrhagia related to chemotherapy. Ovarian failure related to anticancer drugs is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/26/1447?source=see_link\">",
"     \"Ovarian failure due to anticancer drugs and radiation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ETIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are three potential cancer-related causes of uterine bleeding:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Bleeding directly from a genitourinary neoplasm (eg, endometrial carcinoma, gestational trophoblastic disease, cervical cancer)",
"     </li>",
"     <li>",
"      Bleeding secondary to thrombocytopenia induced by chemotherapy, radiation therapy",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      the malignancy itself (eg, acute promyelocytic leukemia, non-Hodgkins lymphoma)",
"     </li>",
"     <li>",
"      Bleeding related to disseminated intravascular coagulation (eg, acute promyelocytic leukemia)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS AND DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common menstrual manifestation of bleeding diathesis is menorrhagia; bleeding between periods is less common. Menorrhagia refers to excessive or prolonged menstrual bleeding occurring at regular intervals. It is technically defined as blood loss greater than 80 mL per cycle",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    menstrual periods lasting longer than seven days. Indirect indicators of menorrhagia include passing of blood clots (which suggests that the naturally fibrinolytic properties of the uterus are overwhelmed by a heavy volume of bleeding), anemia, and signs or symptoms of volume depletion during the menstrual period.",
"   </p>",
"   <p>",
"    A diagnosis of menorrhagia secondary to chemotherapy-induced thrombocytopenia can be made in thrombocytopenic women when other causes of abnormal uterine bleeding have been excluded. Most such women have a platelet count less than 20,000",
"    <span class=\"nowrap\">",
"     /microL,",
"    </span>",
"    which is the level of thrombocytopenia associated with an increased risk of spontaneous bleeding.",
"   </p>",
"   <p>",
"    All women with abnormal uterine bleeding should be evaluated to determine the cause; the clinician should not assume that the bleeding is a side effect of chemotherapy. The evaluation should include a careful examination of the lower genital tract to rule out any lesions, cervical cytology (but if the patient is experiencing heavy bleeding this may not be possible), and possibly an endometrial biopsy to rule out endometrial pathology. Since many women with chemotherapy induced thrombocytopenia are also leukopenic, some clinicians avoid endometrial biopsy as the procedure may increase the risk of infection. A pelvic imaging study, such as pelvic ultrasound, can be helpful in identifying gynecologic causes of uterine bleeding, such as fibroids or endometrial polyps. In women with chemotherapy induced thrombocytopenia and menorrhagia, a normal pelvic ultrasound strongly suggests that the bleeding is due to the bleeding diathesis.",
"   </p>",
"   <p>",
"    The evaluation of women with abnormal uterine bleeding is described in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/24/23944?source=see_link\">",
"     \"Terminology and evaluation of abnormal uterine bleeding in premenopausal women\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no large randomized trials providing data on which to base recommendations for managing these patients. Our approach is based upon small observational studies, case reports, and personal experience. In general, we suggest supporting women with moderate to severe menorrhagia with blood products, administering hormonal therapy, and inducing amenorrhea in those at risk of future chemotherapy-induced thrombocytopenia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Prevention of menorrhagia",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     GnRH agonists",
"    </span>",
"    &nbsp;&mdash;&nbsp;If there is a one month interval before the expected time of chemotherapy induced thrombocytopenia, we suggest administering a GnRH agonist, such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/41/4760?source=see_link\">",
"     leuprolide",
"    </a>",
"    acetate, so that amenorrhea can be induced prior to the start of chemotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/26/37285/abstract/1-5\">",
"     1-5",
"    </a>",
"    ]. Breakthrough bleeding often occurs in the first two weeks of therapy and may require that the patient be supported with blood products.",
"   </p>",
"   <p>",
"    One small study of women undergoing bone marrow transplantation achieved a high rate of amenorrhea by administering",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/41/4760?source=see_link\">",
"     leuprolide",
"    </a>",
"    acetate 7.5 mg intramuscularly every 28 days, with the first injection given 4 to 5 weeks prior to bone marrow transplant [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/26/37285/abstract/2\">",
"     2",
"    </a>",
"    ]. In this series, women using oral contraceptives at the time of their initial leuprolide injection stopped their tablets either on the day of this injection or 21 days later. To avoid intramuscular injection in one patient with a platelet count of less than",
"    <span class=\"nowrap\">",
"     50,000/mcL",
"    </span>",
"    at the time of scheduled repeat leuprolide injection, a daily intravenous infusion of 1 mg of the subcutaneous formulation of leuprolide was successfully administered for two weeks, at which time the platelet count was higher.",
"   </p>",
"   <p>",
"    A retrospective study described the outcome of oncology patients with regular menstrual cycles who received either depo-",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/24/1417?source=see_link\">",
"     medroxyprogesterone acetate",
"    </a>",
"    (DMPA) (n = 42), or a GnRH agonist (n = 39), or no treatment (n = 20) before the administration of myelosuppressive chemotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/26/37285/abstract/6\">",
"     6",
"    </a>",
"    ]. Only patients who later developed severe thrombocytopenia (&lt;25,000 platelets per microL) were included in the study. Severe or moderate menorrhagia occurred in none of the 39 women who received GnRH agonist, in nine women (21 percent) who received DMPA, and in nine untreated patients (40 percent). Treatment with a GnRH agonist was significantly more effective than no treatment, and appeared to be more effective than DMPA.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Initial therapy of menorrhagia",
"    </span>",
"    &nbsp;&mdash;&nbsp;We support women with signs or symptoms of volume depletion during the menstrual period with blood products, and start them on either estrogen, an estrogen-progestin preparation, or high dose progestin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/26/37285/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. A GnRH agonist can be initiated subsequently to prevent recurrent menorrhagia (see",
"    <a class=\"local\" href=\"#H6\">",
"     'GnRH agonists'",
"    </a>",
"    above).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Estrogen",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women who have been bleeding heavily for a prolonged period of time (&ge;two weeks) have an atrophic, denuded endometrial lining. These patients need to have their endometrium stabilized with oral, transdermal, or intravenous estrogen or high dose estrogen-progestin pills. Estrogen promotes rapid regrowth of endometrium over the denuded epithelial surface, stabilizes lysosomal membranes, and stimulates proliferation of endometrial ground substance. However, a problem with this approach is that nausea and vomiting are common with high dose estrogen therapy and also a side effect of chemotherapy. Options for estrogen therapy include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Conjugated estrogen (eg, Premarin) 1.25 mg orally two or three times per day",
"     </li>",
"     <li>",
"      Estradiol 2 mg orally two or three times per day",
"     </li>",
"     <li>",
"      Conjugated estrogen 25 mg intravenously every six hours for 24 hours",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    An antiemetic is often required (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/20/15688?source=see_link\">",
"     promethazine",
"    </a>",
"    12.5 to 25 mg per rectum, as needed).",
"   </p>",
"   <p>",
"    Pulmonary embolism is a potential complication of high dose estrogen therapy. As a result, the dose and duration of estrogen administered should be the minimum needed to control bleeding. In particular, intravenous therapy should not be continued for more than 24 hours. Other contraindications to high dose estrogen therapy are listed below (see",
"    <a class=\"local\" href=\"#H9\">",
"     'Estrogen-progestin'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    Typically, the transition from high dose estrogen to standard estrogen-progestin contraceptive pills can begin within a few days, and certainly by the time that hematologic indices have begun to return to normal (see",
"    <a class=\"local\" href=\"#H12\">",
"     'Prevention of recurrent menorrhagia'",
"    </a>",
"    below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Estrogen-progestin",
"    </span>",
"    &nbsp;&mdash;&nbsp;High doses of an oral contraceptive pill (OC) (eg, an OC containing 35 mcg ethinyl estradiol taken two to four times per day) (",
"    <a class=\"graphic graphic_table graphicRef69223 \" href=\"mobipreview.htm?10/59/11184\">",
"     table 1",
"    </a>",
"    ) supplemented with an antiemetic medication (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/20/15688?source=see_link\">",
"     promethazine",
"    </a>",
"    12.5 to 25 mg per rectum, as needed) will often cause acute moderate to severe bleeding to subside within 48 hours. This regimen may not be as effective as estrogen alone because progestins inhibit the synthesis of estrogen receptors and increase estradiol dehydrogenase, thereby impeding the rapid proliferation of endometrium induced by estrogen.",
"   </p>",
"   <p>",
"    High doses of estrogen-progestin regimens or estrogen alone (see",
"    <a class=\"local\" href=\"#H8\">",
"     'Estrogen'",
"    </a>",
"    above) should be avoided in smokers because of the risk of venous thrombosis. Other medical contraindications to use of these hormone preparations include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Previous thromboembolic event or stroke",
"     </li>",
"     <li>",
"      Known inherited thrombophilia",
"     </li>",
"     <li>",
"      History of an estrogen-dependent tumor",
"     </li>",
"     <li>",
"      Ischemic heart disease",
"     </li>",
"     <li>",
"      Active liver disease",
"     </li>",
"     <li>",
"      Pregnancy",
"     </li>",
"     <li>",
"      Known hyperlipidemias",
"     </li>",
"     <li>",
"      Poorly controlled hypertension",
"     </li>",
"     <li>",
"      Migraine headaches with aura",
"     </li>",
"     <li>",
"      Diabetes mellitus with vascular disease",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A transdermal estrogen-progestin patch (eg, Ortho Evra) may be used instead of OC pills; the patch has the advantage of avoiding oral administration in women with nausea and vomiting. Two patches can be placed; however, this results in high estrogen levels (similar to two 100 mcg estrogen oral contraceptive pills), which is probably associated with an increased risk of thrombosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/26/37285/abstract/9\">",
"     9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/5/18522?source=see_link\">",
"     \"Overview of the use of estrogen-progestin contraceptives\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/24/39306?source=see_link\">",
"     \"Overview of contraception\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    After the bleeding stops, the patient can be transitioned to once a day therapy (see",
"    <a class=\"local\" href=\"#H12\">",
"     'Prevention of recurrent menorrhagia'",
"    </a>",
"    below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Progestin",
"    </span>",
"    &nbsp;&mdash;&nbsp;If estrogens are contraindicated, but progestins are not, then high dose progestins may be administered. Progestin only regimens are less successful than estrogen-progestin regimens, and associated with more irregular bleeding. Progestin only options include",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/24/1417?source=see_link\">",
"     medroxyprogesterone acetate",
"    </a>",
"    (20 to 40 mg per day in divided doses),",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/55/33653?source=see_link\">",
"     megestrol acetate",
"    </a>",
"    (40 to 120 mg per day in divided doses), or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/52/16199?source=see_link\">",
"     norethindrone acetate",
"    </a>",
"    (5 to 10 mg per day) for five to 10 days. Progestins, like estrogen, can be associated with an increased risk of thromboembolic disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/26/37285/abstract/8,10,11\">",
"     8,10,11",
"    </a>",
"    ]. We use progestins in smokers, unless they have a history of thromboembolic disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Endometrial ablation",
"    </span>",
"    &nbsp;&mdash;&nbsp;In rare cases, endometrial ablation can be performed if all other methods of controlling bleeding have failed; however, this should be considered primarily in women who have completed childbearing since fertility cannot be guaranteed after the procedure. Furthermore, pregnancy can be hazardous (increased risk of miscarriage, antepartum hemorrhage, preterm delivery, abnormal placental attachment). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/7/31866?source=see_link\">",
"     \"An overview of endometrial ablation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We suggest administration of antibiotic prophylaxis prior to and after endometrial ablation, since these women are considered immunocompromised and at increased risk of infection. For example, one might use",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/2/4136?source=see_link\">",
"     cefazolin",
"    </a>",
"    in the nonleukopenic patient and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/51/13112?source=see_link\">",
"     ampicillin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/10/36000?source=see_link\">",
"     gentamicin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/21/33104?source=see_link\">",
"     clindamycin",
"    </a>",
"    in leukopenic patients. We also suggest curettage prior to the procedure. This provides endometrial tissue for histopathological evaluation to exclude malignancy and improves the success of the ablative procedure since a thin endometrium is more completely destroyed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/26/37285/abstract/12,13\">",
"     12,13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    More invasive procedures, such as uterine artery embolization, are contraindicated in the presence of thrombocytopenia. However, there are case reports of uterine artery embolization being used to treat life-threatening uterine hemorrhage in acute myeloid leukemia patients treated with chemotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/26/37285/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Prevention of recurrent menorrhagia",
"    </span>",
"    &nbsp;&mdash;&nbsp;After initial therapy, the patient needs to be placed on an on-going hormonal regimen to induce endometrial atrophy and thereby prevent recurrent menorrhagia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Estrogen-progestin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients may be started or continued on estrogen-progestin preparations with 35 mcg ethinyl estradiol or equivalent after initial therapy of menorrhagia. These agents provide the duel benefits of reducing or suppressing menses and providing contraception. The maximum benefit can be achieved with continuous, rather than cyclic, administration. Either pills or a transdermal patch can be used; the latter has the advantage of being retained in the presence of chemotherapy induced nausea and vomiting. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/47/3832?source=see_link&amp;anchor=H7#H7\">",
"     \"Hormonal contraception for suppression of menstruation\", section on 'Therapeutic options'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There will be some breakthrough bleeding in the first 6 to 12 months of hormonal therapy. In patients with thrombocytopenia, this is undesirable since a low platelet count can lead to uncontrolled bleeding. Therefore, these agents are most useful when continued in women already taking them at the time of their cancer diagnosis and those who will receive chemotherapy over several months and can be supported with blood products as needed for breakthrough bleeds.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Progestins",
"    </span>",
"    &nbsp;&mdash;&nbsp;A progestin (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/55/33653?source=see_link\">",
"     megestrol acetate",
"    </a>",
"    20 to 40 mg daily in divided doses) can be given to suppress menses. Patients can often be supported with this regimen for a considerable period of time.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Abnormal uterine bleeding in women with cancer may be from chemotherapy-induced thrombocytopenia, hematologic changes caused by the tumor, or from a source unrelated to the tumor or its therapy. Therefore, all women with abnormal uterine bleeding should be evaluated to determine the cause; the clinician should not assume that the bleeding is a side effect of chemotherapy. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Etiology'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H3\">",
"       'Clinical manifestations and diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Acute treatment of menorrhagia",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We suggest estrogen therapy (and blood products, as needed) for acute treatment of moderate to severe menorrhagia (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Estrogen'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Primary prevention of chemotherapy induced menorrhagia",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We suggest inducing amenorrhea with a GnRH agonist in premenopausal women at risk of chemotherapy induced thrombocytopenia (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H6\">",
"       'GnRH agonists'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Prevention of recurrent menorrhagia",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If treatment with GnRH agonists is not possible or desired, we suggest continuous administration of estrogen-progestin pills (and supporting the patient with blood products, as needed) (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Prevention of recurrent menorrhagia'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/26/37285/abstract/1\">",
"      Lhomm&eacute; C, Brault P, Bourhis JH, et al. Prevention of menstruation with leuprorelin (GnRH agonist) in women undergoing myelosuppressive chemotherapy or radiochemotherapy for hematological malignancies: a pilot study. Leuk Lymphoma 2001; 42:1033.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/26/37285/abstract/2\">",
"      Stabinsky SA, Einstein M, Breen JL. Modern treatments of menorrhagia attributable to dysfunctional uterine bleeding. Obstet Gynecol Surv 1999; 54:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/26/37285/abstract/3\">",
"      Laufer MR, Townsend NL, Parsons KE, et al. Inducing amenorrhea during bone marrow transplantation. A pilot study of leuprolide acetate. J Reprod Med 1997; 42:537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/26/37285/abstract/4\">",
"      Ghalie R, Porter C, Radwanska E, et al. Prevention of hypermenorrhea with leuprolide in premenopausal women undergoing bone marrow transplantation. Am J Hematol 1993; 42:350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/26/37285/abstract/5\">",
"      Chiusolo P, Salutari P, Sica S, et al. Luteinizing hormone-releasing hormone analogue: leuprorelin acetate for the prevention of menstrual bleeding in premenopausal women undergoing stem cell transplantation. Bone Marrow Transplant 1998; 21:821.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/26/37285/abstract/6\">",
"      Meirow D, Rabinovici J, Katz D, et al. Prevention of severe menorrhagia in oncology patients with treatment-induced thrombocytopenia by luteinizing hormone-releasing hormone agonist and depo-medroxyprogesterone acetate. Cancer 2006; 107:1634.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/26/37285/abstract/7\">",
"      Amsterdam A, Jakubowski A, Castro-Malaspina H, et al. Treatment of menorrhagia in women undergoing hematopoietic stem cell transplantation. Bone Marrow Transplant 2004; 34:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/26/37285/abstract/8\">",
"      Kropsky B, Shi Y, Cherniack EP. Incidence of deep-venous thrombosis in nursing home residents using megestrol acetate. J Am Med Dir Assoc 2003; 4:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/26/37285/abstract/9\">",
"      van den Heuvel MW, van Bragt AJ, Alnabawy AK, Kaptein MC. Comparison of ethinylestradiol pharmacokinetics in three hormonal contraceptive formulations: the vaginal ring, the transdermal patch and an oral contraceptive. Contraception 2005; 72:168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/26/37285/abstract/10\">",
"      Th&uuml;rlimann B, Castiglione M, Hsu-Schmitz SF, et al. Formestane versus megestrol acetate in postmenopausal breast cancer patients after failure of tamoxifen: a phase III prospective randomised cross over trial of second-line hormonal treatment (SAKK 20/90). Swiss Group for Clinical Cancer Research (SAKK). Eur J Cancer 1997; 33:1017.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/26/37285/abstract/11\">",
"      H&auml;gglund H, Remberger M, Klaesson S, et al. Norethisterone treatment, a major risk-factor for veno-occlusive disease in the liver after allogeneic bone marrow transplantation. Blood 1998; 92:4568.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/26/37285/abstract/12\">",
"      Jack SA, Cooper KG, Seymour J, et al. A randomised controlled trial of microwave endometrial ablation without endometrial preparation in the outpatient setting: patient acceptability, treatment outcome and costs. BJOG 2005; 112:1109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/26/37285/abstract/13\">",
"      Qian Y, Gan N, Zhou J, et al. Microwave endometrial ablation for menorrhagia in patients with systemic disorders. Int J Gynaecol Obstet 2005; 91:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/26/37285/abstract/14\">",
"      Phelan JT 2nd, Broder J, Kouides PA. Near-fatal uterine hemorrhage during induction chemotherapy for acute myeloid leukemia: a case report of bilateral uterine artery embolization. Am J Hematol 2004; 77:151.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3222 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-118.195.65.247-05EE575892-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_26_37285=[""].join("\n");
var outline_f36_26_37285=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H15\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ETIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CLINICAL MANIFESTATIONS AND DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Prevention of menorrhagia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - GnRH agonists",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Initial therapy of menorrhagia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Estrogen",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Estrogen-progestin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Progestin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Endometrial ablation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Prevention of recurrent menorrhagia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Estrogen-progestin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Progestins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Acute treatment of menorrhagia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Primary prevention of chemotherapy induced menorrhagia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Prevention of recurrent menorrhagia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/3222\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/3222|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?10/59/11184\" title=\"table 1\">",
"      Estrogen and progestin types and doses in hormonal contraceptive",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/7/31866?source=related_link\">",
"      An overview of endometrial ablation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/47/3832?source=related_link\">",
"      Hormonal contraception for suppression of menstruation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/26/1447?source=related_link\">",
"      Ovarian failure due to anticancer drugs and radiation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/24/39306?source=related_link\">",
"      Overview of contraception",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/5/18522?source=related_link\">",
"      Overview of the use of estrogen-progestin contraceptives",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/24/23944?source=related_link\">",
"      Terminology and evaluation of abnormal uterine bleeding in premenopausal women",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f36_26_37286="Brain MRI findings in leptomeningeal metastases";
var content_f36_26_37286=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RADIOL%2F87762&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RADIOL%2F87762&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 547px\">",
"   <div class=\"ttl\">",
"    Brain MRI findings in a patient with leptomeningeal metastases",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 527px; height: 596px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Brain&nbsp;magnetic resonance&nbsp;imaging&nbsp;of a&nbsp;patient with medulloblastoma&nbsp;(*) with leptomeningeal dissemination. Pre (A) and post (B, C) contrast T1-weighted sequences in the axial (A, B) and coronal planes (C) demonstrate&nbsp;diffuse leptomeningeal enhancement tracking along the cerebellar folia (arrows). Subtle nodular leptomeningeal enhancement is also visible in the cerebral hemispheres (arrowheads).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Joseph Farnam, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_26_37286=[""].join("\n");
var outline_f36_26_37286=null;
var title_f36_26_37287="CSVT in a two-week old infant";
var content_f36_26_37287=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F66694&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F66694&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 619px\">",
"   <div class=\"ttl\">",
"    Extensive cerebral sinovenous thrombosis in a two-week old term infant with hypernatremic dehydration, lethargy, and a bulging fontanelle",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 599px; height: 467px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Head CT (A) depicts acute venous thrombus as hyperdense signal involving sagittal and straight sinuses. Brain magnetic resonance venogram (B and C) depicts absent flow-related signal involving left transverse, entire superior sagittal, and straight sinuses. Acute clot appears as hyperintense signal (D) on sagittal T1-weighted sequences. Diffusion-weighted MRI sequences (E and F) show extensive acute ischemic changes in bilateral subcortical white matter, internal capsule, corpus callosum and thalamus (arrows). In addition, thalamic hemorrhage is present (asterisk).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Rebecca Ichord, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_26_37287=[""].join("\n");
var outline_f36_26_37287=null;
var title_f36_26_37288="Hereditary pancreatitis";
var content_f36_26_37288=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Hereditary pancreatitis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/26/37288/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/26/37288/contributors\">",
"     David C Whitcomb, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/26/37288/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/26/37288/contributors\">",
"     William J Klish, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/26/37288/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/26/37288/contributors\">",
"     Alison G Hoppin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?36/26/37288/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 8, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic pancreatitis that occurs with an autosomal dominant pattern of inheritance has been termed hereditary pancreatitis. This disorder has high penetrance and causes chronic pancreatitis in both children and adults.",
"   </p>",
"   <p>",
"    Familial pancreatitis refers to pancreatitis from any cause that occurs in a family with an incidence that is greater than would be expected by chance alone, given the size of the family and the standardized incidence of pancreatitis within a defined population. Familial pancreatitis may or may not be caused by a genetic defect.",
"   </p>",
"   <p>",
"    Issues related to hereditary pancreatitis will be reviewed here. The etiology, clinical manifestations, complications, and treatment of chronic pancreatitis in children and adults are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/46/42727?source=see_link\">",
"     \"Causes of chronic pancreatitis in children and adolescents\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/60/28616?source=see_link\">",
"     \"Clinical manifestations and diagnosis of chronic pancreatitis in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/41/39575?source=see_link\">",
"     \"Etiology and pathogenesis of chronic pancreatitis in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/13/30935?source=see_link\">",
"     \"Clinical manifestations and diagnosis of chronic pancreatitis in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/47/35572?source=see_link\">",
"     \"Complications of chronic pancreatitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/40/31369?source=see_link\">",
"     \"Treatment of chronic pancreatitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     GENETICS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are at least three different inheritance patterns for chronic pancreatitis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/46/42727?source=see_link&amp;anchor=H9#H9\">",
"     \"Causes of chronic pancreatitis in children and adolescents\", section on 'Genetic'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Autosomal dominant hereditary pancreatitis &mdash; This is most often associated with mutations in the serine protease 1 gene (PRSS1) on chromosome 7q35, which encodes cationic trypsinogen [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/26/37288/abstract/1-3\">",
"       1-3",
"      </a>",
"      ]. Rarely, autosomal-dominant-appearing hereditary pancreatitis is identified in a kindred that does not have an identifiable PRSS1 mutation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/26/37288/abstract/4-6\">",
"       4-6",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'PRSS1'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Autosomal recessive pancreatitis &mdash; Chronic pancreatitis associated with cystic fibrosis is the most common example. Mutations in the",
"      <strong>",
"       s",
"      </strong>",
"      erine",
"      <strong>",
"       p",
"      </strong>",
"      rotease",
"      <strong>",
"       in",
"      </strong>",
"      hibitor",
"      <strong>",
"       K",
"      </strong>",
"      azal type",
"      <strong>",
"       1 gene",
"      </strong>",
"      (SPINK1, also called pancreatic secretory trypsin inhibitor gene) also may present in an autosomal recessive pattern. (See",
"      <a class=\"local\" href=\"#H16024358\">",
"       'CFTR'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Complex genetics &mdash; Multiple family members may have recurrent acute or chronic pancreatitis associated with a combination of genetic and environmental factors. This is the case for patients with heterozygous SPINK1 mutations, in which the SPINK1 mutation probably acts as a disease modifier, lowering the threshold for developing pancreatitis from other genetic (eg, CFTR mutations) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/26/37288/abstract/7,8\">",
"       7,8",
"      </a>",
"      ] or environmental factors (see",
"      <a class=\"local\" href=\"#H16023350\">",
"       'SPINK1'",
"      </a>",
"      below). Some apparently sporadic cases of pancreatitis have complex genetic risk.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     PRSS1",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mutations in the serine protease 1 gene (PRSS1), which encodes cationic trypsinogen, are present in up to 80 percent of patients with hereditary pancreatitis unrelated to cystic fibrosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/26/37288/abstract/9-13\">",
"     9-13",
"    </a>",
"    ]. PRSS1 mutations are probably also responsible for some cases of apparently idiopathic chronic pancreatitis or acute pancreatitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/26/37288/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/46/42727?source=see_link&amp;anchor=H6#H6\">",
"     \"Causes of chronic pancreatitis in children and adolescents\", section on 'Idiopathic'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/46/44774?source=see_link\">",
"     \"Pathogenesis of acute pancreatitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Cationic trypsin is the most abundant form of trypsin produced by the pancreas and is the primary catalyst for the conversion of pancreatic zymogens into pancreatic digestive enzymes after they are secreted into the duodenum. Premature activation of digestive enzymes in the pancreas is the major cause of pancreatic injury and immune system activation, leading to acute pancreatitis and later chronic pancreatitis. The primary defense against pancreatitis is to control trypsin activity, either through prevention of premature activation of trypsinogen to trypsin, or by the destruction, inhibition, or elimination of trypsin from the pancreas. These defenses are weakened by mutations in PRSS1, or in genes coding for molecules that protect the pancreas from active trypsin (eg, SPINK1, CFTR) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/26/37288/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Trypsin has two regulatory regions that are controlled by two calcium-binding pockets, one regulating the activation site (changing trypsinogen into trypsin with the release of trypsinogen activation peptide) and the other regulating the autolysis site (leading to trypsin destruction). Nearly all of the more than 20 mutations associated with hereditary pancreatitis are clustered in these two regions.",
"   </p>",
"   <p>",
"    The most common pancreatitis-associated mutations in PRSS1 are the p.R122H (at the autolysis site) and p.N29I mutations, which are alternatively numbered as R117H and N21I using the chymotrypsinogen amino acid numbering system [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/26/37288/abstract/2,3,9,13\">",
"     2,3,9,13",
"    </a>",
"    ]. As an example, in a national series of 200 patients from 78 families with hereditary pancreatitis in France, PRSS1 mutations were detected in 68 percent; among these patients, p.R122H and p.N291 were present in 78 and 12 percent, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/26/37288/abstract/9\">",
"     9",
"    </a>",
"    ]. The estimated prevalence of hereditary pancreatitis in this study was at least 0.3 per 100,000. An updated research",
"    <a class=\"external\" href=\"file://www.pancreasgenetics.org/\">",
"     web site on chronic pancreatitis genetics",
"    </a>",
"    lists the PRSS1 variants with functional studies to more accurately classify the mutations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/26/37288/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The p.R122H and p.N291 mutations have high penetrance (80 and 93 percent in two series) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/26/37288/abstract/9,18\">",
"     9,18",
"    </a>",
"    ]. It remains unclear why some family members with these mutations do not develop chronic pancreatitis. A possible contributing factor for the occasionally decreased penetrance of pancreatitis is the presence of mutations that protect against the development of chronic pancreatitis. One such mutation has been described in the anionic trypsinogen gene (PRSS2), resulting in the loss of trypsin activity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/26/37288/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other kindreds carry PRSS1 mutations at different sites, and new mutations continue to be described [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/26/37288/abstract/14,20-24\">",
"     14,20-24",
"    </a>",
"    ]. One such mutation causes misfolding and intracellular retention of cationic trypsinogen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/26/37288/abstract/20\">",
"     20",
"    </a>",
"    ], while a second stabilizes trypsinogen, protecting against autocatalytic degradation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/26/37288/abstract/21\">",
"     21",
"    </a>",
"    ], and a third increases trypsin release from trypsinogen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/26/37288/abstract/22\">",
"     22",
"    </a>",
"    ]. These mutations may not have the same high penetrance that has been seen with p.R122H and p.N291 mutations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16023350\">",
"    <span class=\"h2\">",
"     SPINK1",
"    </span>",
"    &nbsp;&mdash;&nbsp;The",
"    <strong>",
"     s",
"    </strong>",
"    erine",
"    <strong>",
"     p",
"    </strong>",
"    rotease",
"    <strong>",
"     in",
"    </strong>",
"    hibitor",
"    <strong>",
"     K",
"    </strong>",
"    azal type",
"    <strong>",
"     1",
"    </strong>",
"    gene (SPINK1) encodes a pancreatic secretory trypsin inhibitor and acute phase reactant. It is expressed in pancreatic acinar cells during an inflammatory process, where it normally serves as a critical feedback inhibitor of trypsin. Mutations in SPINK1 interfere with this protective action and predispose to pancreatitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/26/37288/abstract/10\">",
"     10",
"    </a>",
"    ]. SPINK1 mutations can cause familial pancreatitis with an autosomal recessive pattern in families in which both parents have a mutation. However, the majority of patients with SPINK1 mutations and chronic pancreatitis are heterozygous, resulting in complex inheritance patterns. &nbsp;",
"   </p>",
"   <p>",
"    SPINK1 mutations are fairly common in the general population (2 percent of healthy individuals carry a \"high risk\" mutation) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/26/37288/abstract/25\">",
"     25",
"    </a>",
"    ], but less than 1 percent of carriers develop pancreatitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/26/37288/abstract/26\">",
"     26",
"    </a>",
"    ]. Nonetheless, mutations in SPINK1 increase the risk for chronic pancreatitis about 12-fold over the general population. In three series of patients with apparent idiopathic chronic pancreatitis, mutations in SPINK1 were detected in 16 to 23 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/26/37288/abstract/23,27,28\">",
"     23,27,28",
"    </a>",
"    ]. In one of these reports, SPINK1 mutations were more common in patients with idiopathic chronic pancreatitis or recurrent acute pancreatitis than in controls (19.5 versus 2.6 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/26/37288/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with heterozygous SPINK1 mutations have complex genetics (eg, gene x gene, gene x environment) since SPINK1, as a specific trypsin inhibitor, is only required if there is an upstream problem causing recurrent trypsin activation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/26/37288/abstract/29\">",
"     29",
"    </a>",
"    ]. Thus, the SPINK1 mutation probably acts as a disease modifier, lowering the threshold for developing pancreatitis from other genetic or environmental factors. The most common genetic variant seen with SPINK1 is CFTR, which is described below [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/26/37288/abstract/7,8\">",
"     7,8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16024358\">",
"    <span class=\"h2\">",
"     CFTR",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mutations in the cystic fibrosis transmembrane conductance regulator gene (CFTR) can cause pancreatitis with or without associated manifestations of cystic fibrosis. Over 1700 different genetic polymorphisms in CFTR have been identified, and disease manifestations depend on the severity of the mutation and zygosity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/26/37288/abstract/30\">",
"     30",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/49/28442?source=see_link&amp;anchor=H10#H10\">",
"     \"Cystic fibrosis: Clinical manifestations and diagnosis\", section on 'Pancreatic disease'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The association between CFTR mutations and pancreatitis fall into one of three patterns:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Homozygotes or compound heterozygotes for two \"severe\" CFTR mutations &mdash; &nbsp;This genotype results in absence of functional CFTR protein on the duct cell apical membrane and is associated with typical CF. Affected patients have classic manifestations of cystic fibrosis including abnormal sweat chloride measures, and often develop chronic pancreatitis and pancreatic insufficiency early in life [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/26/37288/abstract/31\">",
"       31",
"      </a>",
"      ]. A minority of these patients may have pancreatic exocrine sufficiency during childhood, and these patients are at risk for acute pancreatitis and progression to chronic pancreatitis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/26/37288/abstract/32\">",
"       32",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Homozygotes or compound heterozygotes in which at least one of the CFTR gene copies has a \"mild\" variant &mdash; This genotype results in some retained CFTR protein function and milder or limited features of cystic fibrosis (atypical CF). Affected patients have normal or borderline sweat chloride testing, but may have recurrent acute or chronic pancreatitis, congenital absence of the vas deferens",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      chronic sinusitis, especially if the variant specifically alters CFTR bicarbonate conductance. The risk for chronic pancreatitis is increased 40- to 80-fold over the general population [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/26/37288/abstract/33\">",
"       33",
"      </a>",
"      ]. The primary example is CFTR R75Q mutation, which causes a selective defect in bicarbonate secretion but does not interfere with chloride secretion as seen in classic CF [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/26/37288/abstract/7,34\">",
"       7,34",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?19/15/19706?source=see_link&amp;anchor=H21#H21\">",
"       \"Cystic fibrosis: Overview of gastrointestinal disease\", section on 'Pancreatitis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Heterozygotes (CFTR mutation carriers) &mdash; The risk for chronic pancreatitis in this group is increased three- to four-fold over the general population, although 99 percent of the carriers are healthy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/26/37288/abstract/34-36\">",
"       34-36",
"      </a>",
"      ]. Those that do develop chronic pancreatitis have a very high rate of coexisting SPINK1 mutations, suggesting epistasis between these genes and complex genetics [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/26/37288/abstract/7\">",
"       7",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Several studies have shown that carriage of CFTR mutations, including uncommon and mild mutations, is more common among patients with idiopathic chronic pancreatitis than among controls [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/26/37288/abstract/31,35,37\">",
"     31,35,37",
"    </a>",
"    ]. However, in studies of populations known to be CF carriers (eg, parents of patients with cystic fibrosis), the prevalence of chronic pancreatitis is only slightly increased [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/26/37288/abstract/35,36,38\">",
"     35,36,38",
"    </a>",
"    ]. Together, these observations suggest that pancreatitis develops among CFTR mutation carriers primarily in the presence of additional genetic or environmental disease modifiers.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with autosomal dominant hereditary pancreatitis present clinically with recurrent acute pancreatitis in childhood or early adolescence, chronic pancreatitis in late adolescence or early adulthood, and an increased risk for pancreatic cancer beginning in the fifth decade of life.",
"   </p>",
"   <p>",
"    The clinical presentation is similar to that with other causes of chronic pancreatitis and is discussed in detail elsewhere. The primary manifestations are abdominal pain, maldigestion due to pancreatic exocrine dysfunction, and diabetes mellitus due to islet cell damage. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/60/28616?source=see_link\">",
"     \"Clinical manifestations and diagnosis of chronic pancreatitis in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/13/30935?source=see_link\">",
"     \"Clinical manifestations and diagnosis of chronic pancreatitis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The following findings were noted in the national series of 418 patients with hereditary pancreatitis from 112 families in 14 European countries [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/26/37288/abstract/4\">",
"     4",
"    </a>",
"    ], and 200 patients with hereditary pancreatitis from 78 families in France [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/26/37288/abstract/9\">",
"     9",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The median age at first symptom and diagnosis were 10 and 19 years, respectively. Similar findings have been noted in other studies in which disease onset may be before age five [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/26/37288/abstract/18,39\">",
"       18,39",
"      </a>",
"      ]. The first symptoms occurred at a slightly older age in patients with N29I or without identified PRSS1 mutations [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/26/37288/abstract/4\">",
"       4",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Pancreatic pain, acute pancreatitis, and pseudocysts were present in 83, 69, and 23 percent, respectively, with pancreatic calcifications noted on radiologic examination in 61 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/26/37288/abstract/9\">",
"       9",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Exocrine pancreatic insufficiency eventually developed in 37 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/26/37288/abstract/4\">",
"       4",
"      </a>",
"      ] and 34 percent, and presented at a mean age of 29 years [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/26/37288/abstract/9\">",
"       9",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Diabetes mellitus eventually developed in 48 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/26/37288/abstract/4\">",
"       4",
"      </a>",
"      ] and 26 percent, and presented at a mean age of 38 years [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/26/37288/abstract/9\">",
"       9",
"      </a>",
"      ]. Patients who develop diabetes typically require insulin therapy. However, the diabetes is different from typical type 1 diabetes in that the pancreatic alpha cells, which produce glucagon, are also affected (Type 3c diabetes mellitus) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/26/37288/abstract/40\">",
"       40",
"      </a>",
"      ]. As a result, there is an increased risk of hypoglycemia, both treatment-related and spontaneous.",
"     </li>",
"     <li>",
"      There were no differences in clinical and morphologic data according to genetic status.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The most common presentation of autosomal dominant hereditary pancreatitis is recurrent acute pancreatitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/26/37288/abstract/4,9,18,41,42\">",
"     4,9,18,41,42",
"    </a>",
"    ]. After recovery from the acute episode, affected patients may remain well for a significant duration. Some patients may present with chronic pancreatitis without episodes of acute pancreatitis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     PANCREATIC CANCER",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hereditary pancreatitis is associated with a markedly increased risk of pancreatic cancer, although hereditary pancreatitis patients account for a very small fraction of all cases of pancreatic cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/26/37288/abstract/4,9,43,44\">",
"     4,9,43,44",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/13/27866?source=see_link\">",
"     \"Epidemiology and risk factors for exocrine pancreatic cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    An international study of 246 patients (175 from the United States, 60 from Europe, and 11 from Japan) reported a cumulative risk of pancreatic cancer to age 70 years of 40 percent (standardized incidence ratio 53) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/26/37288/abstract/43\">",
"     43",
"    </a>",
"    ]. Similar findings were noted in a study of 112 families in Europe [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/26/37288/abstract/4\">",
"     4",
"    </a>",
"    ]. The cumulative risk of developing pancreatic cancer within 70 years after symptom onset was 44 percent (standardized incidence ratio 67). In both studies there was an increasingly high risk after age 50.",
"   </p>",
"   <p>",
"    The magnitude of risk was also evaluated in the French series of 200 patients from 78 families with hereditary pancreatitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/26/37288/abstract/9\">",
"     9",
"    </a>",
"    ]. The cumulative risk of pancreatic cancer in affected family members was 10, 19, and 54 percent at ages 50, 60, and 75 years, respectively. The standardized incidence ratio for pancreatic cancer compared to the general population was 87 (95% CI 42-113). The risk was highest in smokers and in individuals with diabetes mellitus.",
"   </p>",
"   <p>",
"    Smoking increases the risk of pancreatic cancer approximately two-fold in patients with hereditary pancreatitis, which is similar to the increase in risk in the general population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/26/37288/abstract/45\">",
"     45",
"    </a>",
"    ]. However, among patients with hereditary pancreatitis, smokers developed pancreatic cancer 20 years earlier than nonsmokers. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/13/27866?source=see_link&amp;anchor=H12#H12\">",
"     \"Epidemiology and risk factors for exocrine pancreatic cancer\", section on 'Cigarette smoking'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21720117\">",
"    <span class=\"h2\">",
"     Screening",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two consensus panels have recommended screening for pancreatic cancer in individuals with hereditary pancreatitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/26/37288/abstract/46,47\">",
"     46,47",
"    </a>",
"    ]. There is no consensus as to the optimal age to start screening; 2001 guidelines from the Consensus Committees of the European Registry of Hereditary Pancreatic Diseases, the Midwest Multi-Center Pancreatic Study Group and the International Association of Pancreatology suggest screening starting at age 40 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/26/37288/abstract/46\">",
"     46",
"    </a>",
"    ], while a 2007 consensus statement from the Fourth Annual Symposium of Inherited Diseases of the Pancreas recommended that high-risk individuals (including those with hereditary pancreatitis) commence screening at age 45 or starting 15 years younger than the earliest age of pancreatic cancer in the family (whichever is at the earliest age) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/26/37288/abstract/47\">",
"     47",
"    </a>",
"    ]. This latter group also recommended that screening begin earlier in people who have ever smoked, given that smokers from pancreatic cancer-prone families develop cancer on average a decade earlier than non-smokers. Neither group gave specific recommendations as to the optimal screening strategy or how often screening should be repeated. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/13/27866?source=see_link&amp;anchor=H20#H20\">",
"     \"Epidemiology and risk factors for exocrine pancreatic cancer\", section on 'Screening for high-risk patients'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of hereditary pancreatitis is based upon the clinical history, radiographic testing in the appropriate clinical setting, and recognition of the autosomal dominant inheritance pattern. Patients without a family history may initially be thought to have idiopathic pancreatitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/26/37288/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/46/42727?source=see_link&amp;anchor=H6#H6\">",
"     \"Causes of chronic pancreatitis in children and adolescents\", section on 'Idiopathic'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/41/39575?source=see_link&amp;anchor=H9#H9\">",
"     \"Etiology and pathogenesis of chronic pancreatitis in adults\", section on 'Idiopathic pancreatitis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Genetic testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Genetic testing is available in some laboratories. However, not all mutations accounting for hereditary pancreatitis have been identified. An updated list of laboratories that perform this testing is available at",
"    <a class=\"external\" href=\"file://www.genetests.org/\">",
"     www.genetests.org",
"    </a>",
"    . An overview of the issues to be addressed by genetic counselors has been published [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/26/37288/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16023237\">",
"    <span class=\"h3\">",
"     Symptomatic patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;Genetic testing for pancreatitis susceptibility genes should be considered in patients with pancreatitis who fulfill one or more of the following criteria [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/26/37288/abstract/25,49\">",
"     25,49",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An unexplained documented episode of pancreatitis as a child",
"     </li>",
"     <li>",
"      Idiopathic chronic pancreatitis, particularly when the onset of pancreatitis occurs before age 25",
"     </li>",
"     <li>",
"      A family history of recurrent acute pancreatitis, idiopathic chronic pancreatitis, or childhood pancreatitis without a known cause",
"     </li>",
"     <li>",
"      Relatives known to carry mutations associated with hereditary pancreatitis (ie, PRSS1 mutations)",
"     </li>",
"     <li>",
"      Recurrent acute attacks of pancreatitis for which there is no identifiable cause",
"     </li>",
"     <li>",
"      Patients eligible for approved research protocols",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    All patients in whom genetic testing is performed should have genetic counseling prior to and after testing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/26/37288/abstract/25,48,50\">",
"     25,48,50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Genetic testing is most commonly limited to the PRSS1, CFTR and SPINK1 genes: &nbsp;",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      PRSS1 gene mutations associated with gain-of-function effects include p.A16V (mild phenotype), p.D19A, p.D22G, p.K23R, p.K23I, p.K23I_I24insIDK, p.N29I, p.N29T, p.V39A, p.R122H, and p.122C [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/26/37288/abstract/17\">",
"       17",
"      </a>",
"      ]. A number of other variants have been reported, but their functional significance is unknown. In addition, PRSS1 copy number variants are associated with autosomal dominant hereditary pancreatitis. Because these are gain-of-function mutations, a heterozygote genotype indicates marked increased risk for disease (60 to 80 percent penetrance). Co-inheritance of other risk alleles appears to increase risk and worsen severity.",
"     </li>",
"     <li>",
"      CFTR testing is also indicated in patients with unexplained recurrent acute pancreatitis and chronic pancreatitis. CFTR-associated pancreatitis includes the mutations that cause cystic fibrosis, but also gene variants previously thought to be benign (eg, R75Q). Therefore, complete gene sequencing should be considered, especially if the patient has recurrent sinusitis or male infertility. Interpretation of results must be done in the context of clinical setting. Patients with two severe CFTR mutations, or a severe and mild-variable CFTR mutation, should be referred to a CF center for formal testing because management requires a structured, multidisciplinary approach. &nbsp;",
"     </li>",
"     <li>",
"      SPINK1 mutations are believed to limit the inflammation-associated feedback inhibition of intrapancreatic trypsin activity. Heterozygous SPINK1 mutations are benign, unless there is a problem causing recurrent intrapancreatic trypsin activation. Homozygote or compound heterozygote SPINK1 mutations cause sufficient loss of trypsin inhibiting function to explain the etiology of recurrent pancreatitis. Heterozygous SPINK1 mutations typically cause pancreatitis only if they are associated with another predisposing factor, such as mutations in CFTR, calcium sensing receptor (CaSR), or chymotrypsinogen C (CTRC) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/26/37288/abstract/51\">",
"       51",
"      </a>",
"      ]. Patients with SPINK1 mutations typically have a more severe clinical course. Inactivating mutations in CaSR also cause familial hypocalciuric hypercalcemia which occasionally is associated with pancreatitis. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?18/51/19258?source=see_link&amp;anchor=H9#H9\">",
"       \"Disorders of the calcium-sensing receptor: Familial hypocalciuric hypercalcemia and autosomal dominant hypocalcemia\", section on 'Familial hypocalciuric hypercalcemia'",
"      </a>",
"      .) &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16022991\">",
"    <span class=\"h3\">",
"     Asymptomatic patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;Testing of asymptomatic individuals (predictive testing) can be considered for individuals who have a first-degree relative with a known PRSS1 mutation, but should only be undertaken after expert genetic counseling. Predictive testing is generally not recommended for individuals under 16 years of age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/26/37288/abstract/49\">",
"     49",
"    </a>",
"    ]. If a family carries a known mutation, negative test results in a family member essentially eliminate the risk of hereditary pancreatitis in that individual [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/26/37288/abstract/52\">",
"     52",
"    </a>",
"    ]. A positive test result confers approximately 80 percent risk of developing pancreatitis. If an individual remains free of symptoms, the residual risk of developing pancreatitis is 25 percent at age 20, and 10 percent at age 30 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/26/37288/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    By contrast, predictive testing of SPINK1 or CFTR mutations in presymptomatic individuals is of minimal value, because mutations are common and most patients with these mutations do not develop disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/26/37288/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of hereditary pancreatitis is similar to that of other causes of chronic pancreatitis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/40/31369?source=see_link\">",
"     \"Treatment of chronic pancreatitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Avoidance of alcohol and tobacco",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among patients with hereditary pancreatitis, several environmental triggers have been associated with exacerbations, including alcohol abuse, emotional stress, and dietary fat [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/26/37288/abstract/9,42\">",
"     9,42",
"    </a>",
"    ]. There is no known quantity of alcohol that is safe for patients with hereditary pancreatitis, so patients are typically counseled to abstain from consuming any alcoholic beverages. In addition, smoking increases the risk of pancreatic cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/26/37288/abstract/45\">",
"     45",
"    </a>",
"    ]. Thus, patients with hereditary pancreatitis, members of affected families, and individuals in whom a specific PRSS1 mutation has been identified should be counseled to avoid these triggers.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Antioxidants and analgesics",
"    </span>",
"    &nbsp;&mdash;&nbsp;One two-year crossover study of antioxidants and analgesics in three children from the same Italian hereditary pancreatitis family suggested significant improvement with the antioxidants [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/26/37288/abstract/54\">",
"     54",
"    </a>",
"    ]. We have observed similar improvement in a subset of patients with non-alcoholic pancreatitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/26/37288/abstract/55\">",
"     55",
"    </a>",
"    ], although the components, dose, and frequency have not been standardized.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Pancreatectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is a current debate over the use of pancreatectomy or pancreatectomy with islet autotransplantation for selected patients with hereditary pancreatitis. The procedure is irreversible, and associated with multiple risks and has not been proven to protect islet cells and delay development of diabetes. Furthermore, the risk of cancer occurs late in life; the published risk may be higher than real risk because of selection bias. Finally, new treatments are being evaluated that may further reduce risk of pancreatitis and pancreatic cancer. Enthusiasm for doing this procedure should therefore be tempered with caution. &nbsp;",
"   </p>",
"   <p>",
"    In younger patients who have functional islet cells, pancreatectomy with islet autotransplantation is believed by many to preserve islet function and can reduce intractable, narcotic-dependent pancreatic pain. Outcomes based on small case series show moderate levels of success: In a study of 18 pediatric patients who underwent pancreatectomy and islet autotransplantation for chronic pancreatitis, islet function was maintained in 78 percent, and 56 percent were insulin independent. Insulin independence correlated with the number of islet-equivalents salvaged [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/26/37288/abstract/56\">",
"     56",
"    </a>",
"    ]. Sixty-one percent of patients were weaned from narcotics. Younger patients (&lt;13 years old) had better graft function and were less likely to require narcotics postoperatively.",
"   </p>",
"   <p>",
"    Based on these results, we offer islet autotransplantation for younger patients with chronic pancreatitis. The typical candidate is a child with an established genetic cause for chronic pancreatitis (PRSS1 or SPINK1 mutation), severe pain leading to narcotic dependence, and residual islet cell function. The optimal timing for this procedure requires consideration of the disability of the patient from pancreatitis, the exclusion of treatable etiologies, prognosis, and islet cell mass. Earlier surgery may provide more islets and diminish months of suffering, but as noted above, the procedure is also irreversible, is associated with uncommon but serious risk, and commits the patient to a lifetime of full-dose pancreatic enzyme replacement therapy. Furthermore, the long-term survival of islets and consequences of islets in the liver are not fully defined, and the clock begins as soon as the procedure is performed.",
"   </p>",
"   <p>",
"    Older patients with long-standing chronic pancreatitis (eg, those who have had chronic pancreatitis for 20 years or more) are occasionally candidates for total pancreatectomy to treat pain or reduce the risk of developing pancreatic cancer. Screening for pancreatic cancer in these high-risk patients can be particularly difficult because the pancreas is scarred and disfigured [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/26/37288/abstract/46\">",
"     46",
"    </a>",
"    ]. Islet autotransplantation is not done in patients with long-standing chronic pancreatitis in some centers because of precancerous lesions and potential cancers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/26/37288/abstract/57\">",
"     57",
"    </a>",
"    ], and there is concern that these malignant cells may be reinfused with the islets. Furthermore, the potential benefit of islet autotransplantation is limited if the patient has marked fibrosis or is already diabetic. However, other centers have performed islet autotransplantation on these patients, and no cases of pancreatic cancer development have yet been reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/26/37288/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A patient's level of concern about pancreatic cancer varies substantially. A high level of patient concern may outweigh the risk and expense of performing a total pancreatectomy. Thus, the decision as to whether or not to perform total pancreatectomy in these older patients should be individualized, depending on the patient's values and preferences, and particularly their level of concern about pancreatic cancer. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/40/31369?source=see_link&amp;anchor=H17#H17\">",
"     \"Treatment of chronic pancreatitis\", section on 'Resection'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mortality rate compared to the general population is significantly increased in patients with hereditary pancreatitis who develop pancreatic cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/26/37288/abstract/59\">",
"     59",
"    </a>",
"    ]. In contrast, mortality does not appear to be increased in patients without pancreatic cancer.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Autosomal dominant hereditary pancreatitis is usually caused by mutations in serine protease 1 gene (PRSS1). In some cases the PRSS1 mutation may promote premature activation of trypsinogen or interfere with the inactivation of trypsin. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'PRSS1'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Other forms of pancreatitis with a genetic basis are associated with mutations in the",
"      <strong>",
"       s",
"      </strong>",
"      erine",
"      <strong>",
"       p",
"      </strong>",
"      rotease",
"      <strong>",
"       in",
"      </strong>",
"      hibitor",
"      <strong>",
"       K",
"      </strong>",
"      azal type",
"      <strong>",
"       1 gene",
"      </strong>",
"      (SPINK1, also called pancreatic secretory trypsin inhibitor gene) or cystic fibrosis transmembrane regulator (CFTR) genes. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Genetics'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most patients with PRSS1-associated hereditary pancreatitis typically present before 20 years of age with recurrent acute or chronic pancreatitis. About one third of patients go on to develop pancreatic insufficiency",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      diabetes mellitus. Affected individuals have a markedly increased risk of developing pancreatic cancer, especially if they smoke or have diabetes mellitus. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Clinical presentation'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H5\">",
"       'Pancreatic cancer'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Clinical indications for genetic testing for hereditary pancreatitis include unexplained pancreatitis in a child, or unexplained recurrent acute or chronic pancreatitis in older individuals. Such patients should be tested for mutations in PRSS1, CFTR, and SPINK1 if no other etiology can be identified. Testing for SPINK1 mutations or CFTR in patients without clinical symptoms suggestive of pancreatic disease is not clinically useful because a heterozygous mutation for one of these genes only slightly increases the risk for chronic pancreatitis. (See",
"      <a class=\"local\" href=\"#H16023237\">",
"       'Symptomatic patients'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For children under age 16 with a family history of chronic pancreatitis but no clinical symptoms, we suggest NOT performing genetic testing (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). For patients older than age 16, genetic testing for PRSS1 can be considered if there is a family history of a known PRSS1 mutation and if testing is desired by the patient after expert genetic counseling. (See",
"      <a class=\"local\" href=\"#H16022991\">",
"       'Asymptomatic patients'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with hereditary pancreatitis should avoid consuming alcohol, smoking cigarettes, limit dietary fat, and try to minimize emotional stress and consider using multivitamins and antioxidants. The treatment of hereditary pancreatitis is otherwise similar to that for other causes of acute and chronic pancreatitis. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Treatment'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?30/40/31369?source=see_link\">",
"       \"Treatment of chronic pancreatitis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In children or adults with severe pain and opioid addiction due to chronic pancreatitis, but with residual islet function, we suggest pancreatectomy with islet autotransplantation (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Pancreatectomy can markedly improve the quality of life in selected patients, but the procedure is irreversible, is associated with significant perioperative risk, has uncertain long-term consequences related to islet cell function in the liver, and results in complete pancreatic exocrine insufficiency that requires lifelong, full-dose pancreatic enzyme replacement therapy. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Pancreatectomy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Hereditary pancreatitis is associated with a markedly increased risk of pancreatic cancer. The cumulative risk of developing pancreatic cancer within 70 years after symptom onset is about 40 percent, but this statistic includes patients with other risk factors for pancreatic cancer, including smoking, diabetes, and a family history of cancer. Smokers from pancreatic cancer-prone families develop cancer on average a decade earlier than non-smokers. Consensus panels have recommended screening for pancreatic cancer in individuals with hereditary pancreatitis, but there is no consensus as to the optimal age to start screening. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Pancreatic cancer'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In older patients with longstanding inflammation and diabetes mellitus, pancreatectomy with or without islet autotransplantation should be considered if the patient has a high level of concern about pancreatic cancer. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Pancreatectomy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/26/37288/abstract/1\">",
"      Whitcomb DC, Preston RA, Aston CE, et al. A gene for hereditary pancreatitis maps to chromosome 7q35. Gastroenterology 1996; 110:1975.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/26/37288/abstract/2\">",
"      Whitcomb DC, Gorry MC, Preston RA, et al. Hereditary pancreatitis is caused by a mutation in the cationic trypsinogen gene. Nat Genet 1996; 14:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/26/37288/abstract/3\">",
"      Gorry MC, Gabbaizedeh D, Furey W, et al. Mutations in the cationic trypsinogen gene are associated with recurrent acute and chronic pancreatitis. Gastroenterology 1997; 113:1063.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/26/37288/abstract/4\">",
"      Howes N, Lerch MM, Greenhalf W, et al. Clinical and genetic characteristics of hereditary pancreatitis in Europe. Clin Gastroenterol Hepatol 2004; 2:252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/26/37288/abstract/5\">",
"      LaFemina J, Roberts PA, Hung YP, et al. Identification of a novel kindred with familial pancreatitis and pancreatic cancer. Pancreatology 2009; 9:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/26/37288/abstract/6\">",
"      LaRusch J, Barmada MM, Solomon S, Whitcomb DC. Whole exome sequencing identifies multiple, complex etiologies in an idiopathic hereditary pancreatitis kindred. JOP 2012; 13:258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/26/37288/abstract/7\">",
"      Schneider A, Larusch J, Sun X, et al. Combined bicarbonate conductance-impairing variants in CFTR and SPINK1 variants are associated with chronic pancreatitis in patients without cystic fibrosis. Gastroenterology 2011; 140:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/26/37288/abstract/8\">",
"      Rosendahl J, Landt O, Bernadova J, et al. CFTR, SPINK1, CTRC and PRSS1 variants in chronic pancreatitis: is the role of mutated CFTR overestimated? Gut 2012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/26/37288/abstract/9\">",
"      Rebours V, Boutron-Ruault MC, Schnee M, et al. The natural history of hereditary pancreatitis: a national series. Gut 2009; 58:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/26/37288/abstract/10\">",
"      DiMagno MJ, DiMagno EP. Chronic pancreatitis. Curr Opin Gastroenterol 2005; 21:544.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/26/37288/abstract/11\">",
"      Applebaum-Shapiro SE, Finch R, Pf&uuml;tzer RH, et al. Hereditary pancreatitis in North America: the Pittsburgh-Midwest Multi-Center Pancreatic Study Group Study. Pancreatology 2001; 1:439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/26/37288/abstract/12\">",
"      Howes N, Greenhalf W, Stocken DD, Neoptolemos JP. Cationic trypsinogen mutations and pancreatitis. Gastroenterol Clin North Am 2004; 33:767.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/26/37288/abstract/13\">",
"      Whitcomb DC. Value of genetic testing in the management of pancreatitis. Gut 2004; 53:1710.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/26/37288/abstract/14\">",
"      Witt H, Luck W, Becker M. A signal peptide cleavage site mutation in the cationic trypsinogen gene is strongly associated with chronic pancreatitis. Gastroenterology 1999; 117:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/26/37288/abstract/15\">",
"      Creighton J, Lyall R, Wilson DI, et al. Mutations of the cationic trypsinogen gene in patients with chronic pancreatitis. Lancet 1999; 354:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/26/37288/abstract/16\">",
"      Whitcomb DC. Genetic aspects of pancreatitis. Annu Rev Med 2010; 61:413.",
"     </a>",
"    </li>",
"    <li>",
"     Genetic risk factors in chronic pancreatitis database. Available at: www.pancreasgenetics.org/ (Accessed on August 08, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/26/37288/abstract/18\">",
"      Sossenheimer MJ, Aston CE, Preston RA, et al. Clinical characteristics of hereditary pancreatitis in a large family, based on high-risk haplotype. The Midwest Multicenter Pancreatic Study Group (MMPSG). Am J Gastroenterol 1997; 92:1113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/26/37288/abstract/19\">",
"      Witt H, Sahin-T&oacute;th M, Landt O, et al. A degradation-sensitive anionic trypsinogen (PRSS2) variant protects against chronic pancreatitis. Nat Genet 2006; 38:668.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/26/37288/abstract/20\">",
"      Kereszturi E, Szmola R, Kukor Z, et al. Hereditary pancreatitis caused by mutation-induced misfolding of human cationic trypsinogen: a novel disease mechanism. Hum Mutat 2009; 30:575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/26/37288/abstract/21\">",
"      Sahin-T&oacute;th M. Hereditary pancreatitis-associated mutation asn(21) --&gt; ile stabilizes rat trypsinogen in vitro. J Biol Chem 1999; 274:29699.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/26/37288/abstract/22\">",
"      Teich N, Ockenga J, Hoffmeister A, et al. Chronic pancreatitis associated with an activation peptide mutation that facilitates trypsin activation. Gastroenterology 2000; 119:461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/26/37288/abstract/23\">",
"      Teich N, Bauer N, M&ouml;ssner J, Keim V. Mutational screening of patients with nonalcoholic chronic pancreatitis: identification of further trypsinogen variants. Am J Gastroenterol 2002; 97:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/26/37288/abstract/24\">",
"      Grocock CJ, Rebours V, Delhaye MN, et al. The variable phenotype of the p.A16V mutation of cationic trypsinogen (PRSS1) in pancreatitis families. Gut 2010; 59:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/26/37288/abstract/25\">",
"      Fink EN, Kant JA, Whitcomb DC. Genetic counseling for nonsyndromic pancreatitis. Gastroenterol Clin North Am 2007; 36:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/26/37288/abstract/26\">",
"      Pf&uuml;tzer RH, Barmada MM, Brunskill AP, et al. SPINK1/PSTI polymorphisms act as disease modifiers in familial and idiopathic chronic pancreatitis. Gastroenterology 2000; 119:615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/26/37288/abstract/27\">",
"      Witt H, Luck W, Hennies HC, et al. Mutations in the gene encoding the serine protease inhibitor, Kazal type 1 are associated with chronic pancreatitis. Nat Genet 2000; 25:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/26/37288/abstract/28\">",
"      Schneider A, Barmada MM, Slivka A, et al. Clinical characterization of patients with idiopathic chronic pancreatitis and SPINK1 Mutations. Scand J Gastroenterol 2004; 39:903.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/26/37288/abstract/29\">",
"      Aoun E, Chang CC, Greer JB, et al. Pathways to injury in chronic pancreatitis: decoding the role of the high-risk SPINK1 N34S haplotype using meta-analysis. PLoS One 2008; 3:e2003.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/26/37288/abstract/30\">",
"      Rowntree RK, Harris A. The phenotypic consequences of CFTR mutations. Ann Hum Genet 2003; 67:471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/26/37288/abstract/31\">",
"      Cohn JA, Friedman KJ, Noone PG, et al. Relation between mutations of the cystic fibrosis gene and idiopathic pancreatitis. N Engl J Med 1998; 339:653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/26/37288/abstract/32\">",
"      Ooi CY, Dorfman R, Cipolli M, et al. Type of CFTR mutation determines risk of pancreatitis in patients with cystic fibrosis. Gastroenterology 2011; 140:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/26/37288/abstract/33\">",
"      Cohn JA, Mitchell RM, Jowell PS. The impact of cystic fibrosis and PSTI/SPINK1 gene mutations on susceptibility to chronic pancreatitis. Clin Lab Med 2005; 25:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/26/37288/abstract/34\">",
"      LaRusch J, Whitcomb DC. Genetics of pancreatitis. Curr Opin Gastroenterol 2011; 27:467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/26/37288/abstract/35\">",
"      Weiss FU, Simon P, Bogdanova N, et al. Complete cystic fibrosis transmembrane conductance regulator gene sequencing in patients with idiopathic chronic pancreatitis and controls. Gut 2005; 54:1456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/26/37288/abstract/36\">",
"      Cohn JA, Neoptolemos JP, Feng J, et al. Increased risk of idiopathic chronic pancreatitis in cystic fibrosis carriers. Hum Mutat 2005; 26:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/26/37288/abstract/37\">",
"      Sharer N, Schwarz M, Malone G, et al. Mutations of the cystic fibrosis gene in patients with chronic pancreatitis. N Engl J Med 1998; 339:645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/26/37288/abstract/38\">",
"      Lowenfels A, Maisonneuve P, Palys B. Re: Ockenga et al.--mutations of cystic fibrosis gene in patients with pancreatitis. Am J Gastroenterol 2001; 96:614.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/26/37288/abstract/39\">",
"      Keim V, Bauer N, Teich N, et al. Clinical characterization of patients with hereditary pancreatitis and mutations in the cationic trypsinogen gene. Am J Med 2001; 111:622.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/26/37288/abstract/40\">",
"      Cui Y, Andersen DK. Pancreatogenic diabetes: special considerations for management. Pancreatology 2011; 11:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/26/37288/abstract/41\">",
"      Whitcomb DC. Genetic predispositions to acute and chronic pancreatitis. Med Clin North Am 2000; 84:531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/26/37288/abstract/42\">",
"      Sibert JR. Hereditary pancreatitis in England and Wales. J Med Genet 1978; 15:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/26/37288/abstract/43\">",
"      Lowenfels AB, Maisonneuve P, DiMagno EP, et al. Hereditary pancreatitis and the risk of pancreatic cancer. International Hereditary Pancreatitis Study Group. J Natl Cancer Inst 1997; 89:442.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/26/37288/abstract/44\">",
"      Whitcomb DC, Applebaum S, Martin SP. Hereditary pancreatitis and pancreatic carcinoma. Ann N Y Acad Sci 1999; 880:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/26/37288/abstract/45\">",
"      Lowenfels AB, Maisonneuve P, Whitcomb DC, et al. Cigarette smoking as a risk factor for pancreatic cancer in patients with hereditary pancreatitis. JAMA 2001; 286:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/26/37288/abstract/46\">",
"      Ulrich CD, Consensus Committees of the European Registry of Hereditary Pancreatic Diseases, Midwest Multi-Center Pancreatic Study Group, International Association of Pancreatology. Pancreatic cancer in hereditary pancreatitis: consensus guidelines for prevention, screening and treatment. Pancreatology 2001; 1:416.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/26/37288/abstract/47\">",
"      Brand RE, Lerch MM, Rubinstein WS, et al. Advances in counselling and surveillance of patients at risk for pancreatic cancer. Gut 2007; 56:1460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/26/37288/abstract/48\">",
"      Solomon S, Whitcomb DC, LaRusch J. PRSS1-Related Hereditary Pancreatitis. GeneReviews [internet] 2012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/26/37288/abstract/49\">",
"      Ellis I, Lerch MM, Whitcomb DC, Consensus Committees of the European Registry of Hereditary Pancreatic Diseases, Midwest Multi-Center Pancreatic Study Group, International Association of Pancreatology. Genetic testing for hereditary pancreatitis: guidelines for indications, counselling, consent and privacy issues. Pancreatology 2001; 1:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/26/37288/abstract/50\">",
"      Solomon S, Whitcomb DC. Genetics of pancreatitis: an update for clinicians and genetic counselors. Curr Gastroenterol Rep 2012; 14:112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/26/37288/abstract/51\">",
"      Felderbauer P, Hoffmann P, Einw&auml;chter H, et al. A novel mutation of the calcium sensing receptor gene is associated with chronic pancreatitis in a family with heterozygous SPINK1 mutations. BMC Gastroenterol 2003; 3:34.",
"     </a>",
"    </li>",
"    <li>",
"     Whitcomb DC. Hereditary disease of the pancreas. In: Textbook of gastroenterology, 4 Ed, Yamada T, Alpers DH, Laine L (Eds), Lippincott, Williams and Wilkins, Philadelphia 2002. p.2147-65.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/26/37288/abstract/53\">",
"      Ellis, JH, Greenhalf, W, Howes, N, et al. Clinical and molecular findings of cationic trypsinogen mutations in 60 families with hereditary pancreatitis on the EUROPAC Register (abstract). Digestion 2000; 61:266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/26/37288/abstract/54\">",
"      Uomo G, Talamini G, Rabitti PG. Antioxidant treatment in hereditary pancreatitis. A pilot study on three young patients. Dig Liver Dis 2001; 33:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/26/37288/abstract/55\">",
"      Burton F, Alkaade S, Collins D, et al. Use and perceived effectiveness of non-analgesic medical therapies for chronic pancreatitis in the United States. Aliment Pharmacol Ther 2011; 33:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/26/37288/abstract/56\">",
"      Bellin MD, Carlson AM, Kobayashi T, et al. Outcome after pancreatectomy and islet autotransplantation in a pediatric population. J Pediatr Gastroenterol Nutr 2008; 47:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/26/37288/abstract/57\">",
"      Rebours V, L&eacute;vy P, Mosnier JF, et al. Pathology analysis reveals that dysplastic pancreatic ductal lesions are frequent in patients with hereditary pancreatitis. Clin Gastroenterol Hepatol 2010; 8:206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/26/37288/abstract/58\">",
"      Blondet JJ, Carlson AM, Kobayashi T, et al. The role of total pancreatectomy and islet autotransplantation for chronic pancreatitis. Surg Clin North Am 2007; 87:1477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/26/37288/abstract/59\">",
"      Rebours V, Boutron-Ruault MC, Jooste V, et al. Mortality rate and risk factors in patients with hereditary pancreatitis: uni- and multidimensional analyses. Am J Gastroenterol 2009; 104:2312.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5884 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-14.112.150.16-37D25D05A2-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_26_37288=[""].join("\n");
var outline_f36_26_37288=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H13\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      GENETICS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PRSS1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16023350\">",
"      SPINK1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16024358\">",
"      CFTR",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CLINICAL PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      PANCREATIC CANCER",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21720117\">",
"      Screening",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Genetic testing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16023237\">",
"      - Symptomatic patients",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16022991\">",
"      - Asymptomatic patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Avoidance of alcohol and tobacco",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Antioxidants and analgesics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Pancreatectomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/46/42727?source=related_link\">",
"      Causes of chronic pancreatitis in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/13/30935?source=related_link\">",
"      Clinical manifestations and diagnosis of chronic pancreatitis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/60/28616?source=related_link\">",
"      Clinical manifestations and diagnosis of chronic pancreatitis in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/47/35572?source=related_link\">",
"      Complications of chronic pancreatitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/49/28442?source=related_link\">",
"      Cystic fibrosis: Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/15/19706?source=related_link\">",
"      Cystic fibrosis: Overview of gastrointestinal disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/51/19258?source=related_link\">",
"      Disorders of the calcium-sensing receptor: Familial hypocalciuric hypercalcemia and autosomal dominant hypocalcemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/13/27866?source=related_link\">",
"      Epidemiology and risk factors for exocrine pancreatic cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/41/39575?source=related_link\">",
"      Etiology and pathogenesis of chronic pancreatitis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/46/44774?source=related_link\">",
"      Pathogenesis of acute pancreatitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/40/31369?source=related_link\">",
"      Treatment of chronic pancreatitis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f36_26_37289="Prevention of varicella-zoster virus infection: Chickenpox";
var content_f36_26_37289=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Prevention of varicella-zoster virus infection: Chickenpox",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/26/37289/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/26/37289/contributors\">",
"     Mary A Albrecht, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/26/37289/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/26/37289/contributors\">",
"     Martin S Hirsch, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/26/37289/contributors\">",
"     Morven S Edwards, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/26/37289/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/26/37289/contributors\">",
"     Anna R Thorner, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?36/26/37289/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 20, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Varicella-zoster virus (VZV) is one of eight herpesviruses known to cause human infection and is found worldwide. Primary infection with varicella causes chickenpox in susceptible hosts. While most healthy children have self-limited infection with primary varicella, the incidence of hospitalization and even mortality in selected groups is significant. Varicella can cause significant complications, such as soft tissue infection, pneumonia, hepatitis, and encephalitis. Patients at increased risk of complications include adults, pregnant women, and immunosuppressed hosts.",
"   </p>",
"   <p>",
"    The introduction of the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/28/4551?source=see_link\">",
"     varicella vaccine",
"    </a>",
"    in 1995 in the United States was a major advance, which led to a marked decline in morbidity and mortality associated with this infection. Initially, when only one dose was required, the incidence of varicella declined 43 percent from 2000 to 2005; after a second dose was added to the routine childhood schedule, the incidence of varicella declined 72 percent from 2006 to 2010 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/26/37289/abstract/1\">",
"     1",
"    </a>",
"    ]. The efficacy and safety of the varicella vaccine will be reviewed here.",
"   </p>",
"   <p>",
"    The major clinical manifestations and complications of chickenpox and herpes zoster, the management of VZV infection in neonates, and the prevention of varicella after exposure are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/44/33480?source=see_link\">",
"     \"Clinical features of varicella-zoster virus infection: Chickenpox\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/20/2378?source=see_link\">",
"     \"Clinical manifestations of varicella-zoster virus infection: Herpes zoster\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/11/4278?source=see_link\">",
"     \"Varicella-zoster infection in the newborn\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/3/41016?source=see_link\">",
"     \"Post-exposure prophylaxis against varicella-zoster virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     VACCINE FORMULATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/28/4551?source=see_link\">",
"     Varicella vaccine",
"    </a>",
"    is composed of the Oka strain of live, attenuated VZV [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/26/37289/abstract/2\">",
"     2",
"    </a>",
"    ]. Two live, attenuated varicella-zoster virus-vaccines are licensed in the United States for the prevention of chickenpox [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/26/37289/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A single-antigen",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/28/4551?source=see_link\">",
"       varicella vaccine",
"      </a>",
"      (VARIVAX, Merck)",
"     </li>",
"     <li>",
"      A combination measles, mumps, rubella, and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/28/4551?source=see_link\">",
"       varicella vaccine",
"      </a>",
"      (ProQuad, Merck). This formulation is licensed for use in persons aged 12 months to 12 years and was created to decrease the number of injections and to increase compliance. Because of production problems at its manufacturer, this formulation is currently not available [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/26/37289/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     EVIDENCE OF IMMUNITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Evidence of immunity to varicella in adults includes any of the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Documentation of two doses of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/28/4551?source=see_link\">",
"       varicella vaccine",
"      </a>",
"      at least four weeks apart",
"     </li>",
"     <li>",
"      Laboratory confirmation of prior exposure to varicella infection",
"     </li>",
"     <li>",
"      History of prior varicella infection or herpes zoster infection",
"     </li>",
"     <li>",
"      Birth in the US before 1980",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Persons born before 1980 are considered immune since the prevalence of disease was previously so high. However, in high-risk groups (eg, in health care providers or pregnant women) age alone does not constitute immunity; these risk groups should have serologic testing or a history of prior disease or vaccination.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     VACCINE RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Below are guidelines regarding the use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/28/4551?source=see_link\">",
"     varicella vaccine",
"    </a>",
"    in various subgroups (",
"    <a class=\"graphic graphic_table graphicRef74296 \" href=\"mobipreview.htm?7/35/7741\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Children",
"    </span>",
"    &nbsp;&mdash;&nbsp;Varicella vaccination is recommended for all children between 12 and 15 months of age without evidence of immunity. In 2006, the Advisory Committee on Immunization Practices (ACIP) recommended the addition of a routine second dose of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/28/4551?source=see_link\">",
"     varicella vaccine",
"    </a>",
"    at age four to six years (",
"    <a class=\"graphic graphic_table graphicRef72958 \" href=\"mobipreview.htm?34/59/35773\">",
"     table 2",
"    </a>",
"    ); this recommendation was maintained in the 2010 ACIP guidelines [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/26/37289/abstract/2,4-6\">",
"     2,4-6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These recommendations were made because of varicella outbreaks that have continued to occur among school-aged children vaccinated with a single dose [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/26/37289/abstract/7\">",
"     7",
"    </a>",
"    ]. Varicella is usually less severe in vaccinated individuals, but these children can still transmit the virus to a susceptible host [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/26/37289/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    All susceptible children aged 19 months to 13 years should be fully vaccinated (with two doses) by their 13th birthday [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/26/37289/abstract/2\">",
"     2",
"    </a>",
"    ]. The recommended minimum interval between the first dose and the \"catch-up\" second dose is three months for children aged &lt;12 years and four weeks for persons aged &gt;13 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/26/37289/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Adolescents and adults",
"    </span>",
"    &nbsp;&mdash;&nbsp;Routine vaccination for all healthy persons aged &gt;13 years is recommended for those without evidence of immunity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/26/37289/abstract/2,6\">",
"     2,6",
"    </a>",
"    ]. Two doses of single-antigen",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/28/4551?source=see_link\">",
"     varicella vaccine",
"    </a>",
"    should be given four to eight weeks apart. Varicella vaccine is highly recommended in VZV-seronegative adults with ongoing risk of exposure (eg, day care employees, health care workers), those who are household contacts of immunosuppressed hosts, and in women of childbearing age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/26/37289/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A second dose of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/28/4551?source=see_link\">",
"     varicella vaccine",
"    </a>",
"    is recommended for adolescents and adults who had previously received only one dose [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/26/37289/abstract/2,6,9\">",
"     2,6,9",
"    </a>",
"    ]. The recommended minimum interval between the first dose and the \"catch-up\" second dose is four weeks for persons aged &gt;13 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/26/37289/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    \"Catch-up\" vaccination is important in preventing outbreaks among susceptible individuals. Vaccination requirements for entry into middle school, high school, and college have been helpful in attaining high rates of complete immunization [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/26/37289/abstract/2,10\">",
"     2,10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vaccination is not recommended in women who are pregnant or might become pregnant within four weeks of receiving the vaccine. However, the Advisory Committee on Immunization Practices (ACIP) recommends that pregnant women, without evidence of VZV-specific immunity, should receive the first dose of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/28/4551?source=see_link\">",
"     varicella vaccine",
"    </a>",
"    upon completion or termination of pregnancy and before discharge from the health care facility. The second dose should be administered four to eight weeks after the first dose [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/26/37289/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Prevention of varicella during pregnancy is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/28/33225?source=see_link\">",
"     \"Varicella-zoster virus infection in pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Immunosuppressed hosts",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/28/4551?source=see_link\">",
"     varicella vaccine",
"    </a>",
"    is a live attenuated virus preparation, it is generally contraindicated for immunocompromised hosts, including those receiving immunosuppressive medications (eg, systemic steroids greater than 2",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    body weight per day or a total of 20 mg",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    per day) and those with hematologic malignancies (eg, leukemia, lymphoma) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/26/37289/abstract/2,11,12\">",
"     2,11,12",
"    </a>",
"    ]. Varicella vaccine should also not be given to persons who have a family history of hereditary immunodeficiency until the immunocompetence of the potential vaccinee is determined (",
"    <a class=\"graphic graphic_table graphicRef74296 \" href=\"mobipreview.htm?7/35/7741\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/26/37289/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    VZV-susceptible household contacts of susceptible immunocompromised persons (eg, HIV-infected persons or those taking immunosuppressive medications) should be vaccinated to prevent acquisition of VZV and subsequent transmission to immunocompromised household contacts [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/26/37289/abstract/13,14\">",
"     13,14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Varicella can be a severe disease when it occurs in immunocompromised children, in spite of antiviral therapy. Clinical trials of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/28/4551?source=see_link\">",
"     varicella vaccine",
"    </a>",
"    administration to immunocompromised children suggest that immunization may be an option once immune suppression is reduced [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/26/37289/abstract/15\">",
"     15",
"    </a>",
"    ]. The vaccine-induced response is usually partially or fully protective in these settings. Important caveats regarding these patient subgroups are discussed in detail below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Children with leukemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;The",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/28/4551?source=see_link\">",
"     varicella vaccine",
"    </a>",
"    was shown to be efficacious in children with leukemia in remission. The most frequent reaction to the vaccine in patients with leukemia is a mild to moderate varicella-like rash (approximately 200 lesions) which occurs in approximately 5 percent of children who have completed chemotherapy before vaccination and in 40 percent of patients on maintenance chemotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/26/37289/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, immunization in this patient group should only be undertaken with expert guidance and consultation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/26/37289/abstract/2\">",
"     2",
"    </a>",
"    ]. If a decision is made to vaccinate, the single antigen preparation (Varivax) should be used. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Vaccine formulations'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     HIV-infected children",
"    </span>",
"    &nbsp;&mdash;&nbsp;Varicella can be a severe illness in HIV-infected children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/26/37289/abstract/17\">",
"     17",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/28/4551?source=see_link\">",
"     Varicella vaccine",
"    </a>",
"    has been demonstrated to be safe [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/26/37289/abstract/18\">",
"     18",
"    </a>",
"    ] and immunogenic in asymptomatic HIV-infected children with CD4 percentages of 25 percent or more [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/26/37289/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. A subsequent study evaluated the safety and efficacy of varicella vaccine in children with a history of severe immunosuppression who had achieved immune reconstitution (n = 17) and in those with moderate symptoms and CD4 percentages &gt;15 percent (n = 37) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/26/37289/abstract/21\">",
"     21",
"    </a>",
"    ]. Regardless of immunologic category, 79 percent of HIV-infected vaccine recipients developed VZV-specific antibody",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    cell-mediated immunity 60 days after the immunization series. A multivariate analysis indicated that detectable HIV viremia at baseline correlated with a lower likelihood of immunization response.",
"   </p>",
"   <p>",
"    The authors concluded that the recommendations for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/28/4551?source=see_link\">",
"     varicella vaccine",
"    </a>",
"    in HIV-infected children should be similar to measles vaccine. Both the CDC and ACIP guidelines recommended that single-antigen varicella vaccine should be administered to HIV-infected children with a CD4+ T lymphocyte percentage of &gt;15 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/26/37289/abstract/6,13\">",
"     6,13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     HIV-infected adults",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although data on the use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/28/4551?source=see_link\">",
"     varicella vaccine",
"    </a>",
"    are lacking, most experts feel that adult patients with clinically stable HIV infection and a CD4 count &gt;200",
"    <span class=\"nowrap\">",
"     cells/microL",
"    </span>",
"    would have comparable immunity to the HIV-infected children described above. The CDC and the ACIP have recommended that single-antigen varicella vaccine may be considered in VZV-seronegative HIV-infected adolescents or adults with a CD4 count &gt;200",
"    <span class=\"nowrap\">",
"     cells/microL;",
"    </span>",
"    two doses should be administered three months apart [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/26/37289/abstract/2,6\">",
"     2,6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We feel that more data are needed on the safety of varicella vaccination in VZV-seronegative adults with HIV infection and varying degrees of immunocompromise. We suggest varicella vaccination in those individuals with a CD4 count &gt;350",
"    <span class=\"nowrap\">",
"     cells/microL.",
"    </span>",
"    Decisions about immunization in those individuals with CD4 cell count",
"    <span class=\"nowrap\">",
"     &lt;350/microL",
"    </span>",
"    should be made on an individual basis after discussion of potential risks and benefits with the patient.",
"   </p>",
"   <p>",
"    If vaccination results in disease because of vaccine virus, therapy with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    is recommended [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/26/37289/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     EFFICACY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple studies in different countries have demonstrated the efficacy of varicella vaccination [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/26/37289/abstract/22-26\">",
"     22-26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Outside the United States",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most extensive use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/28/4551?source=see_link\">",
"     varicella vaccine",
"    </a>",
"    has been in the United States and Canada, where it is universally recommended. However, the use of varicella vaccine is expanding in Europe, Australia, Latin America, and Asia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/26/37289/abstract/27,28\">",
"     27,28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A report from Japan evaluated over 1.39 million subjects who had been vaccinated from 1987 to 1993 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/26/37289/abstract/29\">",
"     29",
"    </a>",
"    ]. The following results were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Clinical symptoms were reported in 580 of 8429 vaccinees (7 percent), and seroconversion was documented in 2347 of 2565 (92 percent).",
"     </li>",
"     <li>",
"      Evidence of humoral and cellular immunity to VZV persisted in 26 vaccine recipients for &gt;20 years.",
"     </li>",
"     <li>",
"      Despite 100 documented contacts with varicella patients, only two vaccinees (2 percent) developed breakthrough varicella with mild clinical features within 12 months of vaccination.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Within the United States",
"    </span>",
"    &nbsp;&mdash;&nbsp;A review of postlicensure data included 17 studies on",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/28/4551?source=see_link\">",
"     varicella vaccine",
"    </a>",
"    efficacy before exposure and two small studies on efficacy after exposure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/26/37289/abstract/8\">",
"     8",
"    </a>",
"    ]. The majority of estimates assessed protection against clinically diagnosed varicella, with most of the studies defining severity of illness by the number of skin lesions and incidence of complications or hospitalization. The following results were reported:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One dose of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/28/4551?source=see_link\">",
"       varicella vaccine",
"      </a>",
"      was 85 percent effective (median; range, response rate to 100 percent) in preventing all varicella infections and 100 percent effective in preventing severe disease.",
"     </li>",
"     <li>",
"      Although the two studies of post-exposure prophylaxis included small numbers of patients,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/28/4551?source=see_link\">",
"       varicella vaccine",
"      </a>",
"      appeared to have significant efficacy: overall prevention of infection was 42 to 95 percent while prevention of severe disease was 88 to 100 percent. Similar data were observed in a prospective observational study of 42 susceptible children immunized within 36 hours following exposure to varicella in a homeless shelter [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/26/37289/abstract/30\">",
"       30",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In summary, the post-licensure experience with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/28/4551?source=see_link\">",
"     varicella vaccine",
"    </a>",
"    has demonstrated that one dose is usually 80 to 90 percent effective in preventing clinically diagnosed or laboratory-confirmed varicella and exhibits 95 to 100 percent effectiveness in preventing severe disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     BREAKTHROUGH VARICELLA",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Definition",
"    </span>",
"    &nbsp;&mdash;&nbsp;\"Breakthrough varicella\" or \"mild varicella-like syndrome\" (MVLS) refers to infection after exposure to wild-type virus in those who have been previously vaccinated. Most studies have noted MVLS occurring in &lt;1 to 3 percent of vaccinated children each year after vaccination [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/26/37289/abstract/31-33\">",
"     31-33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most documented cases of varicella in vaccinated children are mild [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/26/37289/abstract/34\">",
"     34",
"    </a>",
"    ]. Patients with breakthrough varicella may have a maculopapular rash rather than a vesicular rash. Breakthrough varicella generally results in fewer than 50 lesions and no fever compared with a median of 300 lesions and fever in more than 90 percent of unvaccinated children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/26/37289/abstract/31-33\">",
"     31-33",
"    </a>",
"    ]. However, breakthrough varicella is still a matter of concern since infected children can transmit varicella to others [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/26/37289/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Primary vaccine failure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Breakthrough varicella may arise from primary or secondary vaccine failure. \"Primary vaccine failure\" refers to the failure to mount a protective immune response to a dose of vaccine, whereas \"secondary vaccine failure\" refers to the gradual loss of immunity after initial vaccine response (see",
"    <a class=\"local\" href=\"#H18\">",
"     'Waning of immunity'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    In an effort to determine the etiology of \"breakthrough varicella\", serum samples from healthy children immunized against varicella were tested for evidence of seroconversion using a highly sensitive and specific assay used in research laboratories (ie, fluorescent antibody to membrane antigen testing; FAMA) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/26/37289/abstract/36\">",
"     36",
"    </a>",
"    ]. Of 148 vaccinees, only 113 (76 percent) seroconverted and 24 percent had no detectable VZV antibodies after one dose of vaccine. These data strongly contrast with earlier reported seroconversion rates of 86 to 96 percent by other commercial antibody testing methods (eg, gpELISA).",
"   </p>",
"   <p>",
"    These data suggest that many cases of varicella in immunized children may result from primary vaccine failure. Some experts have advocated that vaccine immunogenicity should be reassessed by directly comparing results of gpELISA and FAMA testing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/26/37289/abstract/35\">",
"     35",
"    </a>",
"    ]. Another explanation for the lower seroconversion rates may be related to the absence of circulating wild-type virus, which may have previously boosted immunity in patients with asymptomatic infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/26/37289/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Potential risk factors for primary vaccine failure include younger age at vaccination, steroid use, or receipt of other vaccines prior to varicella vaccination [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/26/37289/abstract/8,38,39\">",
"     8,38,39",
"    </a>",
"    ]. However, in a study of more than 7500 children who were immunized against varicella, no difference in the rate of breakthrough varicella was found between children vaccinated at &lt;15 months of age and those vaccinated at &ge;15 months of age.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Waning of immunity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among patients who initially attained a primary vaccine response, breakthrough varicella may reflect an intrinsic waning of immunity over time [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/26/37289/abstract/40-45\">",
"     40-45",
"    </a>",
"    ]. Several postlicensure studies have indicated that levels of protective efficacy fall from 97 to 84 percent eight years after immunization, consistent with waning immunity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/26/37289/abstract/40,41\">",
"     40,41",
"    </a>",
"    ]. This observation raises the theoretical concern that previously vaccinated persons could be at increased risk of acquiring varicella infection later in life, when the risk of serious complications is greater.",
"   </p>",
"   <p>",
"    Loss of immunity against varicella infection is suggested by a large observational database among persons who received one dose of vaccine. The Varicella Active Surveillance Project was established in California in 1995 to enhance community surveillance for varicella cases occurring &gt;42 days after immunization and to determine their relationship with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/28/4551?source=see_link\">",
"     varicella vaccine",
"    </a>",
"    status [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/26/37289/abstract/46\">",
"     46",
"    </a>",
"    ]. The study was significant for the following results:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      After one decade (1995 to 2004) of active surveillance data from a sentinel population of 350,000 subjects, a total of 11,356 subjects developed varicella, of whom 1080 (9.5 percent) had breakthrough disease.",
"     </li>",
"     <li>",
"      Children between the ages of 8 and 12 years who had been vaccinated at least five years previously were more likely to have moderate or severe disease than those who had been vaccinated less than five years previously (risk ratio, 2.6; 95% CI 1.2-5.8).",
"     </li>",
"     <li>",
"      The annual rate of breakthrough varicella significantly increased with the time since vaccination.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Cases of breakthrough disease have led to the adoption of a second dose of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/28/4551?source=see_link\">",
"     varicella vaccine",
"    </a>",
"    for children between the ages of four and six years and \"catch-up\" doses for adults [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/26/37289/abstract/47\">",
"     47",
"    </a>",
"    ]. Studies of patients who have received two doses of varicella vaccine demonstrate geometric mean titers that are 12 times higher with two doses of vaccine compared with one; these levels approximate those seen after natural disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/26/37289/abstract/37\">",
"     37",
"    </a>",
"    ]. Although long-term follow-up of antibody levels are not yet possible with MMRV vaccine, early data suggest similar seroconversion rates at one year of follow-up [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/26/37289/abstract/48\">",
"     48",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Vaccine recommendations'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Secondary attack rates",
"    </span>",
"    &nbsp;&mdash;&nbsp;Breakthrough varicella is a concern since these vaccinated patients can still transmit infection to other susceptible individuals.",
"   </p>",
"   <p>",
"    In a surveillance study of more than 320,000 individuals in Los Angeles county, secondary attack rates were analyzed within households according to disease history and vaccination status [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/26/37289/abstract/43\">",
"     43",
"    </a>",
"    ]. A total of 6316 varicella cases were reported. The following findings were noted among susceptible young contacts (1 to 14 years of age):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Overall, vaccinated patients (eg, those with breakthrough varicella) were half as contagious as unvaccinated patients; exposure to vaccinated patients with varicella was associated with much lower secondary attack rates compared with unvaccinated patients (15 versus 72 percent).",
"     </li>",
"     <li>",
"      However, the contagiousness of vaccinated patients also varied with the number of varicella-associated lesions. For example, the secondary attack rate was similar between vaccinated patients and unvaccinated patients if the vaccinated patient had &gt;50 lesions.",
"     </li>",
"     <li>",
"      Vaccine effectiveness for the prevention of all disease was 79 percent overall, 92 percent for moderate disease (50 to 500 lesions), and 100 percent for severe disease.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These data support the observation that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/28/4551?source=see_link\">",
"     varicella vaccine",
"    </a>",
"    decreases disease severity and decreases the risk of transmission, even in those with breakthrough disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     TRANSMISSION OF VACCINE VIRUS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     From healthy individuals to immunosuppressed hosts",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is a theoretical risk of viral transmission from health care providers or family members who were immunized with a live attenuated vaccine to an immunosuppressed patient. However, a review of the literature revealed no major risk of transmission associated with any live attenuated vaccine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/26/37289/abstract/49\">",
"     49",
"    </a>",
"    ]. Transmission of vaccine virus from healthy children to other susceptible contacts is uncommon and only described in a few case reports [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/26/37289/abstract/2,50,51\">",
"     2,50,51",
"    </a>",
"    ]. Thus, healthy household contacts of immunosuppressed patients can receive",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/28/4551?source=see_link\">",
"     varicella vaccine",
"    </a>",
"    since the risk of transmission is low [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/26/37289/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The American Academy of Pediatrics, the CDC, and the ACIP do not recommend any specific precautions except in the event that the vaccine recipient develops skin lesions; in this case, physical contact should be avoided until the rash has resolved [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/26/37289/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     From immunosuppressed hosts to healthy contacts",
"    </span>",
"    &nbsp;&mdash;&nbsp;In contrast, in a study of 88 susceptible siblings of children with leukemia who developed a rash after varicella immunization, evidence of transmission occurred in 15 siblings (17 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/26/37289/abstract/53\">",
"     53",
"    </a>",
"    ]. As noted above, persons who develop a rash after immunization should refrain from contact of other susceptible persons.",
"   </p>",
"   <p>",
"    Immunization in this patient group should only be undertaken with expert guidance and consultation (see",
"    <a class=\"local\" href=\"#H4\">",
"     'Vaccine recommendations'",
"    </a>",
"    above).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     ADVERSE EVENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ten-year safety profile of more than 55 million doses of administered",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/28/4551?source=see_link\">",
"     varicella vaccine",
"    </a>",
"    has demonstrated that immunization is generally well tolerated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/26/37289/abstract/54\">",
"     54",
"    </a>",
"    ]. Worldwide, there were 16,683 reports voluntarily submitted to Merck as part of a global postmarketing surveillance program for an overall reporting rate of 3.4",
"    <span class=\"nowrap\">",
"     reports/100,000",
"    </span>",
"    doses of vaccine distributed. In the United States, data from the Vaccine Adverse Events Reporting System from 1995 to 2005 continue to suggest that serious events are rare",
"    <span class=\"nowrap\">",
"     (2.6/100,000",
"    </span>",
"    doses administered) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/26/37289/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Serious adverse events suspected to have been caused by varicella vaccines should be reported to the Vaccine Adverse Event Reporting System (VAERS). Forms and instructions are available at",
"    <a class=\"external\" href=\"https://www.accessdata.fda.gov/scripts/medwatch/medwatch-online.htm\">",
"     https://www.accessdata.fda.gov/scripts/medwatch/medwatch-online.htm",
"    </a>",
"    , in the FDA Drug Bulletin at",
"    <a class=\"external\" href=\"file://www.fda.gov/medwatch\">",
"     file://www.fda.gov/medwatch",
"    </a>",
"    , or from the 24-hour VAERS information recording at 1-800 822-7967.",
"   </p>",
"   <p>",
"    Adverse events reported in association with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/28/4551?source=see_link\">",
"     varicella vaccine",
"    </a>",
"    are listed below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Injection site reactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pain and erythema at the injection site and fever have been the most common adverse events reported with vaccine compared with placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/26/37289/abstract/54,56\">",
"     54,56",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Rash",
"    </span>",
"    &nbsp;&mdash;&nbsp;Out of the 16,683 case reports, there were 3192 reports of rashes, half of which were vesicular in nature [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/26/37289/abstract/54\">",
"     54",
"    </a>",
"    ]. The probable origin of vesicular lesions appears related to the timing of the rash in relationship to vaccine administration, as determined by polymerase chain reaction (PCR) analysis of vesicular fluid samples. Rashes that occurred within the first two weeks after vaccination (median of eight days) were related to wild-type VZV; vaccine-derived virus was generally isolated from rashes that occurred 15 to 42 days after vaccination (median 21 days).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Febrile seizures",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the pre-marketing data of ProQuad, there was a signal of a possible increase of febrile seizures associated with this vaccine. At the time of licensure, the manufacturer began a prospective study in 31,000 children 12 to 60 months of age to evaluate the risk of febrile seizures compared with historical matched controls who received MMR and varicella vaccines administered separately at two different sites. The study suggested that ProQuad was associated with an increased risk of febrile seizures occurring 5 to 12 days after vaccination compared with controls (5 per 10,000 vaccinations versus 2 per 10,000 vaccinations, respectively). Data from the CDC also confirmed this observation; the risk of febrile seizures was documented to be 9 per 10,000 vaccinations with ProQuad versus 4 per 10,000 vaccinations with separate immunizations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/26/37289/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In February 2008, the Federal Drug Administration (FDA) changed the labeling for the ProQuad formulation to reflect this increased risk. However, the indications for ProQuad have not changed reflecting the overall good prognosis of febrile seizures, the low incidence of this complication and the overall benefit of vaccine in preventing the morbidity and mortality associated with varicella infection. Following this observation, the ACIP removed its preference for administering combination MMRV vaccine over separate injections of MMR and varicella vaccines [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/26/37289/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Disseminated vaccine virus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Disseminated vaccine virus was identified in six immunocompromised patients and one patient with Down syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/26/37289/abstract/54\">",
"     54",
"    </a>",
"    ]. Vaccination of persons receiving immunosuppressive therapy or with primary or acquired immunodeficiencies is contraindicated. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Vaccine recommendations'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Meningitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Three laboratory-confirmed cases of meningitis caused by a VZV strain in the",
"    <span class=\"nowrap\">",
"     Oka/Merck",
"    </span>",
"    vaccine have been reported in children, including an immunocompetent child [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/26/37289/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h1\">",
"     RISK OF VACCINE-ASSOCIATED ZOSTER",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since the licensure of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/28/4551?source=see_link\">",
"     varicella vaccine",
"    </a>",
"    , theoretical concerns were raised regarding two main issues:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Immunization might lead to an increased risk of vaccine-associated herpes zoster, particularly in immunocompromised children.",
"     </li>",
"     <li>",
"      Widespread varicella immunization in childhood may increase the incidence of herpes zoster in the general population due to decreased circulation of wild-type virus and a decline in T-cell immunity.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Studies monitoring herpes zoster incidence have shown inconsistent findings; two suggest no change while another shows an increase in incidence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/26/37289/abstract/59\">",
"     59",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A case of acute retinal necrosis has been reported in an individual with inflammatory bowel disease and protein-losing enteropathy who was receiving immunosuppressive therapy and who had received the varicella-",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/4/5190?source=see_link\">",
"     zoster vaccine",
"    </a>",
"    one month earlier [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/26/37289/abstract/60\">",
"     60",
"    </a>",
"    ]. VZV was detected from the vitreous by polymerase chain reaction and was found to be identical to the Oka strain of the varicella-zoster vaccine. As noted above, the varicella-zoster vaccine is contraindicated in patients receiving immunosuppressive therapy because it is a live virus vaccine. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/20/2378?source=see_link&amp;anchor=H12#H12\">",
"     \"Clinical manifestations of varicella-zoster virus infection: Herpes zoster\", section on 'Acute retinal necrosis (ARN)'",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H8\">",
"     'Immunosuppressed hosts'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Further studies are needed to define the risk of vaccine-associated zoster. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/8/23688?source=see_link&amp;anchor=H10#H10\">",
"     \"Epidemiology and pathogenesis of varicella-zoster virus infection: Herpes zoster\", section on 'Impact of varicella vaccine on incidence of herpes zoster'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h1\">",
"     VACCINE PROGRAMS IN THE UNITED STATES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The National Immunization Survey (NIS) is an ongoing 50-state survey that provides estimates of vaccination coverage among children aged 19 to 35 months in the United States. The CDC initiated the NIS in 1994 to monitor vaccination coverage of children during the first two years of life.",
"   </p>",
"   <p>",
"    Between 1997 and 2005, national varicella vaccination coverage among children 19 to 35 months of age increased from 26 to 88 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/26/37289/abstract/61\">",
"     61",
"    </a>",
"    ]. By the start of the 2006-2007 school year, 46 states (92 percent) and the District of Columbia (DC) had implemented entry requirements for varicella vaccination. Implementation of day care and school entry requirements for varicella vaccination has led to high rates of coverage among children in the United States [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/26/37289/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Impact on health care utilization",
"    </span>",
"    &nbsp;&mdash;&nbsp;Varicella remains the leading cause of vaccine-preventable deaths in children living in the United States. Prior to the introduction of vaccine, four million cases occurred annually in the United States, resulting in 10,000 hospitalizations and 100 deaths [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/26/37289/abstract/62\">",
"     62",
"    </a>",
"    ]. Vaccination has had a positive impact on health care expenditures:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A study using retrospective population-based data that included enrollees (children and adults) from 100 health insurance plans from 1994 to 2002 demonstrated that the total estimated direct medical expenditures for varicella hospitalizations and ambulatory visits declined by 74 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/26/37289/abstract/63\">",
"       63",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Data from the Varicella Active Surveillance Project (VASP) were used to compare rates of hospital admissions for varicella-related illnesses from 1995 to 2005 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/26/37289/abstract/64\">",
"       64",
"      </a>",
"      ]. Rates of hospitalization per 100,000 population decreased significantly from 2.54 (95% CI 2.1-3.0) in the early vaccination period to 0.6 (95% CI 0.4-1.0) in the late vaccination period.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Vaccination strategies and cost-effectiveness",
"    </span>",
"    &nbsp;&mdash;&nbsp;A decision-tree analysis found that compared with no vaccination, the one-dose and the two-dose program of varicella immunization were both estimated to be cost-effective from the societal perspective [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/26/37289/abstract/65\">",
"     65",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The specific population of immigrant and refugee adults remains preferentially susceptible to primary varicella infection compared with adults from industrialized nations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/26/37289/abstract/66-69\">",
"     66-69",
"    </a>",
"    ]. A cost-effectiveness analysis was conducted in a cohort of 1480 adult immigrants and refugees from six disparate geographic regions who relocated to Canada to determine the optimal vaccination strategy for this patient population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/26/37289/abstract/69\">",
"     69",
"    </a>",
"    ]. Four vaccination strategies were compared with no intervention; the strategies evaluated were:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Vaccination of all individuals",
"     </li>",
"     <li>",
"      Serologic testing of all individuals followed by vaccination of those who were seronegative",
"     </li>",
"     <li>",
"      Vaccination of an individual with a negative or uncertain history of varicella",
"     </li>",
"     <li>",
"      Serologic testing of only those individuals with a negative or uncertain history of varicella followed by vaccination of those who were seronegative",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The optimum strategy identified was targeted serologic testing in immigrants without a self-reported history of varicella, followed by vaccination in those confirmed to be susceptible. Such an approach would prevent an estimated 37 percent of varicella cases.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h1\">",
"     ZOSTER VACCINE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Issues related to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/4/5190?source=see_link\">",
"     zoster vaccine",
"    </a>",
"    in prevention of herpes zoster infection are described separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/22/36200?source=see_link\">",
"     \"Prevention of varicella-zoster virus infection: Herpes zoster\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?27/22/28003?source=see_link\">",
"       \"Patient information: Vaccines for babies and children age 0 to 6 years (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?26/57/27538?source=see_link\">",
"       \"Patient information: Chickenpox (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?17/42/18084?source=see_link\">",
"       \"Patient information: Why does my child need vaccines? (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?41/36/42566?source=see_link\">",
"       \"Patient information: Vaccines for infants and children age 0 to 6 years (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?2/40/2691?source=see_link\">",
"       \"Patient information: Chickenpox prevention and treatment (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For all children who are less than 13 years of age, we recommend varicella immunization as suggested by the Advisory Committee on Immunization Practices (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). Two doses should be administered instead of a single dose to decrease the risk of breakthrough varicella. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Vaccine recommendations'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H12\">",
"       'Efficacy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For all healthy persons &gt;13 years of age without evidence of immunity, we recommend routine varicella vaccination, as suggested by the Advisory Committee on Immunization Practices (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). Two doses should be administered instead of a single dose to decrease the risk of breakthrough varicella. Adolescents and adults who had previously received only one dose of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/28/4551?source=see_link\">",
"       varicella vaccine",
"      </a>",
"      should receive a \"catch-up\" dose.",
"     </li>",
"     <li>",
"      Evidence of immunity can include documentation of serologic status, history of vaccination, birth before 1980, or prior illness. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Evidence of immunity'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Immunization is particularly important for health care providers and in those who are household contacts of immunocompromised hosts. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Vaccine recommendations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Vaccination should be deferred in women who are pregnant or might become pregnant within four weeks of receiving the vaccine. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Vaccine recommendations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/28/4551?source=see_link\">",
"       Varicella vaccine",
"      </a>",
"      is not generally recommended in patients with immunodeficiency (eg, transplant recipients). However, varicella vaccine has been demonstrated to be safe and effective in certain subgroups of HIV-infected patients with relatively preserved immune function. In HIV-infected children, we suggest varicella vaccine for those with a CD4+ T lymphocyte percentage &gt;15 percent (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      More data are needed on the safety of varicella vaccination in VZV-seronegative adults with HIV infection and varying degrees of immunocompromise. We suggest varicella vaccination in those individuals with CD4 counts &gt;350",
"      <span class=\"nowrap\">",
"       cells/microL",
"      </span>",
"      (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Decisions about immunization in those individuals with CD4 counts",
"      <span class=\"nowrap\">",
"       &lt;350/microL",
"      </span>",
"      should be made on an individual basis after discussion of potential risks and benefits with the patient.",
"     </li>",
"     <li>",
"      Breakthrough varicella refers to infection after exposure to wild-type virus in those who have been previously vaccinated. This can occur due to lack of response to vaccine or waning of immunity over time in individuals who had a primary vaccine response. Breakthrough varicella is usually a mild disease. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Breakthrough varicella'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The risk of transmission of vaccine virus is generally low, but can occur in contacts of patients with vesicular skin lesions; physical contact should be avoided until the rash has resolved. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Transmission of vaccine virus'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The ten-year safety profile of more than 55 million doses of administered",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/28/4551?source=see_link\">",
"       varicella vaccine",
"      </a>",
"      has demonstrated that immunization is generally well tolerated; rash and febrile seizures have been reported. Because of the association of febrile seizures and the quadrivalent vaccine containing measles, mumps, rubella and varicella antigens, the quadrivalent vaccine is no longer the preferred vehicle for varicella immunization. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Adverse events'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/26/37289/abstract/1\">",
"      Centers for Disease Control and Prevention (CDC). Evolution of varicella surveillance--selected states, 2000-2010. MMWR Morb Mortal Wkly Rep 2012; 61:609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/26/37289/abstract/2\">",
"      Marin M, G&uuml;ris D, Chaves SS, et al. Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2007; 56:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/26/37289/abstract/3\">",
"      Centers for Disease Control and Prevention. Notice to readers: supply of vaccines containing varicellella-zoster virus. MMWR Morb Mortal Wkly Rep 2007; 56:146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/26/37289/abstract/4\">",
"      A second dose of varicella vaccine. Med Lett Drugs Ther 2006; 48:80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/26/37289/abstract/5\">",
"      Advisory Committee on Immunization Practices. Recommended adult immunization schedule: United States, 2010. Ann Intern Med 2010; 152:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/26/37289/abstract/6\">",
"      Advisory Committee on Immunization Practices. Recommended adult immunization schedule: United States, October 2007-September 2008. Ann Intern Med 2007; 147:725.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/26/37289/abstract/7\">",
"      Lopez AS, Guris D, Zimmerman L, et al. One dose of varicella vaccine does not prevent school outbreaks: is it time for a second dose? Pediatrics 2006; 117:e1070.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/26/37289/abstract/8\">",
"      Seward JF, Marin M, V&aacute;zquez M. Varicella vaccine effectiveness in the US vaccination program: a review. J Infect Dis 2008; 197 Suppl 2:S82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/26/37289/abstract/9\">",
"      Advisory Committee on Immunization Practices. Recommended adult immunization schedule: United States, 2009*. Ann Intern Med 2009; 150:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/26/37289/abstract/10\">",
"      Marin M, Nguyen HQ, Keen J, et al. Importance of catch-up vaccination: experience from a varicella outbreak, Maine, 2002-2003. Pediatrics 2005; 115:900.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/26/37289/abstract/11\">",
"      Centers for Disease Control and Prevention (CDC). Varicella-related deaths among adults--United States, 1997. MMWR Morb Mortal Wkly Rep 1997; 46:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/26/37289/abstract/12\">",
"      Cohen JI, Brunell PA, Straus SE, Krause PR. Recent advances in varicella-zoster virus infection. Ann Intern Med 1999; 130:922.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/26/37289/abstract/13\">",
"      Kaplan JE, Benson C, Holmes KH, et al. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recomm Rep 2009; 58:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/26/37289/abstract/14\">",
"      Centers for Disease Control and Prevention (CDC). Notes from the field: severe varicella in an immunocompromised child exposed to an unvaccinated sibling with varicella--Minnesota, 2011. MMWR Morb Mortal Wkly Rep 2012; 61:541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/26/37289/abstract/15\">",
"      Levin MJ. Varicella vaccination of immunocompromised children. J Infect Dis 2008; 197 Suppl 2:S200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/26/37289/abstract/16\">",
"      Gershon AA, Steinberg SP, Gelb L, et al. Live attenuated varicella vaccine. Efficacy for children with leukemia in remission. JAMA 1984; 252:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/26/37289/abstract/17\">",
"      Prevention of hepatitis A through active or passive immunization: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 1999; 48:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/26/37289/abstract/18\">",
"      Bekker V, Westerlaken GH, Scherpbier H, et al. Varicella vaccination in HIV-1-infected children after immune reconstitution. AIDS 2006; 20:2321.",
"     </a>",
"    </li>",
"    <li>",
"     American Academy of Pediatrics. Committee on Infectious Diseases. Varicella vaccine update. Pediatrics 2000; 105:136. (Updated May 16, 2006).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/26/37289/abstract/20\">",
"      Levin MJ, Gershon AA, Weinberg A, et al. Immunization of HIV-infected children with varicella vaccine. J Pediatr 2001; 139:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/26/37289/abstract/21\">",
"      Levin MJ, Gershon AA, Weinberg A, et al. Administration of live varicella vaccine to HIV-infected children with current or past significant depression of CD4(+) T cells. J Infect Dis 2006; 194:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/26/37289/abstract/22\">",
"      Johnson CE, Shurin PA, Fattlar D, et al. Live attenuated varicella vaccine in healthy 12- to 24-month-old children. Pediatrics 1988; 81:512.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/26/37289/abstract/23\">",
"      White CJ, Kuter BJ, Hildebrand CS, et al. Varicella vaccine (VARIVAX) in healthy children and adolescents: results from clinical trials, 1987 to 1989. Pediatrics 1991; 87:604.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/26/37289/abstract/24\">",
"      Gershon AA, Steinberg SP, LaRussa P, et al. Immunization of healthy adults with live attenuated varicella vaccine. J Infect Dis 1988; 158:132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/26/37289/abstract/25\">",
"      Kuter BJ, Weibel RE, Guess HA, et al. Oka/Merck varicella vaccine in healthy children: final report of a 2-year efficacy study and 7-year follow-up studies. Vaccine 1991; 9:643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/26/37289/abstract/26\">",
"      V&aacute;zquez M, LaRussa PS, Gershon AA, et al. The effectiveness of the varicella vaccine in clinical practice. N Engl J Med 2001; 344:955.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/26/37289/abstract/27\">",
"      Sadzot-Delvaux C, Rentier B, Wutzler P, et al. Varicella vaccination in Japan, South Korea, and Europe. J Infect Dis 2008; 197 Suppl 2:S185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/26/37289/abstract/28\">",
"      Macartney KK, Burgess MA. Varicella vaccination in Australia and New Zealand. J Infect Dis 2008; 197 Suppl 2:S191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/26/37289/abstract/29\">",
"      Asano Y. Varicella vaccine: the Japanese experience. J Infect Dis 1996; 174 Suppl 3:S310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/26/37289/abstract/30\">",
"      Verstraeten T, Jumaan AO, Mullooly JP, et al. A retrospective cohort study of the association of varicella vaccine failure with asthma, steroid use, age at vaccination, and measles-mumps-rubella vaccination. Pediatrics 2003; 112:e98.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/26/37289/abstract/31\">",
"      Watson BM, Piercy SA, Plotkin SA, Starr SE. Modified chickenpox in children immunized with the Oka/Merck varicella vaccine. Pediatrics 1993; 91:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/26/37289/abstract/32\">",
"      White CJ, Kuter BJ, Ngai A, et al. Modified cases of chickenpox after varicella vaccination: correlation of protection with antibody response. Pediatr Infect Dis J 1992; 11:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/26/37289/abstract/33\">",
"      Clements DA. Modified varicella-like syndrome. Infect Dis Clin North Am 1996; 10:617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/26/37289/abstract/34\">",
"      Gould PL, Leung J, Scott C, et al. An outbreak of varicella in elementary school children with two-dose varicella vaccine recipients--Arkansas, 2006. Pediatr Infect Dis J 2009; 28:678.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/26/37289/abstract/35\">",
"      Shapiro ED. Second dose of varicella vaccine for children: are we giving it too late? J Infect Dis 2008; 197:935.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/26/37289/abstract/36\">",
"      Michalik DE, Steinberg SP, Larussa PS, et al. Primary vaccine failure after 1 dose of varicella vaccine in healthy children. J Infect Dis 2008; 197:944.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/26/37289/abstract/37\">",
"      Marin M, Watson TL, Chaves SS, et al. Varicella among adults: data from an active surveillance project, 1995-2005. J Infect Dis 2008; 197 Suppl 2:S94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/26/37289/abstract/38\">",
"      Salzman MB, Garcia C. Postexposure varicella vaccination in siblings of children with active varicella. Pediatr Infect Dis J 1998; 17:256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/26/37289/abstract/39\">",
"      Black S, Ray P, Shinefield H, et al. Lack of association between age at varicella vaccination and risk of breakthrough varicella, within the Northern California Kaiser Permanente Medical Care Program. J Infect Dis 2008; 197 Suppl 2:S139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/26/37289/abstract/40\">",
"      V&aacute;zquez M, LaRussa PS, Gershon AA, et al. Effectiveness over time of varicella vaccine. JAMA 2004; 291:851.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/26/37289/abstract/41\">",
"      V&aacute;zquez M, Shapiro ED. Varicella vaccine and infection with varicella-zoster virus. N Engl J Med 2005; 352:439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/26/37289/abstract/42\">",
"      Macartney K, McIntyre P. Vaccines for post-exposure prophylaxis against varicella (chickenpox) in children and adults. Cochrane Database Syst Rev 2008; :CD001833.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/26/37289/abstract/43\">",
"      Seward JF, Zhang JX, Maupin TJ, et al. Contagiousness of varicella in vaccinated cases: a household contact study. JAMA 2004; 292:704.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/26/37289/abstract/44\">",
"      Tugwell BD, Lee LE, Gillette H, et al. Chickenpox outbreak in a highly vaccinated school population. Pediatrics 2004; 113:455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/26/37289/abstract/45\">",
"      Lee BR, Feaver SL, Miller CA, et al. An elementary school outbreak of varicella attributed to vaccine failure: policy implications. J Infect Dis 2004; 190:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/26/37289/abstract/46\">",
"      Chaves SS, Gargiullo P, Zhang JX, et al. Loss of vaccine-induced immunity to varicella over time. N Engl J Med 2007; 356:1121.",
"     </a>",
"    </li>",
"    <li>",
"     American Academy of Pediatrics Committee on Infectious Diseases. Prevention of varicella: Recommendations for use of varicella vaccines in children, including a recommendation for a routine two-dose varicalla immunization schedule. American Academy of Pediatrics Policy statement. aapredbook.aappublications.org/news/Varicella-040907.pdf (Accessed on April 16, 2007).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/26/37289/abstract/48\">",
"      Shinefield HR, Black S, Kuter BJ. Varicella immunogenicity with 1- and 2-dose regimens of measles-mumps-rubella-varicella vaccine. J Infect Dis 2008; 197 Suppl 2:S152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/26/37289/abstract/49\">",
"      Kamboj M, Sepkowitz KA. Risk of transmission associated with live attenuated vaccines given to healthy persons caring for or residing with an immunocompromised patient. Infect Control Hosp Epidemiol 2007; 28:702.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/26/37289/abstract/50\">",
"      Salzman MB, Sharrar RG, Steinberg S, LaRussa P. Transmission of varicella-vaccine virus from a healthy 12-month-old child to his pregnant mother. J Pediatr 1997; 131:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/26/37289/abstract/51\">",
"      LaRussa P, Steinberg S, Meurice F, Gershon A. Transmission of vaccine strain varicella-zoster virus from a healthy adult with vaccine-associated rash to susceptible household contacts. J Infect Dis 1997; 176:1072.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/26/37289/abstract/52\">",
"      Kappagoda C, Shaw P, Burgess M, et al. Varicella vaccine in non-immune household contacts of children with cancer or leukaemia. J Paediatr Child Health 1999; 35:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/26/37289/abstract/53\">",
"      Tsolia M, Gershon AA, Steinberg SP, Gelb L. Live attenuated varicella vaccine: evidence that the virus is attenuated and the importance of skin lesions in transmission of varicella-zoster virus. National Institute of Allergy and Infectious Diseases Varicella Vaccine Collaborative Study Group. J Pediatr 1990; 116:184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/26/37289/abstract/54\">",
"      Galea SA, Sweet A, Beninger P, et al. The safety profile of varicella vaccine: a 10-year review. J Infect Dis 2008; 197 Suppl 2:S165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/26/37289/abstract/55\">",
"      Chaves SS, Haber P, Walton K, et al. Safety of varicella vaccine after licensure in the United States: experience from reports to the vaccine adverse event reporting system, 1995-2005. J Infect Dis 2008; 197 Suppl 2:S170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/26/37289/abstract/56\">",
"      Weibel RE, Neff BJ, Kuter BJ, et al. Live attenuated varicella virus vaccine. Efficacy trial in healthy children. N Engl J Med 1984; 310:1409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/26/37289/abstract/57\">",
"      Centers for Disease Control and Prevention (CDC), Advisory Committee on Immunization Practices (ACIP). Update: recommendations from the Advisory Committee on Immunization Practices (ACIP) regarding administration of combination MMRV vaccine. MMWR Morb Mortal Wkly Rep 2008; 57:258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/26/37289/abstract/58\">",
"      Levin MJ, DeBiasi RL, Bostik V, Schmid DS. Herpes zoster with skin lesions and meningitis caused by 2 different genotypes of the Oka varicella-zoster virus vaccine. J Infect Dis 2008; 198:1444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/26/37289/abstract/59\">",
"      Reynolds MA, Chaves SS, Harpaz R, et al. The impact of the varicella vaccination program on herpes zoster epidemiology in the United States: a review. J Infect Dis 2008; 197 Suppl 2:S224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/26/37289/abstract/60\">",
"      Gonzales JA, Levison AL, Stewart JM, et al. Retinal necrosis following varicella-zoster vaccination. Arch Ophthalmol 2012; 130:1355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/26/37289/abstract/61\">",
"      Lopez AS, Kolasa MS, Seward JF. Status of school entry requirements for varicella vaccination and vaccination coverage 11 years after implementation of the varicella vaccination program. J Infect Dis 2008; 197 Suppl 2:S76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/26/37289/abstract/62\">",
"      Centers for Disease Control and Prevention (CDC). Varicella-related deaths among children--United States, 1997. MMWR Morb Mortal Wkly Rep 1998; 47:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/26/37289/abstract/63\">",
"      Zhou F, Harpaz R, Jumaan AO, et al. Impact of varicella vaccination on health care utilization. JAMA 2005; 294:797.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/26/37289/abstract/64\">",
"      Reynolds MA, Watson BM, Plott-Adams KK, et al. Epidemiology of varicella hospitalizations in the United States, 1995-2005. J Infect Dis 2008; 197 Suppl 2:S120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/26/37289/abstract/65\">",
"      Zhou F, Ortega-Sanchez IR, Guris D, et al. An economic analysis of the universal varicella vaccination program in the United States. J Infect Dis 2008; 197 Suppl 2:S156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/26/37289/abstract/66\">",
"      Lee GM. Varicella vaccination in adults: is it cost-effective? Clin Infect Dis 2007; 44:1049.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/26/37289/abstract/67\">",
"      Kjersem H, Jepsen S. Varicella among immigrants from the tropics, a health problem. Scand J Soc Med 1990; 18:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/26/37289/abstract/68\">",
"      Centers for Disease Control and Prevention (CDC). Varicella outbreaks among Mexican adults--Alabama, 2000. MMWR Morb Mortal Wkly Rep 2000; 49:735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/26/37289/abstract/69\">",
"      Merrett P, Schwartzman K, Rivest P, Greenaway C. Strategies to prevent varicella among newly arrived adult immigrants and refugees: a cost-effectiveness analysis. Clin Infect Dis 2007; 44:1040.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8275 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-122.72.76.133-5682FA82D5-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_26_37289=[""].join("\n");
var outline_f36_26_37289=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H35\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      VACCINE FORMULATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      EVIDENCE OF IMMUNITY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      VACCINE RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Adolescents and adults",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Pregnancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Immunosuppressed hosts",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Children with leukemia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - HIV-infected children",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - HIV-infected adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      EFFICACY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Outside the United States",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Within the United States",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      BREAKTHROUGH VARICELLA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Definition",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Primary vaccine failure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Waning of immunity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Secondary attack rates",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      TRANSMISSION OF VACCINE VIRUS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      From healthy individuals to immunosuppressed hosts",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      From immunosuppressed hosts to healthy contacts",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      ADVERSE EVENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Injection site reactions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Rash",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Febrile seizures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Disseminated vaccine virus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Meningitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      RISK OF VACCINE-ASSOCIATED ZOSTER",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      VACCINE PROGRAMS IN THE UNITED STATES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Impact on health care utilization",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Vaccination strategies and cost-effectiveness",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      ZOSTER VACCINE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/8275\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/8275|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?7/35/7741\" title=\"table 1\">",
"      Use of the varicella vaccine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?34/59/35773\" title=\"table 2\">",
"      1996 1999 2007 recs ACIP",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/44/33480?source=related_link\">",
"      Clinical features of varicella-zoster virus infection: Chickenpox",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/20/2378?source=related_link\">",
"      Clinical manifestations of varicella-zoster virus infection: Herpes zoster",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/8/23688?source=related_link\">",
"      Epidemiology and pathogenesis of varicella-zoster virus infection: Herpes zoster",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?26/57/27538?source=related_link\">",
"      Patient information: Chickenpox (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?2/40/2691?source=related_link\">",
"      Patient information: Chickenpox prevention and treatment (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?27/22/28003?source=related_link\">",
"      Patient information: Vaccines for babies and children age 0 to 6 years (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?41/36/42566?source=related_link\">",
"      Patient information: Vaccines for infants and children age 0 to 6 years (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?17/42/18084?source=related_link\">",
"      Patient information: Why does my child need vaccines? (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/3/41016?source=related_link\">",
"      Post-exposure prophylaxis against varicella-zoster virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/22/36200?source=related_link\">",
"      Prevention of varicella-zoster virus infection: Herpes zoster",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/11/4278?source=related_link\">",
"      Varicella-zoster infection in the newborn",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/28/33225?source=related_link\">",
"      Varicella-zoster virus infection in pregnancy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f36_26_37290="Female pattern hair loss 1";
var content_f36_26_37290=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F87193%7EDERM%2F87194%7EDERM%2F87195&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F87193%7EDERM%2F87194%7EDERM%2F87195&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Female pattern hair loss",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAF6AfgDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5spRSUoFMYtFFFACGkp1IaAEooooAM0UdKVF3HikBf02Lcw9q7TS4sKtc5pEPI4rr7BcAHFWS2bFmuFGatNIqjrVHzAEyOoqrc38cWd7AUnoKxoyTt2OKha8SFS0jfrXK6h4iVAyxde2K5m81W4uWO9yAe1TcpRO3v/E0UOVQ7mArm73X7iYHL4U9hWFuIG5zmombceaW+5aSRPNcyStl2JqHdk0wZJp4AHuTQV6CnkAGkwKmWLMZZuParFlaGYg7Tj2pNjSuVEjZjhQc1bFoUXdICK6Ox0jaN7ABRzzUElr9vuWVTtt4z8x9ahyNFEoaNppu7gO/EQ5+tdK91DbMkUKgbQTx7CoJriO2QQ2gz24FVY4drSz3XGEIxnpRzDsZlzLdXYLljs7VQdQoKryT1PpV25lMibYsrGD2NZ87gfIh6daaJZHI+FCKSR396artHkq2GYYOPSmpy/HbnmnRxNK3y8L3NUSCfMAFGfYVYFsVUFh17VZgEcEe4MMevc1BcXW5iVNIdu5A+1SeOahL+vNIzZHJpoyadiWwJwc96cj4OSNx7UBfUVPCAg3OuQO1FwRCELHLn8BUyKQuUwvvTJJlOSBgmomldhjPFA7pFgSIhJbljUDyM7Z6Co9uRyaeCBgdqLCvcF6mlYZxjihmHRaQgsoYH2oC6JVRRHvZh6YpvmADgUwAZ6jNTRKnc7ee/SgfoRYZj1qzFGqDL9aE4dkiG73pShX75z7CpbKSJC3GEWm4c9TUiJkBgCB6VZmWMKp2kNik2WkVY0B+8Mip1RC2D0qBJvLkOEB+tSNcxsQNpU+oqWmx6D5QIxlOaiRi9TlGeLOcr61FGhGcEYFIAII70oiYnLE4NKibm4596tmHYAGPJ6UXCzFt4lcDPQHpWhK9sqjYnzgdPeoC0VuibcO/fHaqzS/MWx1PT0qR2JGZ5ZMtwOlWAyImFGWqqZQTTTKAcd/alYosl2dTntVeRicjtQJyDxTCxc8CgBCqjtT4xz7UCJs/NxS8KKAJ1bAoqAyDFFAzlqWkpa7DzxaKQ0ZoADSUUUAFFFFIBBVmzTc/tVYc1qadGMjNNIDoNJhwQT0roIHWJMuawreRIkAYgAVn6rrJkDRwHA9qpsSjc2tU1tIgVQ5fHauUvNRmuGYuxwe1U3kLksxyTUZJrPctKwMxY05OOtJxihjgY9aLDEY5b2ox3pUXuaXq2B1oHYYOtWraHnzWHyCm21uZptoB2jkmtvS9Okv7pURf3KdT2pNlxiQWtjLeMDtITtXWabpXlRqABtxzmrJthbiKKMYPfFQa7qYs4hb2/M7jHHas27miRU1m/USG1tuFX7xqlDBczxkWwwD1punabNPcbpA3JyxroL69ttKtBHDgyt972pWC9jLeFNMt/MmOZyO/P41iXl/51vKQSFJCj3qLVr57uXexOMcA1TTLRxlxwSSBVJEtkkr7bcdhmqLPkk9aluZN5CryoOKZGoznHA/WqJuPhiXAL9+ijqaSWXnH3Yx0AFDMS/ueM1G5C570xDpGONx79BUDZY9acAWGP1q2lqPLDyfIv6tRsFrlNUzUuwIOeDTzsQktx6LUDyFmzQJaD2YY+XimPIXwKZk0E46UxNgw980cDrRmkPWixNwJB6LRjNL9KOB9aLDEHNWFTbxLlVYcVHG2wg9SKWR3mfc7Z4/KhlIVVGeeAOKmCAEZOf8AZFPt4GueEHzjqPWt+x0Blj82chVPrUNlqJlw2/m4CptB44q0bXyRgqM/rV6VY4pkW1y5747Vr2lpAiBphvc8movc1SOUZJCCMEL6UwQeYMF+R29K6e/tvMbMeI1x0x1rAlR4nztyO+KV2U0ilJC0W7bgk1SwQ53cHrWlJMgYcHPpilghM8qqsZJPbFVcykr7FO3ed/3cWME4rSS0EW8zOGYdh0p80aWvyv8AK391Rk1bj1DFoI1gSMAfePU0m7lJW3JILO0Nt5lzdJEvUKvU1Vub6JrXykj+VTxJ3xVSSWEoQVBOetQGdVXAAx6GiwicTLtOOPc96ZuJ9s9zTY5UYYJHFEuXI2YxSGTRR85d8j61NJFCseY5dzelVFQ/xZqaMBRwOfekNIlSIFT8uTT4uD0xUQdugXrT3DqOaRQsjbhUDdadtYnmggZxQFiL+KinHgE9qKLglY5ylpKXtXWcAGkoooAKKKKACkPWloxSAdGMsPStKCQRjOeB0rOj4NPJJ7nFO47XLdxePLkAkKaqHnjtSUp6cVJaVgzxTRThQpGcGgVhp460qruPNSiFnGVIPtViCEgkuMAUrlRRFtAU56VHtIO0DLNwParMyBRxVnRbXz7hpWHCdAaVyrdDQs7VhbR2sK/vH+8RXbabpy2FoI0++QMmqXh+y8rdcyjLt932FWdQvDFHJhsFupqGaWKupXsdtlVO+XoPrVDStNEsrT3bbpG5x1p9jatKxnmBLk/J7V0NtbJZWxncc+9ICjeXCWlsUgABxya4fULjz5GUsSF+Ymt3xJqCxhlTBkfr7CuXLYhLnlmOAKpITIP9a2cY7n2qzL+5hRcfO6cewqW3iGwlgM45FLcR75y3bAAH4VRJR2YjUYwW5pXAAwB7Zq3OhU5PXGAvcVWm/djJHOOKYis3yMoPJpirvYk9PWrFvB5zlmO1V5JPerdrB58m7YPKHIH9TQFiCCNQnmP0XoP6024nLNuOcdqnunByqgeUp7dWP+FU5Vb77kc9qQMhbLtuNB6dBTs5NNxk0yGMoxmpAnNPKYGewouHKQhTnmg+lPx60BT+FO47EfQ4pcZ609VHU8/TpTlO44QYPrRcLDFQk8A1dsbGa7k8uNCfXHanWFs91cLCuXY8BR0H1r0HwtoCQZa4fGTjaowKhs0jEj0DSLfT4Q7xNNOeOB92rGtxSiLa+wE87AecVv6le2+l2x8oLkcAY5JrkpZGnuTJcBpbg8qi9FqGy0jFd5IsCEHnjgYoVZFLNM2B1wT1rZu5IYDlkMlzj8BXPXLS3NwTNhFB7VJZPcXTFAvzIi+p61QkkJP7p2ye9OmRrlmYsI0UYVfWqjSiMEIcHuaaXYls0bGWONiLxspgnkZqePUYnUxWSiCXt/tfQ1iRqZOS21eu5qY0hKFYxnH8QFVykXLzTzJMN+0OnJBHNV7i4uLyTO0n6DgUkUZuFxdE5/hkP9af9qe3/dRDJHtR6B6kPkMGIdefrThBHzk49hSu8kp5V1Pfikw8YGRkN0osxkqiJVwFz706KZcfd6UkNtJIpYLgVMbby4gzkc+lIeognDKRtINIs5XjFGfl27fxpBHzyDj61Fy0Sic5FK9wc4IpCg4wKHjJI4pDsAnGelNkkycqKVomUZ2mpYYCy56UAVxuYcjAoq4ls5PJ+WigLnJCg0lFdh54UUUUAFFFFFwCiinqKQ0rgBinDk0hHvUoAxikWlYQjjikAp+CADxSgdSaBjGx2pgB3cdacMZOelLGuSMHvQBctIMpv5HpVzblVUjjNKoC20YX1qaciG3BY9O9Rc0SsZl4N0ixr1zXYaLpaQ20Q6k8tXNaTB9quw56AivSLWELCHbAUjjFFwSvqN/1KnnCgcZ7VkwW7Xl0DJ9wHd9a0rgq2Y26Hk/SrVlbBbffjAxxUssIIVTJwCO1ZniTUTFCinGDnCitG/vEs7ZgSN+M/SuBu5nu2MshJdj8ooRJm3MpkmZ5MtnsatC2It7dyADt3D3NQyx7ckj5ia17t8vBBEMyeUqkAcDirQnuVdNtmlm55XOT9KsTQxK/mHt82K17bbaabJCQMnl3xyMdhWRc7SgI4eToPRaYIzGJaR2bJPoOwqtDDJdTYXnJ5J6CtK2s5Zz5USku7dfQetaK2McYMERJCj5j/eNILGVb2jTypEgARRye1TX0kcKtBD91eGcdz6fSta4jSxs2HSZx0H8Nc3MysGYdDwvv6mgNiq75OR90dKgJLHnn61KVMjYXp7VLHAd33TxQSVtm5eh/HvTxAxYALk+ntWlDbGTOBk9z2FX4LDahZFO0cbqLgkYywiNSSMv1qB0Z36cVtXFuyjEihGPTJAJqjPGqDb5i5x9cUDaKbBVPZm9ugpqxPIefu1bhtDLgrnaenHWkuZEiLRR5ZxwT2FK4WKrr/wABTp7mpYYnkARBgZ4A6miKHfggFmPvXYeH9GGze/ynGST/AAilKQ1ENC0w2Y8zbmX0HvXREPb24aabDkcInJz70tuIoQFgKvIegPX/AOtSXSFJQ+5Wfsq8KtQ2aJE1rYRx2D3t825jzukONo9hWPFcTu8osYkRW/5auORUtzIJJR9qlMijnGflHsBWPqWrmRnjtsJEv3m9aNx2IL2UK7QxMZXY/M/rUEZEW83DhIwuMN1plu/lKJm4P8Of51SlDXtw2C0hPO49KBXGT3GUK24AB/M1VSBi26VDt7g8Zq64S1B80jd2HeqFzdtckDogq4kSJWiadsyMERei5p8FrKoLhkCjuTVe1TzmAVcjOOvX6U/UfMhZY5RsAHCj+tU9SSa53PGqlgwHQk4Wo49zfK0yBh3BqmZHAG/lfQ0xHKsWxg+lFg5jbto1dCqOGc9SM1MsEhi3ByAODkZFM0tAhQ5wHHSt0xhoXTbx7VlJ2NorQ5i4kYMY2JRfVelVXMqbVZiU7EdDV/U12P06iqMLqspjfmMnn296takS0ZpWEYkHzfdqaa3kgbbjIPINRaZiK58pj8p6H1FdI1qXTb1FQ97FJ6HN5YdjU6OXUHGCOK0ZbMgkEjdVPySjnI4qWh3AP5g21PFAQuev0qCNNj1fSQKvWixLZBKCF+UYoqdnVs4oosK557RRRXWcgUUUUAFFKOaXGKQCAc0/pmkWloKQJyealA3NimxDmrNvFvlUCkWhhTGR6U1jgYrRuoPLIB9M1nSD5qQyLGT7VoWUG84Az71TQZIFdDpkW2Nj6DNARIGQ740z3qK/3OhUnC5rQaA+ehxhsZFUrpGnvFU8ktgVCNHsa/hiwLIHAwM12xV0hVcAnGay/Dtt9nhQt0HWtNfn3MAfnPPsKljSI4IDKQxXOTxjua0tS2wwR+b8iLyc8Zq3pMEUEKzzAgLzzXL+KdU+1O8gP7lDwM9TSA53Wrp7+7CAkID+lUZlCSMEx0OPYVMVKJ5rDMsnX2FVvKkk+UcgnLH1qkguR2iG5uRx+74wK3orffdy3BBHPygdscVVtIxDiL+L7z+wrSL+WG2HnNaWIYy8QTiG2i+bn5qqXNugmYBTtHGfX2rXtI1jjeRMBz9360sUQAjAwzx5Z2PTdQBQijktoxFCpE8oy7Y6CrVrp6xwNI5wkY3M3941px2yQR+bM26RuSO49qy/EuogWIiiAAc/dH9aljOc1RvOKBC37+RsE/3R3rNuI1aXESnb91ffHetqK280CSPJKoIlye56kUWliJrwBQSi8KB3NMRn2tk2zdjaPXFXVsi7BEJGR09PeumaxWNVQgBlAJH9Ks29iIovMZNxbtigZjW9ssUGxY1HGSTzxVS9u1K8N8i8KuMD6n1rW1MlF8oYU5z9feueuAZHDOcxj7ox1pXGilMjOoPV35z7Uyys3upQFB2A960LOzkv7kqgIUn52HT6VoarLBpdmbe25dsYYdaBmJqdwltG9tbHLnh3Hb2FZ9nZmQb3/wBWv3iaks4muJj5uducnFdHpOmS6jcCOBMQqcnHepcraAl1KmmW6IwkZc5GQCK6ix0i+vcNJ+6jPOCeQPetSHR44pI0hUST8Fz1x6CurtdMxFuuWz/ExY4ArPcZgWOlW5lENu22NRmWc9/YVQ1S5soPMW3iLxL8ufWrfiHV4Y98Ni25F4J6fU1wGp6nJdqUX5YRwNvc0yxmp3zXE3lhsIOTt4x7VmGZAwbbnHIX0+tKqSTNtRCV9BWnp2kK6EyPtIJLf7IoQmZyW8uoEtMx5OFRRwBVi4+z6ehLncE4VBwT71e1HV7fS9ONtp4Dzv1cjO2uPlled2eU7mNWlchysTTu947zyMiBeg7mq3UjHC0h+blvoK0bC0lkKtsG1jtyRV6Iztdl/QrM3dxAm3CMc8elP8XwRDVAkIwEUDnvXQeHLUWsM9yRny8xp9e9cxqcsdxdSSSktcB8e2Km5djNlT98qAbiBk1XZW25AyM4q/Gv+kSOTzjtVS33NM8R6ScD6jpVITVjfsVUWKSn5jHxW5ZnzrZpeqkVkaYVNjMoXt+taekMf7KccgLxmsZas1T0Oe1/KyAk9DWTJ8zhjxmrWtTGa4JOeO1Q3ETIiAAkkDtWsFZGc3qT20mUQj76Hr7V3ejFZ4kyd2RXnVsdre/Tiu08G3BbKbhuBzUTKgzdubIbcqORVCS0yCNtdSyB8AYJ71VuLEk5UVKZbVzkZYCpwRxUBBAINdLc2+VIK4NZFxB8/SrtcyehkO7K3WirF3a55XNFSUrHCUUo60Guk4xKKKUDNACrxzSjrzxR2xS96QwxijvQetKBlqRSJ4E3E4rR0wbLkE8jNVbFMyjHQ1tW0ISVzjqKlstEOqfNLwMDFYsi8k1tXrbskdcYrM8oMwFJMbQlpF5koxwPWulFv5aps5DcE1iWClZ1BHGRXTDConGccmh6DRVuiWuOM4wFHtTLW0J1uGMjKjnircEIebeRlS1bOhWwk8RsAOF5qehRtW0CwwMjjqdwrRsNPaRncgKm3OPah4QykjP3h/Ot2RUhs9oODjGakpI5DWrt5Lny1G2FF6ds1yWo7JLpYwfkB3Ef3j6V0eqNjepxwSzmuYZdzSTcjP3BVRBlR1eW4ZFJwTj6Cr8MCRKNwIx29cVPZQLFFvc8Hj8alCh4Xds7M7c9/wAKtIzb1IrK287fI5QKWAYk4zTzGiPvOeSPl/lT7EbFZnU4XJAHTNTWdv5t0SwIVDu696bYFgKAGV/ljiXr6tQkoSHdgM+flU9Paor9vMmjijAEKH5s/wARqjLKz5aJdvOBnsO+KlsdixLOpkCq5kk/jc8c+mK567d77UNi8AHArdSHbamRe/G49WP+FU9Et1Ml3dMMrGMIfc0IC15YjhEMA5I2Bj6Vr6bYLaorMFMgHOe3pUVhbbj5rDOMAE9jW9plnvkdn/hGM9/c0vUEJaWPmyqCRuBy7ehqPUZDKTBCNiLwDj7xrRvbhEi8mE4AGTjrmqMcLIyu5zIecegp7jsYFxbBEczHk53fSsaS3a5mEcC4HRRjoPWum1fYXKk5jX5mx1Y+lS2NrHaxtLKR5zLuJ9PYUmBjzQRaZZHooA545NcfclrqRpTypOdtbeu3Ml/dCI4EQ7D0qtBahZgHXZHGu8jufQVLY7DtL07DwxFfmkOWHtXf6ZDDaW6QREKCckjqfc+1Yehwhi00qlnbkKOwraSORyMEgHggDj86Q7mgNQtrJQIASM5LHguf6Vha54onmifoIR91BwP/AK9N1Vzu8pAqjHzMBnj0rnTA17c7IwzqvT3pMpEMaXepFi7BIzyRjAqvPbxxzRxW/wC+BHYY5rbuDJDCIUGJCMHHYVQhlFrDJJCAHkXarMOnvSGOaAW0McVsMv1dR1H1NZWqah9lg8gPlySSg9T6mn3eqGzsjHAV3yEl3PWuXcO773LHJySe9XFXJk7DXd5pCzYJ9qRxzgGnkYOEFIsZMm08n0FabGVmWNLtDe3yRgfJnJx6Cu60q0juHjUr5dtGS2D396zvCtqsavlSrS/IPYd66a7VbezmC5UEBFHGTWblcuKsUNQu4rDTvJhTeXJckcYrjZYSWwqbWyBzxXTa6v2XSJC4AncgL6ha5nTYZbuUGQFtql+TQhhNbwRspe4Vmc8rGM9KpeWkN2u6JyGYEbmp80DtBvCsRnOeg605pBc3pllYfJhgqcjAFWiXqbemSoYywjUDcfkzV6OMw6ZLub7z5G30qro8DsiOUCooLHd3qS8uVSKfcRtHAx2JrJ6Ms5O+y10QuWqGWRs7cnI4qdo5I7k+ZkfxZHQioF+eZi/fvWyM5asbFlWGc9e9bXh27+y6jjPcj6isdyzS5JFSQPsuww4yaUldCWjPYtIuBMoatpogyg965PQgwsklQ5GMkV0dvchkUdDWB0FO/tmzkdDWReW23Leldb5QlwewqhqFpmMlRzVxZEkce+CcGipZ4tsrKww1FaWuQjyyg0lKK1OUSnCm0uKAHZ60UhFCdaQxT1p6jnNNNSx8ikVE0tKwblVbgHpW95TrcqOoIrnbUHKkdu4rp7di0cLg528H1qWi0UL+3KOCPun1qjFFmbBFdHd25kCjHvms6O1K3AUjPNTsWVIIttyvB6iugiDecSy9sYFZqxlbocZwa3kQ+eGI+VsUmBDp6FS4PQNwK2/DeF8QSM3QjFU4YPKu3AGQTWv4Qi87WPmA6ZNIZ1cMYJkXAAQbiahvLlFsfNz87cKPep79mtkYZAVzkGue3tMrPKSsa52CkUcxrFyTujXqTyf71UY1LTBGX5QOlWNRO64Y4HDcfQCksOI3dvvnOParSIbuOWMupEhCqvGB+dTzkgRRr93rgD2pGRmTGQu5QWPpU9vteXaoJk2nA9u1XcRAsX8Axk4J9ia2kjKKFjKlznn0qCG1Bm+YZdWBP5VuQ2QWAzSYzg8HuKhspI5eeBnkRVTkZwPX3qNrVTMtuWwFxvYevpW5grJLMWw7qe3QZ4FZtvGAhfqCxyT1JpICHVl2WTNHtI5VcdDVe1KpYxQKMjO5wO57fhUutBohAoPy7QSvYGk0u3b5WIbe/KD1qxI2mUo8EKLyPncn1PStKa5FtaHZjPrjlj/hUSxQ2YDTv5lxJ82O1VZ1a4lLkERjgLjqazbKQsCq0SsA3mM+ef51duRhSSeAML6mltUBb5wdq4GB3an+Xl8ycBThF9KE9AsZsdoy/vJBls5H1qjrMpjhI7d/8BXSKheQqv3lGBnoPeudvrf7VduDnyYzhSRwT3oA5yyi2b5pQWYdscEnoBVu3s9x3vueR2+bHIJ9q1WsvOmgtUGFzzjsPet/TdNiimEjJuWIYAApAR6ZZeSuGQj5RkKOT9fanzzgDyreMsGOM+taRkzbMEVkyfujjcfQmsK+WWaU28L7WP3yo+6vfFAzJuFS5uvIjfcAf3so6D2FSssFqjYPlQqMKg+8/wCNazW9vpVqF6yuMgEdB6/Wud1BmupkxlUBJPPJ9foKTKTKzsU3ybQZJOcdlUetc/qt2GypIeY+nQewFXJvOvP3MHzLu6ZOFHvUL28doGcL5shO1Tj7x9vakM52RCZDJcHPfZUYDzPzgDv7VeuIsyMWGX6cdBU9rZ7YxczoGiU4Rem8/wCFWRYom2KdMc9z/D9afbwhGiRVIDNhWPU+9aEsPnMoxiaU/KB0UVteEtIbUL952Tdb24wufWlcdrG9pNn5NupgiDEYRGxySeDTbgJBqTGc7obXt1DSelbmpTJZLtt8AQJx/vGudjbyYBLOhlJzIQ38THvUlHN+LZ5JRsncKXbeTjnHYAVJaosGiKYV/f3J2KGPQetUtSLXU6TXI/eytk+mB2rY06yFxdRFyTHEOnTFVcmxzPiCOVJI0Zvm2jIHT8KbptoPtMcAILS4LHHRf/r1d1xftd9Lcvt8lW2qvYgf0pNMXZGbpwwkZ/lIp3sibXZvK3lwzArmKIqq+pNczrczgGPPLnLgDpW1JO0SkMTiIbv95jXOrBcX1w5iUttBZz6DvUrVlPRDbebZAVdPMtjw395Se61Vktgr5gbzIz0YDn8fepWTEffb2FXtKhkkYOIx8iHOP4vrWjdkTYykHVccjnNQkEOrds1pNFEyMWYpLuI6fKRVe4iYQocZHqKaYmj1HwM32jSccEDitQxlJ8ehrnvho4Ni0YznODXZ3Nt8xcD5RWHU1WxNY4kXI4bPIqaaMemapwEq6kcA1ohtwO7t3qkJs43xHYEEyIKK6XUoRPEVA+bH50VrGRm0fN1LSUtanKKKQdaUUqj5s0MANIOKVqb1FIY4jGDU0Bw/PSmRkNhSaeAFfikWkbllAHHH3TWrZRmKXafu1laTNjCN0rfijfdleU+lJlI01j82JSh5FZ13FsulYdc81pQEIFZfugfOPSmTeXJKF6DtUjKFxb4bzVB6jNdBYxK8K46479qqJGroyDk9609IiDqpJ4U4IpMaYllCWvXDc5XFanhVPL8RMinnaQaXSolTVGUnIJI5qfT42tvEbSKMYOPrUlmn4hUySRxA/X2rCvCYUJb7pXao9a6meLfLMzKC3X865vxSFVrdEHMa5YHjrSQM5CUM10odeCam8lDEQmQ2786kRQ07lhnjK+1PtMmBSenPIrS9kSiK4VhIkbDaT85+laVoFik8zb/q4xj8aWO1E0pzhgFC/jWjDbKLCe6IO/BRR7etQmVYrWEbSSQFVJMspyfWuiitppIpDIRhzj6egqtaQOkOnIi/MSSWI4ya3ZrScrDbxL8pc/MPQULUGc5f28YkVYjuVcIW7Mfasm4tvIhQsw+ZgF9s9TXTapA0btEF2Rx7QD3JNY2qReddQxxBmSE4YerHmjYRzuo4urouQTGGwP5Vd0xZVZZSfuJxn+EVJNEISZWUZ3HkdqtaJaPe2+05EYGMdM8U76DLFpbtdzG5f/V8BTjqKtm3Yuvy/MMhF/qa1rSNU09ZChMY/wBUuOpq/a6cyxPdTSbfMX5mPYd8UrXHc52K0cyK33j0QD19avNZLbxI8hLSNlUA/U1e06MzztNjCk7QfRR3qS4VXv5ZZSTHCB0HT0FIGc3fu1paFF4Zhj3p32MxWMYcANjgZ6570khW6vjNIuArZ/LpVnd9pnVznaOR9KdxENjp4jnUsN00vHyjOK6K+ENhZsuMYHOP61VWf7MC5KtIOAqckE/4VkzLe3sgMxPlA5/3vc0r2AbcXOY2lf5I+ijufpSWuIbUylMMfmJPr6VKLTdmV3QpHwGboPoO9QySGZgzbjCnOCOvufakOxlajI0MDTzhnnk6DPPtj2rLjspJIJ9wZWYYMnoO4rblUXMn2mYZCnEaZxUqWzTJmX93bZyV7tQM5pbeOJAkIMaMMDuT71j38BhlaOM7524Oedgrs74w2cRuGUZIKwRjr/vGucSIQ7ri4/1pXO0ep6UikYws0hjhMwz5nMcefv8AufQVdgsHugyzZ8pDvzjH4UmnW7z3u5QXc9cjp7V0eoRGKMQKwErcNt4xR0FY5JLYSTSshCqpAQetd/pcQ07SBGgG4jzJMdB6fjWNo2kpLdx7cbEbdub+L1P510+o2yjZHzvY/d7/AFNAbmHOjXc4i3fLnzJWPAwP4aZq6iGzkllK75BgZHQVtRQRwlxIoZgcuQevtXN+Kr4tv3KoVD0HXcf4QPagZzEcC3OqI6/NHEPuity8k+x6UxRSNxzgj1qbQ9JxD5knyvIckZ6CmeLsrGkLDYZOMH9KLgcTqBkdEV3BLn5VX+GtHT4y0kEK87DuOelUbO3U6gwkHCnABPeuijs9lpPeAKEB2Kuf1ptiSMjWrjc/lJnYe47mqlolxFBIIX2oWAYZ605ATMS4yq96jvImGEJI3HmhMqwxYZbve5XYnYVtQwNZaVcSceZIAiinxWTRpbxy8A4Y56hankAuXhJyIBkj3xSbBI5ZoWaUxtnPTpRcoyrEkI+bHc1oNKPtcjnHU4NUbpd92gHCrgGqTJkjvPhhEXE6OMkHgD1r0qS13QEHmuI+FSqsUkhwCzHrXobsihgvIPPAqHuUjnHh2xnI6UsTfKQW7dKtSnMTfJ3I571nTOyNjKDP41SZMl1Lcm5o+vI6UVFG7kcfyopknzcBmg+1TRwlz0NXYLEsRkV0s4ygkZI4BzUhTYOetb0OnYjyRism+AWQgVI0UXpgp7c0ymDFqZPpUIPNWI5MfLgYpDiX7GTyiCR0rrdLv1kiCMNrDoa5G2VJWUfdzXQ6ZabJgWyV7EVJojpoYvtKf6s56ZHeomhMMwRxlT0Jq5pm9MkSEAdsVeli+1RkYz/EOKTZRmJuiuVYADA6etaNmCoeVB1+8PSprOIbfLnTJHQ4q1aqI7jOPlY7WBHFS2NBAN1xDJggA54rYmgaLVUlHQ4zmoFtlid42YjIytaMwJtPOyG2L+NIZfgAcSEnpmuB8QTGW+uc/dPyiu0SYLaqVyCyk5rh7ol7xQwy7yE8UrjKbxvCxbjcFAx1q5pltjTnGfmVsdKr3YxcNtyA/wDStLRlCwzo5JGeD6802JIlS38qcDO1dvzH3NbhtwNE2RjkoefWobaxLHMrFvMyR7YFb2nW/wDxK9ozvVAAPrQUN063WbT9PYn7kZUr6Y4rX05d0sruxCIMLVTQ7cxXMsEg6jenvmtOa28lltkJAxl8ULTUTOdvo91y8kgO1RkD6etV47MLGrOoDKpdvdj/APWrp7+3SKKKEoSznBHcjrVae0R3l3g+XGmSq9ST2oQHBXsCbZVBzuY4OO1bXhvTHm0ryY0G6Vwu7PIANRnT3ub/ACy4jydq54x3ro/DyLFcMuGO18KOyj1pp6g0XTZCAqjPuCHGFGef8AKx9bla6lNpC22NuHK9FUdvxrdvpJH3Jb/JK/yqB/Cvqa5+SCQOY4ASN21m9fU/WhscV1Ft2VFIhBwRhfcVT1W5EMZgicYPLY6s1aT7Le0eVhhFG2MVyhDSXPmyBiV5HtUNgkWYF+QPtAVByAeretatnZpZ6WLib/j4uDwn9welUrC1lu7pI1UeQh3HHTPqa6CxiSW5LTFZPKO1SwwM+3rTQMj03RfOjFzcZjg67VGGf/CjVbQb/MlwsYyERen09631WV2UJ8oxkD29aydTQTXUVpYASznqSeAe/wBBT6COckjku1CW6HC8ZxwPwqOfT2jCwIxLHgg9/rXcJYw6ZalCyyXB52L3P+FZKxmO43kK1y3Crjp70krBcwWsLe1jDSENIAAqeh/rUV5GI4g1wSAuBtB5Y+1bN3biKeN5cb2JZT2XHesC+KoxmfgHhd3J/wAmkNGBdRNczvcTD5F+6p/QCsi/TzJNkQ3SMduPU+v0ro3DTD5mxnuOi+9MsdKWe6whI2/M8jdAPSgq4zR9Ojs0MkhwFHJ7/SopoTNdBdpLsSAvf3rblXz5BDbDCodqsegPc1o2mmRWdsXJ/fSdXbkhf6ZpPYEw0a0jtLd7mdAGCiOFP5ml2CKOW4lVmncZOOw7CteO0WRY1QcYAQHpn1ouraGR1hQ4tIv9a2eXb+tOwI5h4/Ismu7jJY8xr7+pFcNeBrrUVQRl2U/XJNd74gfzI5LhhstoRtjU/wATVS8M6dyLh0zK3zKT/e9KkodZWIgKtMPmVeR1x6CuG192m1INKzEBmc/h6V6rq8Een6aWkJDEEnP8TGvK9UWV7eeYkLuPlp7GgSdzF0yA3EisMebcOT9BXT69AlpYpaR5YqATx3qXwxpMZ1IhTk26Abu2T1qfxISkyhMbs85oA5W1sQFCFGyxyQRU1vpazajEW+6h3yEEEDHaugsYRbwXN9MSyRrnDdCao6cp2NhdhmzIR04oBoraqTPc7YX2tJ6joPSku447eDYFZn2bRg1Zt7ZpHkuW+8OFz2FVb+3cK+11jyRh3OAPWkUc28WQSqkHcAfaq6oPtRcglQMVuyfZraD94ZLiTryNqk+/es2ANLJtVUXewAA+tWhPU9S+F8Xk6ZmUDcScEmuxmJRzgnb6KtYvgmFYtPyMA57VuXMhIkP3eMZNSMyGUNgeWxAbJLEc1nXYkLsUjUAcAk1tIFWHOP3kjYGTz+VGqWMUFykE05VAB5zouSh7getCEzBQSI22dyh67duDRVnVIpbfUmSWUzvtUrKT95SPlP5UVZNjxC1suRxW1bWQUfd5qxbQAY4rRiiAXnpW1zgKE0GITjpiuG1A5nbHqa9G1DbHYu3bHSvNLo5lY+ppdSkQioyKkNMqwADBqSJSTgYz71GKkUAgYOD+VALc07ONjjI49q7HR4yVQpyvfNclpqsGXO459Oa7jRCkbAM2B345FQzVbHU6fbiZfmULj14rUhslC/u1Oc+tZ0F5AvfcOx6Vp211/EkZI9RWdykWF04sueA3aklst1vyuVHVh1Wr9vdFowxgOaUJKpLPCQr9eeKQzJk348t2BZR8rDvV3TcXG2PO0kEN6VNPDG8Z/dgSKOD6VlwTS27K205R8kjvRcpK5pTx/wCiRwnIkRipI7iuVuIWWdJCGIyeg75ru7vZPAtzCPm4LA1g3ttsaNCgJSQkkHtSsBgX8JWaRWHyxgZx15q5p8ZRyjABSRU1zAJr2+iXOGVSCexq1aQifTSVJ8yI4Prj1pgb9qiNNDGo5DHB9sVoaWpWZsr8mNp/pVTSWEwjmXggBG/LrWvaQsd6/f8Am/P0p3GS2sL/AGqCUEcc9O1bAtUkmad8ADkj19qpxbhCBCi7ujD+6Ku2sgaMeZ90dc+tCJZnfZ5bvUZnkBCRJhR9aguY2WwZxzJJ8oFau9fOOzlpOp9KoyqDHIpfKIW27fWgEc6kfkXtvjkruVhWjANl48Q+XcANx6Cm2EWXRGBYrk5PvV21ZWaJmQlskHI6kUlqUyW9iWzsnkUhp5fkQetUxpchSKCNyu0ebM/qT6VpTYubkP5RHlnj0q0flV2zmVjuPH6VaSFexz+vWsUdgq7SSoL7T2Hv9a56TSmhgjMxwZDlmHHHXFdTNA88wMu9hI+cHqQP6VV1+LN7bRZDSEE4/hX2qWuo1poZENybeLZAqqzjYp6Bc+talo8aLHbwhHaMEs7nAz/U0/TtMWe9UONqQjqB3781eeyXewRBhm+UAc4HrSWwN6lO4nmmj+zwZxtwz44/Cp9MtjZwnykAcglnJ/zxU0VsI4lWNGklPX0zTJ4pX/dCZDGpJkYHge1AeRViLM0k2d+D94/xH0oURxuxT57h8/NjOB3qC6vDGBHDxH97I6gVWgMqwmRgV3jgk4/AUXCxHdADeZ2AUAbm9fYVg6miyFZJUIVv9XF3x/eP+FXLqYPvlYiRg3yqOrY7n0H86hW1mu99xIQARgE/zpXApCEE7iwUY9OAKvWtkxHkmZQrHe+Dgke/pVuG0jiRdyYQtlM9XPqParSwTSZWGBYkPMkhGWY+ntTYFeyhgD7yDt6Iijk471dgVLq8Bkj3gHKQg9W9T/hU1rZSTuY7YgAfec9B+NdFp9lFY2bEjMj8AfxMe1JK4PQx7syQDa6ESNxkHiqLwsI/9lcjB6A+prcey8zfNcPnaeg+7msbV3McJEI2q3yru7mhlROUnQ6nqghPy20B3Y7MfWus0qyWMGbaFjUcE/0qDRNIZBukXMr/ADDPpWxfgJb7ISPLXhv9o+3tUW6g30Rw/je4achSzbEHAxXHapGIWsNORSZEXzZAf73Wun8QSk6gsZJZU5bHc1gW6tLqMk0pDSSSCNT6GhFWOx8LaYljo3nuuZ5iWPua4TxDIJdTk2nIB2/rzXp2qTLZaLvk4bbsjUetecWVqlxf5ILB2woxzgck02CHauyLpttawAjz+WDelRPGFt5pQDlyIkP6UupObnVpGQbViQIo9KvyRrGsEP3jGN592oGVYbUxxgMfljUlvrWTrAVryOPgpEuW/wB6ujton2ySScqvzsPU9hXO3gDCRz1kbPH1qdRmNeIHkEag7u57E9qfotru1BSRkoeg9asSxCOIuVySe9avhKzElyHPC5zVbCPSNGhW106LIwcZNNlmZyAvQHLE96mOBaoGf5ugHYVHDGXkAYHLfdUdh70DCNFiTc7fvCPxFa01vJfhZ7jSJnkI5ZZQiv7kGqSQ4YEgcdqv6tDFcXDzf2nbpuwSpY/KcdKaJZzGufaDqEguYlhkwBsHIRccAfhRUWpr5U5SOZJhxiRDkEn60VQHnMQ59quRjIxVNTVmA9TmtjzjG8UXDRW5UHrXDync5NdV4rctKAa5OTgke9CLWww9aSg0VQgxTgcHNNpyAnOBQNGhY3skLgodprp7LX5doEqR46ZxzXJ20O4cnPtWpCqgbVQkjuazkaxOts9dJZQ0aEetdBBq2APmwp7A1wll5RbAiye/tWpaxnPETYz1BqCz0XStZgdgJN3H410SatC5VVwwPb0rzjTndWCxqAT1IFbtuhOABKGHU9qQI6yYwzncjqr+gqvBamZyBtY45zVC2MiBQgBY9MitC3nkRhkRbuvFMaLlgRFbmGZCwyQGqe6tEM24D5ZEIpskhldX2tn+JQODWmHV4AVfLAfxdafQl3OfvtPEeoIYhzLFsI9SKdFpxTBiGXYbmHT61uahCJbSKRFYSx4Kmp7e2R9rgZyORmkikY1ra/ZZdq4AAGR2IrWiZ/JVomEYAy2aZfW4GZEGB0K1JGwDbGGFI5BpAXYDlBIhy3fHer8ao8av1XsB3rJiAiyyEhG4x6VpQHyyOxYDC44FNCaHTqZpUVUwufvZ6VBLCsYVVICkn8hWszRwqpZccDJbpmq/loXZ8ZBzjPHHtTtcSZiQCVruUBSFC9qe0YjkiZRtjDcn0zV4QqJZGDY6HioLkApGnByw6DpStYsvRoitkZ6YyalygiDMAMfdz/SoRFuQbuqj8zUlwxkVVKh0XHAHSqWiJZmGR/t5JyyAbj7e1UrhlkuZrmVQJNwVAe2a6GGDMimQrhlyQgx9Kr/Y1aSX+NRgRrjoccmla400Mso9gACnaFyxP8RqWFHmlY4IVuCfarLW5CBFyGABCnkCq003lx7Y2w7cE54X8KOWwtytqVwEkMFoh3Yxxyc1Qv45V0+OAoA7chV7n1NaenIttA9zIGkkbhQR1qvJInnbnc9cyPjIz6D6UWAzbTT4LW3ku9QyIl5CjufWsW/1KS9uDtj2x9EQj7o9MDv610tzaf2vOI3JMSDIUtgD3Pv7U77BBZJ5dqirJ/fA5qWuw763OQgsd8m50d3yWfA43dhVz7LNdMoC7IIQM8/ePv8A4V072jRRrGq4kbOBjPJ71chtLKyjEbsAU+d2b+JqaQuYwUtzbwrcXR3TsuIw4xtHsKnsbf7QyQruOfm9AM9zWraW0mq3jXF2m22QYSMDlvQ5rbgsIo9sduAC/wB7Hf2ppCcrFKx0+MP+6jURL3/vGnXNpJJcAYXGPl56Dua2ZALeMQxLiT0U/pUZtpETbKcs3XjhaqxnzdTl9RVSQqgmNePl4rn2gN3dKWztByq44QDvXV6o0UaNFGQWbl2NYUcUs0RAUqsrbVY9WHsKyaOiL0JrcFkaU5VTwB3Iqh4gulsbRy5USDlQByDWwUESkmTKp8oYjAHpXCeI7n7VcmGN8k53P6Ad6T2COruc1LI0pmll+/jPufQVd0DTzNqFtHKAI4R5z4H3mPSqEcbSXKAjzCDuAHfHTNbljKI7eW4kBG5iTjvjjH0qUaspeOLsyTiG36DIAzwO2ao6fElrBNKuRsj8tST+JNLcb5pvPnAZm+fHp6Ci9GLWO1jY7mG5ivpnmgDOsYmcmZh/rG3jjr6VYZAtyxLE7R27k1aigCqqr1XlvalghGfNKnYTu+uKAEux9ntFhO4yOu5zmufuf9IlWMAeWp9O/eti7lyJZpSMev8AKsu2jkaFn6K3600JlKeNHkCYyo6AGup8PWrAqWAVAOF7Csy2twbiMMADjPTtXVaVbsi8KCzfhTYol+3XzpxuBEa8ZxnJqzGyrI0iHnOM04oYYwCwUe3Wn+Sj4EgO30pFMlgujbs22CKXd3kGQPpTJdTUAk2Vl9SlVbxY1O3CqO3NZEgjkLquRGPvH1PpTJsV9UuRc3bSiOKLIwEjGFHvj1opurw2qDbazGVjjd+7xjjsf0opgeeiplfC1CaAflNbnnHN+JSTMG7Vzcn3jXV+IIS0IbHSuVlHJ4oRSI+opp6040mO9UAp7U+I4NM4NSIOlIpF6CU7gFGPetqwt95BeQce9YUIlAG3qehxWvYQSg5Yb29KiRojdhQL0GQO5FatpN8m3Cp6e9ZFvb3Hl7pQdvoTU8CSNIGYhUHAFQUdNYyRpgm42sewFa63ahfklbHsOtYGlW/mSfKNxPXjpXQIrujCNMKp6nikNFyGZcjaJWPfPFaGn208x3BQg7c81mWCSyEnK7B1J710gtpPJRI5eT6DAFAy9AWghGTjb/FxToUjmk8xVBbPJY/0osNPRg/nOzqOBk9614reOJgFRR7YpiughwkYyMp6GmxohG1BnHYdqrXcu5HUHAJP6VZ06cSQKSBwO1Ax5tDKQNxVQe1Nk06IL8zEoeoLZq65LxEk7C3cdqqb2zg/OE5BoEiAWJ3ARTSKuex/pUioomG64cybsBTwTUtxtXa6S7WXljXOpePJeNIQGRDtU59+TTGlc69xamZz+8kweQWJxSSBSMZfucE9qzlni8xVOPMxvP096uSXZ8s+SEYAfN7fSqvYa7EkChiOeCO/QCnELvw3JBPNVnv4E+djkEfdHUUySUy7ndwqqoJVT1PYGgLamnYyCTKAER+p71MzMGDADYvcdaqQTJ5SZcKCOg7U+CRbuMmLJgVuWA6mmJliLlmkUZ3Hn6e1Wvkg3KP9YMc+1QxSqsRE21QOeuOPeoI5Y2eWRTlTjGc5470GbVyeXIYsqMCcNnNUJIftd15SDG3LO3oPen3OoxwOInYPLg7QBzms4arbW5NvNJiVj87A4Dn6+1JtGkYtouag88abljLkjhQ2Nq1TErlI47jEMjfdXOOPU1a8+Jd8zFhtG4dyfoKcVWQefNskB+YLnJ+n1p7iLFgryW7iArHGnJbGS3oRQ9lucfZisk7AZbOAnuxqO6dxChtR+5CbmLfKfoK1dOmSbSst5Sjo0ec8/WixErrVEdpYeV92bfOfvMRyR7DsKdJYwTHdPs2L8wUjBJ/z2p8aytO9rud/KAZWAG4oatSxytDJKMyGMcxlRwRTsRcj3xQbU8pS0g4Re/8AgKntvLWPGNsmecDt6VWhiin2yLGS0q5TacAY6/lU6eUoYREjB6sfvGgmw+M/MzMFyxyD3/Cm312tvGNnzv0A6/nSSyJEMMQTngKOW9hVNw8Mplm2HK52AkbPqaBpamXf2zSCOF/nknO9yoxgVG6fvAsZOYBtXsBU/wBoFy080gAkbEaKB1HsKy9Um2I0IJjQDGQPmrNmy7Gb4ju4oYXRuSRzg9a5H7P5yPKSy5GAPQVqT24mLySv+6Byu481m6hKZIzFGCjMMc8ACoNY7GNbidUkkChd5Kqe+O5rS8tTbLAudnAc+gp9rFEAGlcBQPkBPU9zillMcUAVmxu5UZxj1zUlXKEyqshIGFHOcc47VFbQj7Q8uSe7D+Qq1Gr3DcKSijO48VLbLHHCSzbY8lmz1NOwXKc/dAQm/wCX6L3NRXjuYvLi59FHU0GWMyySysWUnOF/lVR2e6kO3MUS9Djkn60gZUuGDnyCCEBy2BnJFWFieUAHEar0FTQ26whhgM56nrxVox542DczcA9cUxDtOtEVWkY72Pc9vYV0FlhIA7hQc5yay4rdWkSJPuryxXgE+lasMCFvlLnH48+1S3cqJN5gdwzguR0GO9Bd2zkgHso61KY36bsZp8NqBIpXcWzy1NFPYoTxl8K5CD+I9TWqbKOzku5orNAIwkNsHG7zWPO73qvND8xUAf41buILe3tpgXuHltHQM2/AGeu0dvrVIzZz3iSCOC/dIowmVVmReisRyPzopmvQi3vCiOzoyiRWbqQwyM+9FAHlZpF60h6mkB+atzzyK7hEqlSOK47UrfyZmAH4V3LfMK5nWbV/ML44NC0Gjm2pmanlXacYqLAxVDHRIXbAq9b26lwvLMfSq1upJwOtbdhAzMiR/fc4JqWaI07SKOJEVhlwPyrd0u3jgV5pSHY9Kox26xMEbnHXNWyp25P3R0FSUiaaczNkDCj9akjDSAZBAA602MBlCJ1bAArReHEqwoegANS9CkaeneXa2hYnkjmr1xKVtY1j5Lnk1mXcQWSCA5JbBOKsX04Esap9xOKQzXs2RYxGP4etbrXRit1wBuPFcjZymS6RUOVzya6S2dbq+WJ/uR8/U0ik7HR20xighUjDNjPvUktzl+oBAIFUby5SNw4OAkZwfesjRb57u7UsM4zQ2TbU17yYRwPu6KpLGr2nyiPSbdhjLRjpXParOVs5oyOXYY+mal0+7bybaPqFQ/lii5Vrm7JqH7tQTgntUumXIkh3kEgn5gepFc88iySEA5Gwfz5rS0ZwtoFBJ25APpzQDViTVNQVLO72nnacGub0CR3heSRl8uLDkHuc8UnimXyYpo2Owufm+ntWbZyfYvD4kPzSTZk2/wCz2pdS1sdVYXsV4GkVwkkkhDeyiujtJS1viKMYOfvDt615p4ZMtzJbxDhJD8xHb1r0yOeO2gihQDa3yhj/ADNaRd9yZeRSvnitYwHx+9xuyKqLcKsa20bqwRsyMOpx61S8TXaRWNw7MDIcFAfTNYXh+/33FzPK2MYY85z60XtoGtjqtY1ZDLFEjAAgDae5ro9MvIUtEhUncMKmBwa80huYJZVnmy0275E7KK2n1SVvKVWCxscgr91TjmmmJq+h1soVrr97+8cDOz0+tJqF+q20YbAJJDHHygdhWTpmpia8MFuqSRx8FmPUY5pNZnjhky583AJGOct0AFD0VxWu7MoTXjw3Ia3hLNKQBk4Ln+gpjxtcPJDMUnkYEKig7Y/p/jVe0imuZSgYmZv9ZL2Qf3RXTabapYXQKIGBUqXPGR9aztfc15uXYZ4c0SS2twbiV1lU/wAR3FlB6e1aEkkFksgEQzDJkdy2alXLNGOGf5gVzWFqFw5R3VwiiUBtw6jHSrTsjN3kzZhux5TxXRGXbIO3CnjpmltRFAk6s4VHb93k9D2NZtxIG0yKJwSpAdeeQ3rSaBOZSFlZWYglC3JNPmBxujoxOWu7aa33Ss0TxrtPcc8jvUtve3MRK3IbaT5u5ehHpWBp0Xk6lJMSwZ32oykjBP8AKrQnkkmkCXK/uTv+foxHUGmmZyikzcEjPpga3LBi2QPQ/wBBiiARt5bxrgSKQ6k4zj2rP0jWopr2X7PEYgP9ZC/Tp61DLqrGONnGDBKNw/vIT/SmZ2ZsxWnlyvsXB3ALvJPH9KgubhZnkXG9Y2/1YHUj19akFykZaSRyybgSfT3rHu7lVnjbf5UgB6j7wJ60m7DhG7JxbzRyGeWSOKSTLBQPuCuY1a4SWQwQjdGBmR1Gct6CtW6meZZLhl80A4Jzk4/pWFcXinevkSIi84X5QRUyZtFGLfXkUMG5U3P93HYfSsVHmkzu+V5OTnr9K1L+dJpl2COWQDhR0QetQLfTRrhoWxnlyvJ+ntWTNERLZxqWMxxN0Oe3+FN8iGWbaokIwA75zk+gqd7gyxGO3YCLILN3b6mpbW2mniBtRk9iOg980XAiis5TL5fKRjl8HkCmtZRyShgZDGOXLDAIq+bcQjyp5Rnvg8GkdRMyxrvI68d6AuZVzGjr5ccQVc8sDUKxJnduYxjoD0JrVvLOXPI2dmA7VBLakqQ3QjHA/lQFjLuZEW32gZBON1Rae/7xmmO0jhAKtLbRxOzzHcq8baYFVpcxKMDt/wDXpFGnZI3lKZAQHO7Ht6mti3KklYsDaeW7VmxRSSRlWbGR+VbFqqRQIygkLwM0mMkEIb72f8akJ2kKo4Hamhwec00seT0NCBkEx+c4/OtQx3bQutxp8UrSbSWMoG8joSM1kSuAc9R3HrVm+SC9ka4S+iiVsHbJkNH7Ad/wq0QzA8QwXole4vItoY7cqQVX0HHSirWpXMMsGpSJKWE+yNIyOW24zIfSimxrzPGyeab3pT1pprc84mjHrWVrcoSEjHatKM1j+IEJgzn60ho5Sdtzn0qMCnN940gNUUWLZiM+ldLoZAJkPUdK5kMAFA6mtyylNvb5zk1DZotTcM/m3Ow9upq9LMAEUEZXkj1rnLecoPMPVjk59KmiuTMGdSSztgfSgo6rRk8648w9F5/GtVSFcuBzu5JrO00+RaK5POOlXLKTz23cbQenrUtDRLFMftxml6j5UGaW6yI8dX6mkiVTqCBvuj5selF4B9pdAcEDrSWoXJ9GEnBPLEkYFdXoAaNHkb77NwT2rndFQhEVTk85NdHpy+X5Y/gJNSUV9duZBI0YBI2c4NS+FY9q5BySetZ2sTYu5iOc8Vf8Nl4bOafGAucc0WuNi6nvdJlj5K5PNPspNttbyqMkZRhSbd8DliQxUn61U0ktJAFY/KDxQlqO+heupVt5lkUcMuD+dW7O62S+UGON2eOwrBv5HJ+ZuA+D7Vck/cos0XGTnJNIrRjPHxMc8RyGeT5cjjmsXWLp0tYLflTgRBvStHxBP9okhdyGO4bO/PrVLyVudRYEBkh+Yt2JoEnY3/BkRFxGMjbzGp7D1NdbqAEaEO2PLU5xWFo9usEUrKduFDLjvVDWNVc+d8xAfke9UtES9WZfia7dw425BjCKc9OayoZVtm+UEqw2DB7gdaXVmMl4sABLKodhnpWdfzFLQFM7gfm+lJA2aemXiPcNEHBxwXx1Oc4FbYkEU0cRBESJ5nl5+8e9cNptwqXNvI5xl+o/nXQPqfnXzyZLFYtgI781Vwujo7W5FlYvPHkN95Qvck9KspcS3gRBxL/AP7oHU1z+pTiKK0gaUp5aGQn1roPD6eW0RmUFp03AHrik30HdHWaNZrHE3lA8ADP97jrWgjCcKrc/NuIHBplkV8tjuwB19iKqgPbtGysckndkce1CZO5na1dSW9x8ytwcbgeue9QXJjk0xpF3ORLgc5/So9cJa79VxvIPY1G0cf2OEKfmdtwOcZqb6mita5sXUzC3iRsHahD5GDwKp6Cv7tMMQUUlPanaiU+1Mm9siMnB+nSl05xCi4OCeB+NWT0N6eRXiiYZDOoyPp1NYqXnlam8ZbiVNuT3YdKsXF7suIApyrHd/jXP3uw6k7iXajoXQ++aGyUu5uxXpWX7PIF8vYMlRtw2ev8A9am6lI0MlwsgMuRwfusMfzqhaPkbrjI3k89at3e67gkDcMEypHOf8KL6BazLltqKh3WUB1MeEIPVcUjTJGomB8xF9WzjNczAzkiLBSXGRzxmrVoT5c6yE/J8wHqD1FHNcfKdHBco8LJEGDE87hVG7trmRczGMx+sfUe//wCqswTtAwWP5kcfKT1+lWGnlZl+fbn7oU/pRcLajYbCIKQmyRSxPTBPtmodRs4RAskZCNk7BnOfwqcCV5yI5BHIRvTHINY+rWt3MXSWfywwzj1PfBqJLsVHfUyvMV7hV8hVizhgnr9K25Z5o4vlCxoOCRxj8KzNKhMUj71BI4wepHrU32jz2ZZJPm/hz0PtShtqOe9kR3kBVUmJMrD0PBqeO+e4VTtEbKMHPAqjFK9pdbC3mW0nOCM7D6VoSlVuFdow2eq+o9abJTBXl++WOe28ZK1CZ9qsoYvMTjfjk/QVdvDklYos7lzz0qDQ4Vnlk83iQHgelIpFW90ohFf/AJadcHmmTWksY3BMbcZ966TIjUI20NnAOPSoZFVlbLZ/qKVhpkEG37PkEKxHJ65qW2beoTaWz6VStWWEtE/HPBPOa1rELy2OBnBpFbDA7jIKkEcc0g2nkuM/yqzOVBUqOKgc+q800K5VkHYkbc8n2rYu5WhS7jhtof3AVo1MYO5O596ynUeYB8uDT7+4s7G78tri78+Ebd6EDHsPaqJZleJQVv5CQF3orBcAbcjp+FFZ2r3Ec1yzwmZ1bndLyxPfNFAHlp6mmHpUjdaYeldB54J96qmsws9s+D2q0nWi/JNox46UAjgZFIdgajUdav3ARSxxzVA9cjvQWixbAGZc9BWlPLuKxp/EcVm2fEmTU8T7rtT2WlYs0NQmSLZHGc4X9auaW21Ih1Ocn2rAmfzLg+ma39HKmaEN92pLR1UbkgRjuOprS0qPeuV6L1rKDA3BC+lbWiERpeFjgBOPyqWUWdECzX8pJOF4FR6wwW6d1AzuxR4SKsrTZzmSofFjBJZ0UjcGBFIRtaAAiEgjiugiIVeTwmWNcp4dmBCgnqcke1b0jEWchBIYjikWjMvmBs/PLHl+Ca6jRyI/D0oIG4DcRXIak/8AxLIyvTdiur0gmTRJz1ONp/KmhWIlKchjlSMis/R8C4ZAcDkYq7ppWUMTj5Y8H2rNsmEepgAEs4JFCBi6gVZZtv3m7Z75qw10smmOj/Kyrzms7VSIZmxxn5hiqEVyTcsmfvoVb3pjLt0VTyWcjCrkd/wqbRsRHkbg7gk+tYr3SSFjI3KY6e1amlkKYi7H5iCMevWnYlPU62eRbQSoG+VQMe/euR1i4zeBif3aoH/Gr+pXJ+0BkICsCrFj1xXKajcLd3oKZ8ocv74qRllpv9bcTgmSYYjQnr6Z9hWfmS4tQzlSWfg47URztdSzTkE4X5VH8I9KsFmtrGZgilpgI09EPHNUkSU4bVZ/PV/3UoLKn91v8DVqxBQKGLCVvlA6EE1WgRv7NMpOZDOc/TpVlp4ytqAN7fOcnrkDjmk1Ydy5qT/bNTRZPuhVU4Ndva3flz2ILkqCAAK83E5klGxQGJGTnJHvXQ2t7IY7d7gj92QCR7GpZSPW9MKzRuDlcyEY9qtygGIBjnFYfhu6RwpVs7ct165rQnuN0UxX7ynA980E21Mq6AKxlgrYLr0/KqawiWO2iGPlds/hUsrljE2eCSTVO1ZjNG2eA7N/SktzTZE151mYN8yrj0rQiU/2QGcfMjAqR1IrB1CZpJrqKMZJcRn2rrZIWGlLJlSDDkAdsCmtWxPRGFfTJFcwDcMhiV/Ks2VsyqXPysrKuB0Gabr4eG+QbvmKbgPTNUtRl8r7LHGw+4wI96ktHRWUgWwHJO4j6rz2qzcO0G2eEDO0hh2IH9axNNmBtCD8xEe5T9K2rkqdOSYYOxSTVENamRdXAT7PIM56kk9qvW0ifaJG4bK9uhB7VzmoXGbGI8/u3PIPUH1qxpl6JJ1UHIOB/jST1KtoWtT3QyxRtkpvABBq3vIjaKQEHOVOOtUNUbN1tP3lQsAT1PapYrwS2/mRff2A8/SkMkaZ0eMscMp3A+9aGohJ7eOYcoxwcc4NYLyeaoXG3eP1qbSZyiz2kp3AAOqn09aEyZLqNuZiHWaMbzHw/bIqjeY+0Bo+FPTFalxCpkYEgeYm5e3IrGvWRZyit8pAI9qoW5WnL+eGBOw/KQOx/rVieV4o0kMh3xHbg/SoLwlDvBOSNw9MipdReO4hyB/rEBJxSGtDQlvvMsYlDEk96mi3qY50G1sdu+Kxo4tsMRQkgHnBrats7lUOSgGeRnrUjNSZhIgY87xu+lP8vZbIzAsSMEjtVa2DlUViAVJBFX7kNGpG4AcdqBmG8fmNwfunIxWppbq0I3HA9Kz0izd8MeSeRxVm0RoZCF25PPPGaSKZdkAbOAcdiT0qAopBJyTU29yMMgB7fNULmQcAL6ZzmqJK8pUcFcDvVvUXu0uSkOmRyW6qBG7QlyVx3NQCKCQuLm58oYGCEJzUUht1yf7bnwf9hv8AGqQmYmrPI923mwrby4GY1TbgY64opt6EN2/l3LXK4H71gQTx7+lFA0eYEetNIFSHnmmsK3POI+jU64j8y3b6YppHNWYBkYPQ9qAOD1SPyZStZ3bitvxNHtvOBWH3xQiizCV288U6OUcgDBqBcnIFOQDaxPWg0HwEmbPvXS6Sm67RP7oya5eL9c8V0Gjy+VcMwPO3vUSKidJbuTcvkjrgVrWdwFjuUJ5K4rAt5fni3dWbNXFkQXNwu4ggE1BZs+DLhGg2A8iTkfjVbx3OEufNXjcwFReEmXcFiGHLnOKg8dgiEBvvB6ENm/4aJezjlOOTgV0cr7po4ieGGK5nwvhNLiXPvW9bMZb9C4+7GTQxoydRbFkYh1E20V2HhtJTYvtxsx09a43UyBqEcafxzA12PhmcqLiPnAPI9BSWo9itZv5E1yhHLLgD8az5ZGtr+wmRckNtIqzqcgi1TYOC4wKzdfnMVmsqnEkTBx6HBovYajfYXxTN5cxYcKxGPasKVyspk+bjHI9DWhrt5DqmmGe2bL7uRWR9oBtFz97yycHqaaYpKw22bbHcZ+Y5AHuM1vWMxW3RiNyjpnt61x9jNmGbJIw4JJPaur0Ii6t3O7CgHg1T2IW4/Vbgnc4/1YXeoPc1iJgnaHBAO4475q3rk5juVijGTt+UfWq9zG0VpGhA3JgEgdeeaQ7iqdkRAYgtnGPf/wDVTrhjPAEjxlSG49TVSWRDdsi42KNuSeoFOlnEUqbV+ZUXODxyasgsSyFLRoAoHlvgk9Sc1PNE0UzuAgCWxJBPTPH51lzXIT7RuUbWcEc9+9S6ldM08zxjI2CPA9TzRYC40CppkUgIRgigjHJzzV22l8yQA/d28j34qpNIJbERn7qxg8dQQKs6U6vnPPmouAPrzUSWpaZ2/he4NrdiF/8AVtwDmt24n8i+K7tydcevFcQkzFF8skMo3+9a9rMb5VnVirbBmoZS7mveMu6Nc4AUkH61ifbxHKCrZ2tg/iavTykwqWPJjK/lXKSzn7PcNt+7IPzwaT3Gje0ScXWsqB/G7M31rroJHltWt0bhEYEfTtXE+DHVLmylYAM+7b+XSutdjaXtznG1gZOfQinHuD3sc5PKb7xXAhwFjt1B9zisW6kYa7BFzldxarGl3O+9nuFyr7yCRz0FYt/cunimVwNyqeT9RUlnVQsIlViSo2nI9M8GtiVk+w4Rj80XfpWJFcCbTbgkbiFAzn1qWJybS2iYdF29evtTuK1zGvpNlsyNwA27iovD7ltQIHRAX+vNQ665SK4AztDbB/OqGgSt9sjZWwVyCB6DtS6jZ3F5b77qJ8ESvGW+pBrJgu9kkyrx5b7SPTmtE3Jvnjkzlo4d3PGCW6VjSEf2zex8ATx7gv8AdYUMEWPtBW/ljHQjetV57vybqzuT8uP3T+wNZV3I0V5bvvYqAOc9Qa2vENkv2JWUcTQgg/7Qpagy1dXZ8qE5VjG+Dg+tULn/AI/osEbWySKoWMrzadvY5aRODnuvWpbebz7i1Y4b5iKaYrEmrXAjgU8ckg+1RLcBY7R8bhgowz61Bro/cSIxwyEis2C6/wBBV94OOoPqKdxNHTmcIbdBjY3U461p2sw2Slf4BXL6nKYbWGQHABVj7ZrS0G5E8cwByGJpDOntZ1M8THGD0rQvn3Rlj0HNc5YSM0KMSPl+X8q272UCyOOrClcditbsS6vjgk1ccfMjL1PFVrKMqoVugA/OrErYK0IGWdwCYqu4AzhiPYVIx+XJ6jmqksoGcd6skYYJ7xmW3XftHOWAqncaNqODiFT/AMDX/Go7tgcc8k4Bq1c2+lRG7V4LmVrRkEjebjdnqQPamkIxpraa2nMUy7ZAASMg9fpRV7UYIra8dIE2QlVaPnOQRkH8aKQ0eUt0qM9KlYcUwjiug88iNWIenvUJFTQ8YoA5jxVERKpIrm2wDXb+KYd9srAcjmuJkHPtQiug0HAwDzTkHyNk80z1oHSmO5JESCMc1qWMuLjJHBHIrJTjFWYHxIpqGXE6Qzf6px2PFT2tzu1A5GdwrJaXNsOcYOas6PIDqUIfowx9KzsanUeG5RDfSrjDCT9Kd4++e3c8dRis23LW/iZYc8SKGq/4vTzLdix5GDigC94amzpUbhuMYP1rpdOnLzK79Dx9eK43wTIJrGa3wPlb8s10OmORIqE9G4pPcuJS1eUwa7abTwJRnNdXplz5ernn93OCp+tcT4oDx61FL/AHUn2ro9R3RCGdDhUIbihaFMn8Sq8F3Dcg5Cvj8Kq6ugm0pmbqrn9RWnrEYvNMZcZcpuU+9YtleCayUucjoyn2pNX0HGVjFsVjisN4OcnaRWVey+UCc/Ic7RnkCtSJUKXsPGNxIHpWLqH/AB6tjBYEA+1NCm7kFq4MskRf5N3Q98Cuy8IzhkBlP3sjmvOklMdyzA55Ga3tB1EQxkfeK5GPUmqM7WNmYmfV7lwdyRHaKvX0nyrlcKeOKr6TGDp7SEZeR8k+tOvW8uKRWBVl+ZfcelJCOdiuDNd+WBtJJ5PXGanhvU+3yGUcFCPpg1SgKpdzTNxHHGSvfJPAqhO+bmQR8gAEnNWK2pr3oO+VkbIKhgAfatOHEjbWG1QqysehPFcvJdlVTngrsOa0Lu42TuRI2PKVD+lMRv6VLJLKwnIxIfLz68cU/TmaKNQWCuu9friqmmXSLNEkuCA6yEnt2qafDONpXmRkPbnnBpMaN2xuj9ph8wsCBt/A1raLPIjXKEYIfHPpXGCZwImBLE4BOa3rS8KL57HKscOnrxUNFXOha82qhLdUdgPSuV1SbbYykk5eRf5UXF7i2EiPlex/pWJfXr3CPbsQR5y5Pp0qGWtj0TRVWP8As8LwQmM/WtvxDebbm2csQoVlf06cVh2jGOSGNgCY0GP9oipfFzn/AIR6c5/0hBv3D1p9B9ShoS7LS1Zz/rfNmz+NYCy+dLeOwAbazfUE8V0EmIbKxXIytkBx6tWBdx/ZJ9SQAbFhQAmpKRu6NcE6cqls+aEI4+tWNNuAZ3hbd+4c89eKwdFm2wWuPlU7SPTgmtizIGp6srEAhQV9zTQGH4nuHjabcCB8smKp+EnQ3a7gcupbP4mrXjmTbpkchQhzGYznrx3rI0C48ptPJX5TGFbHXOaQM9IhAhlnaKPMYiVX9jXPazIlvrkVwCWVuD/Kt3Q7sSz6vGcbHAwc+grB8V2nkyxTBv3TxZHsaCrWMTXpmS0LAkNDJtPuCciuzmdb7wRFcx/6yJQ5x6155d3Iu7d4y+BjB/Cu48Hsx8KgJ86qrRuD+hpxIkc5pE6iOYc7Y33N7A06yud9zDFB/rBKSPfiqNo5g1q7tXACSJuGKj0iZY9YXedvlyY4/nSA6DVWDRvKQT5gya5q1ciC/h2jI+dM11mqBPss7gDYzfLjse9cHPKYtTKknDKVP40xHS3MwudAhGCZQh78YFSeDrny5ircll/pWVYTD+x4xuyq5iY0vhKdW1AxkfKuRikM7q0fy5mjJ4LBgK2JZg7RQEDrnFczPMY5YHY4+YrnHX0ra0cedetPJ34GalJ3K6GyvyOB2pJj8xY/Sklcm4VF7CibjA7d6tCHSOT3OBWdcykkkDip7iXYCBWVdSbcY61SJuQXMpJxg81rCS5g1ONL57QvLEqT7hlcdvMx36dKwsSyOXRThcEkDIHpmuklitrpjcXNtqEUz4MiRxblY+oPbNAmzP1t5xeyfawgkGANn3QuOMe2KKq+ILtpZ5HeJoAqhEjYcqoGBRTUbi5rHm7cimkcVIRTWFbWOEiapIT0pjDmljznigCW+gE8DL7V53fwmKV1IxhjXpsZyMHkEYrmda05XllZRyaBpnGCkPepJYzFIynNR9jTGKhqVWxj2qAVIppWKTNQEm34OKls5Cl1C4PQiqcc37nFLFLllXp71FjRM6fU7oxavZXS+mM1p69MJrZm/vJXOagxkskO7JXvV03Jl0tGJBO3HNJloueA7lYNaeBzxIBiutT9xq7Rk/KzZBry8XBtry1uU45HOelegT3TTpHPGw3YDZ9aloa3E8YAlZmHUEVrwyf2hocM5PG0Bv5Vl6q32rTmYDdxz9KreGL4rp81ucsg457Uh7nX6PcNLAYZSC0WV+tcu0n2bV7yym4SQbkPvWlZS+RfQuT8sy49twrN8ZRmK/gucHK9T7UJCuZaTCG9mWU/eG3/AIEKoau4W3KqRtYZ+ppdZcCWGUHOfmOO/vUGoMHsw6kFcZUmgZisSzOGJDbe9S2MxVWOTk9vSorv5ZA/J3d6baud4HXB6Yq0Tc9K0t9um2yOMAgDPoar6u5SB5SAxUEGlsLsTafGGI+gHSlneK6Qx7tqPkSUrDOTu7hYLFIjy8reYSf7vas9XX7cyBuG6D+VP1qYPeSAgqykoOOMDpVG1kAuPNlPES547ntVIl6F/VUCyMF4Xd8uP1q1q8wNxMQMLlF/AAVQEgkcZ5Bbv+dWdalaSd4zgdCMDBJxnmmI0LKbfcq5IGF+7nqPUVfmm2MFV9yswkznpXLaXdGO6jYn6itFpM+SRyNrLx9c/nQPqdHpkoYtGeSjHg9xVy0vNsroRkFsH24rlLO6YSsysRHgEt3Bq1BfAqgJAZWySD1+tQxmtFOPsrxnlgG4+lZ1k5muFzn57hVb3pbmQRxXYVxuBHT0NUtClEt/aRlypa43H6VDLuev6TOZdahBCmJVIHfnjmpfFRQ6VqYHAjjx+NZGl3n2e8hTBUGQ9ewJ9aueKXQWl8pYlJCq5z2zR0GtWZVhKJ7ywhlYk+Uh/AUvid1S6v49mcxx9PzqtoG7+32UKcRp5a5pusy7766lH3W+Q/gBR0KHacVms4Nrj93BkEdua09JYtPdy5BKKD7nPesDRBIy3CEgbCAD7A1u2oMc07KuFdQhHvjNIGVfiPbpPoLTGQqyFcge4rjdM3N9kVG2lWWu18eOj+GXYDIZR+BFef6VK7NH5YJfepI/GhgmereByjQ6iXwz5bmtGe2W/htoZwNsqsin04rG8HL9mN8GJ/eBvwNdVZwj7NZu55jXcKSWxTkeJ+J4Tpd/JAV2kMQM11/wsujNFqNjIxwy+Yhz7Va+Kuhi6ja7gT5gu7jv61xHw51Iwa3FuOMqY+vWrS1M2zT1wmy8Uwt8vKsnNZPnND4gJUEq6nPt71v/ABFEcGq6fcAfKXweOmRXNajGYtdhJOI3Q4z39qTQ7nbJKZdMaPGd3Kn0IrgvEDt5sdzEcFW2sK63SLgvahe6HP4Vg6/bKJbpAD5b4kQ/zqRkek3I+y3kDYGcODT/AArJ5Oq85G7Jye9YtndKkwHRXTbzWppblvEEKgjYWC8VVgueiayGGlwOBnJDCtWyfyYEBHzhd1Z2tEGwiiBwSQBVm3bzhGAei8kVNh3N2zYKhkY8t61DcTguTnhapS3XkptB6DkVRa6JXk81Qi3NcF884FUmYyNz0qMM0hqZU4poVrj4HdQ6IzBHwGAP3sdK6G7mitJfIuNdvVcAbvkJ2+x5rnNwTnOD1zWneJ/aEa3NxpMrzuAcJcrEJvfaeefaqREnYy/FVucXUkV891LbhfOWVcNtb7rKc8jpRWBrWuSbNRintPJu7hljkJOBFGmMRgfh1orSxlcwjUbdTmpSAAKY3WqOchPek/iqQjrTSMUAWoDkCob2Aupx1NOtz0q0RkUmJHnuv2vlNnGD1zWJivRvEWmi4tGZF5APNefTRmM4IwaSLWpFSimnrTielUNEkZ7GnhsMD2FQA4bNPzkUmikzaWQSWpGeMdDTrCXdA0XOAeM1mRSfJjPSpLOUo5APeoaNEySQFrcjqUbmun8N3vnLDDM2CDj6iuVdyGkyOD2qa2uTDcQunGMUmtCrnoMEvlzzWzgY2nGazNLuEsNUkhl/1chxn61ZmmW4WG6jPIUZNZd/lZHPPHINQNHQliIJbbdmSJvMial1O8Gp6XAG5lHysKyXllFrBexcnGDTI591woQ7fMGR6VTEZt+GkhKkENF8mBVOGYSWLRHO5c9a07/K3jhvvMAR9awpQbaYNztJwR9aSH0EmcvCRjkdahgby3JJAwOKluIxhvL7dfpVZCFOOzVaRLZ0/hnVVESwy5LFiM1qXqvbPK0edjLnnsa4O0nMUxG7HOQfeuwtNRW5sSs33ipDew9aGCehz2rEyETAZ3ct9azpH2RALnLNk/TtWjeoqTeVncDkbvWsqfhiMng4poUixbyEM5J42/kas3VyTPBIR2BIrN3YiAB5fmrF2zZi8wHdtFBIxzsnO3gZyMelaVrcsLSdV5wRIv0rOO2S0VsjzIW2keqHoaS1b94VJIBBFOwJ2NCKXbJg52Hk4P5UQzFpyu4bcgfhWerjJGTkdPpTUk8uQE/dzzU2LUjcmuG3u4PBTkfpSaAx+2QuuWfcx/SqNxMJI1OcHBX8Kl0GUxXsbq+CGxj1BqWi+bU9WmmRrOxkT/W7MEf1qtrV1586KX2rI6N9KL23drNZYMgRgMAPTvXKX2oMbuNixBRsYqLFI6awvWj1m8m6DYJE/DirAk83RLqZwMvISSPSsDUZSkUFypI+XYx9a0xdJD4QlHG9iSM+nrQVa5P4XkWe7uNpBSQ7AT2NdOmYvPD4PlhG/KuQ+GaBr25DkbAvU9Axrr7xt1zLtxk5Qj144oEc346l+z2FzCc+TJ86CuM0S6EEImTG9cHn611Xj2Yy+H4c5EqnGfauM0YiYSxhBgr39adtBX1PWtFvFkNyVA3bNx9811Nl+8htgDgGPivNPCl0/wBrdTzmMA+2K73TbnPkIxxhOMUhsk1iP7Vo8gYjdGe9fP8AHIdN8TMRlQk3HtXv1xIySzxEYVhnHrmvEviDZrZ68sij5ZOSfeqW5L2Oj8f3K3enW1wrnK7WP1rI18O0Vnc8bM9e/IqTU7mObw4VOApVSWxnmqupzvLoFo3UKVPHtQwR0Nng6Ta3EOQdpDVl607PbK69YvlPuKteHbpJdKniz2+X6ViXc8kc00ch+UrisyzAt23XPPOG6HpWxo77NejO75c5NYMLATMc87s1r+Hke41rnsCSa1e5nzXPSLqdntQ4JYHAHtV/Tp1SBsHmuenn2WwjXqOKvWLGObHVXA/OoZZpyu0jB2OGHSolJaT9KkI6E01cF9wxkUDLkS7egpzyhOOtV2n44zzVO8m2ISDimlchsdfXgj6DOCDj1pdbtDrGoPf2upWYglwf302x4eB8u3rx7VjmO4vWItoJZivJ2KWx+VRto9+4JNhdZ/64t/hWqVjJ3bHeKJY9S1R3tpPNjVEj80jHmlVALfjRWr4hhWLVwpQIRbw5XGMHYM8UUc7KUEc6w4phHtUpFMYcVZxkTjnimVIw/Woz1oAVDtarsRz71QJ+artucYpMCxJF5kTKeQR0riPEemCNWkQcg5IxXoMS5xis3WbAywONuc0hpnk7rg80ytbUbMwyMCuME4rLddrc00UJTlPPtTT96gcCmNEkZ+bFPLbXBFQg8gilY5NIq5dRhIcHqelR7tj4I5FQxuQR7U+U7ju9amxVzo/D+oNnyJM7G4ye1aFx+7Bhl5weD6iuStJmVhg4IPFdV5ovtNSZOZY/vAVEkWmWtCljYT2cp+Xkr/8AWqjqMTwoHj48p+ntWatw8V1HKmQytn8K3b10uLczIMo6/MB2NIb3B4/t1j58Z/fIM/WsmeEXFoXT76nkd6k068a1KqW/ducHNQvIIr90Q4VzQkMzHYq+Tzgcmo9vyc88bgfxqzdx/OcdT1qqMFGXPReK0IZWc4l445rTtrwwzh1+6Bgg1nMP3o9+aZE53EGnYm9jauwjwNIrZVug7of8KyOZSq4+YnH1qaK4KEqRlCORURPkyl1HGPl+poSG3oRyHdMB1x8v5VJNIXdT7dKhH3yT1FOJHyfTrTJT0JIJhG4dxuQgo49QaYGKTgnkA/mP/wBVMyMMAODzSDDAZ4x3HagTZPOBHK2DwDikIypxj1zTrwiSQGNQqugIGc845pkb7lP94dKVhjo3ZrdznoRUtjIIruNj61WZyrEjuOgojbGD170WGnqeuW+oldNkzyqjKk/TpXFamzSahCsXzMwBIrR0zUY7vQbiPI3xqWx7VkaS5udT88HIVQKyaNkza1i4V9Khj5DoRkVZ1OQQ6RDFu3GUDHt3rK8ZSjNtNGMErhgO9F/dGc2xVceVGM/lSaLi9Tq/h/tW1vnTO7Acg1vfaVkYTZwM4OK4HRLyWyuWQHHmR1uG5KwQbs4Lc1nJs1jFGX4r1INZyW7HLK/asjw4q/akVSQzgkiovESqmoyK7EAnK0zRW23wLH7oNaLYynZS0On0W7az1mRHIHmqQK7zQLsBAZDl4zzn0ry6+LQtDeAbgXGK6/R9SV4WdCN3XBqWOOp2Gt3IPlyRnk8Ee1ec/EuD7RZRXQ+8hwRXTRyyEq8pJ3HisnxvEJtJmOMDGcURbuKfY5WxuFk8MSxMBuQ5zUlsvn6AUJ5VTxXL207x2r5J2Ht610WlTKulsXPzMCOauWhMRvh+byGliXJGOtLrO57hpOORjFR6UoEsjr0HUVZ1lMIG5244NQM5J3KXBx1rqPBMYe8nlc9K5Odj9pyO3rXaeCV2xNIf4zWstjOO501xB/qwTgE5rWCoIUHcVjXk4kv4UX7q8mtAyEjANZM0TLcku7AGc/WlXhaqxuAM4yfWlkn2qc9aqMRORJPKE+YD5vSqErGXrQpaV8c1aWAqAR1q7pCSuQ2UlzaMxtLiWAt94xtjNWX1LU0P/IRuv+/hrQ0qO2FveXd1F5y2yKRFnAYscZJHYVV1BbW/sZ7rS4zDdQKWmtAd2U/vp3OO4pasbsjKu7qSR2muJXkkIwWc5JAorJ8e3sNlqrQWqrGnkQvtHTLICT+NFNIi5ZNMankfNTWrU4yM1ERzUxFMIoAixyasW7c1Awp8RwaQG1aHpWgY1lQgism1fGM1rW70COU1/RBKpZFG4VxOoaa8YLKvTrXsk0AkB7iud1DSQd5Cgg+tFrFqR5IwIfB4PpSdq29e0t7edmCnYfbpWLjrQVYQdKM4FGQM0nWmIUEge1SBsrg1H2pF6mkUnYmVsHI61p6LfG3utrHCPwRWSppwbHI60mi0zd1Rdk4dD8jVLpmofZJVif5oXPPtVC0m89fLmbJxxk1WmYqxXHINRYtM070Kt1Kin92TuX2qvc5kCOMhlHNR204dlVzkjvU02AAVOcdfegdxiy+fbsrYEsfr3qsMAru4yCDTSreYxXim+Zu27uoNUQISPlJ6hSKrAYI9qsBtr4/HmoiQVPr600SwX71OnbConXHOajB24Oe1I+TTEwzyT+dO3fu/oc0w1JDy5XbuLDAFDEmRoxByADjtU92u11kBTEw3YT+E+lVzwcHrSj5qAJnwbOI4O5WKEnt3FRKSrZp64MMqkHIwR+FRA0BcmPOMHpzTScHPr2pY/nUkDpQeRjoaCi1BM0UTbTgH5Tj0rS0BmMyrEuMHkVksR9kBH3gcH3re8GMPtfzqMAdTUtFxkTeMJk8wJGegHBHSqmiqZ5U3sTublT6Cm+JriO61h/LHyjir3hiENqcW/GxhUtWRalqaepWA+0pJGSGxwK1Gfy7FFmTHIw3YVadY31vacGNVxVPxNexWtm8YAIPArPlLU2cd4muYrjWsxkFUGCR0q1o0BdZJ9vyEbKxhA0rs5HXkV0eijy4FiBOSckVbIvfUuavbPb2cKBtyAg1YtZItgAfy3Az9aNbniFkquMSZ4ot7dfsKuwAYVBVzestRjaBY5CCB3FZ3ii6zYTIGzGRxVaWIxBGjPuayfE16GtFiQjceTQkJs5tcMUjUcZrekjVNNODyKzdJt/3O91Jc8A+gqW7kMUJiZs+lUwjsWNFdhM3oa1bpln09kkAXHesrSmEUW5xgZzmqur6iWQpHS5bsb7mQy77jyx84zXa6PMsNokUYGRXI2C7SXx83vXTaTG4UMe9VJ9CYrqbNmp83fLjca1w4wB0rLhBAzjmrkIaTgn60kPcsK9KFLkGmxqoPNOedI+4p3HyotxKqD0ps9wsak5rLu9USMdRWHe6k8mdpOPalYHLsdPZalqEVxJJpEMk0qrtkVI96lT2Yelc/cR+JIrtbi00zUop0bcrpCeD/AIe1UdIvb+z1OK6sy5kztaLnEqnqpA65q3c6XrYllmSHV4bdmLKpZ22L2Ge/1qrkPUwfEs+o32ryz61CYL4ogaMx+WcAYB29siipri3lkcyTO8j9Czkk/maKXMKx1jdaYalIqNhxWxyEZppqQimNQBEetIpw1OIptAF62bkVsWzdKwrdsGta1fgUCNiPoKe0KyKQRUNuwIGDVpWxTQjntY0dJkYMuRXmev6K1hMxXJjzx7V7bKAw5rkvEtl58bLtyDSaLjI8gdCDzTRmtrUNPaLcSOO1ZMi7WxSuXYZnGKQn0ofrS8YpgC9KKPpSjnI70hpj0cqQR1Hepmcvyaq9DTlcikO5JnawI6g1ahn3E5HTrVFm6U9GAfIosNMsM/7wFDxUI5Vx3HNNUnGO4NOGS5BosAMejE1F/ERUiHqrdqbjPXqKAGnpikQmlY5OaYOtUhMVu/cUK5VlIOCDkGnYyKYRzSJ2HuuTu65OajPWpEI27T09aYykGmNrqSQH94CwyDwfxqNgUJRgQRwaAentUsuJG3DqRQLdDI32vuBxUzgk5Uhs+lV+lSwNj8f096Q0IxOzHerem3jQTAbsZ4zUcsIxlTn+tV9pPTOfSgrYsTSGS5ds5J4Brq9HiMen/aNvzoMj2rj4tzOOenSuosNS/wCJW8Sj5icE+lTJFxepuaZO0ge6kPvXN61ePqOoeWuTGDwBTLrVttt9ltz8vdqr2MiW7maRuccCosXcsqDDfJGy5UcnNbKCQTefbqNgHNcwLlp7gknqeK6TT7pEh2seMUmFxbmHz7yB5CSCckGt+QxmJEQd65CW8PnSSAny16U611xkyW5x2osM63U7iG1s8tgnFcFIftV4WP3Se9LqmqPdEAnj0qvHKigMD81NIXU3hPFb24AI46Vh3Mvm3G9gcA9Kjkmd8Z5FOWFpz0IBoSHvsOmvGZdicU2C2kkcFjkVoWunKCN361qLBGijbjPtSbC3cq2VhhtzYIregCqqj0rOAKUv2vZxkUgubSyKvUj86WS+WMZBAxXPG6LdWNQSSM+ck/jTC5sXOs4PytWdcaq75wetVNiEjceakEERIC4/OkBGsryNlmNXoFTHJFNjt4gc7qspCgxtapbbA6PwlIFF/HazxW+pSxBbaWQhe/zKGPQkd6urp/imOTes88TZz5j3YCj3J3Vl6HZW0lvfXl+jzQWqKfJRtpkZjgZPYUuqabBe6XNe6MksbQDNxZO+8ov99D3X19KNbE6XKfjG8t5Nana3eOQbUWSSMYV5Ao3sPYmis7xlaR2OsGC0QJF9nhcKDnlkBJ/OilY0SRvHpUZHFPJpvaus88YetMYd6eaa1AEZ60w1IaYwx1oAWIkGtS1fmslThsmrlu+DQBvW0nFXVbIrHtpOnNaUbZAoEWd2RzVK9iD5qyCaifk80wOO1nShJG3Ayehrh7uyMbMrDkHrXrd7AHU4x/hXKappoZmOMGoasaRZ53cIUOKj6cVsajYlHIIPFZckTRthhTRTRGKMfMCKUikPBpiFPJppBFK3WjjbigQ3NPHUGmYI4pynFIaHPwaQk8EHrT3wyKQPY1Hj5cHrQUSuvKuOp605hlM9xwaiDHA59vxqWM8cjnpmkxkXfB4NG3HTk1JJHuUkfeFMRiOCMH+dArDQeaQipdu7pxTSOtMLEdPQ7hg02gqRyDQKwpU+lAOVxjkcj/CnJIemM1KPIY8gqc0XHYhO1gMLtpyoyjKgn1qee02oJInVlPTnmmQTSwMcAYPYjIpXHYcJF+4pOP5VNayvZ3KyqgZl/hYcEUjTQTKRJDh/VeKSJk2srMT/AHSe1Fxlq5W0u0aS3UwXBOWTPyn6VntHc26F9rqh79jUjow+6R9KuW26VRHLKwi/iA5xQOxkq5BpzuWPJ4q9f2UUVwUik3oR8rAUxrBkwWIwaVwsyokpU5HarUF07Ntd9qd6WJERjvTd+FNeEEnajY9hS0BJizXJlAHRRwFqNZPQc1NDErPhlOBWisECben5UN2KSZlDGclaXBJ4Xit1ILcrnIIqZJLZFx5YqXIqxj20bMfunH0q/tMYGABVsPEPmA49KQusj/dAqblDEYjnOWpWd2+6+38KsGKPYMMM/SrcMFv5YzgtSuIzBkDLEkfWmSSL/CvFac8UAUYoit4CvOMUAY2/LZAwKfuJHHWtZ4bYA4AqlJb/ADboydvtRcCi6vkc1Nboxbkn61OE/vcfUU5Vxyp/Ci4EcjMpxyDUsZk4JY1E+WYcVJh9vFIDX0nWLjSpXkgCOHXZJFKu5JF9CKjttektbxLi1k8q4UnG3pg9RjuPapfDlgtzLLNcxeesbJHHBu2iWVzhVJ7L1J+lXo7h7jULqykXSrmGEMUhS3EazBeWEbgZUgA4J64oFYy9c1FtYvmu7lIkkdFQ+WMAbRgcUVR1u1Wyv2jgd3t3VZoWbqUYZGfcdDRQVY6g8Uw9Kc1IK6zhG4prU8000hER4ph7VN2qM9TQBGRT4Ww1I1MT75oA1baQcVq275ArFtuorVt+1Ai+DxSMD1FInSn/AMNMRAQe4rM1K33IWGc1rjrUE/3Gp2C5xV/aqwO4fWua1OxIXcoyK7bUf9Y1Yt4BsPFZvQ2i7nEOuGwRio3Xoa0NQADjAFUm6UJltXI+tITjpSnqKD0qiBcbhmmU5KRutAyWI5QrjnrTHGOQaW3/ANaPrT5PvP8AWpQ7XREvK4H1pUY+nSkXqaVfv0xFqI7gGQ8imyruOVGKS36yVK/3R9KnYtaorE7TShgeCOveiXoaavSmncVxWjwMjpTenBqxb87s+lRSUDGqgYkg4wKZ0qRehpr9aYh0XI2FiB1B96DuDHP3u9MP3T9Klm/1n4D+VIYgJz0zU8LLkBlAHc1WHWpl7/SkPY02a1KYGc/3qaYmidZIiHU/eA7iqkf+pNT6WT5xGeOaksfexJDMGhZjG4ypI/SiDdLOqswBP96rE3+oH+9VSY4cEcGpbA07+3MBH+rYnutRpI8Y+ZAc96pliQMkn6mpSTsPNIZPGQwb92M1YtEgmO2UbapxnhqkH3KLFLXQ1BaWqk4YkVGbWBH5UgHoarW/T8a07j/VJUsLWIfs8CFcng9s1aZIFUFRx61TIBZcjvVtQPL/ABpITGMY9/f6VYZIHjwBtNQt/Sq0v3hQBeForL96kntNsfyvVYsQi4JpykleST9aLgIbYYzkk0xZHUhccCrMfan4GelAEUsKSxcdaqJG0ZwRWg3UVFL1P0pgVemTiljkGcGlk6CoP46QG7o2oQWxmhnlMEcpR0nC7vJlQ5RiO46g+xq7IIY55bpV0iyaQMGvIbszbQ33jFF1DEE4z0zXKTdKgjA3HgUXGolnWrwXl+0sKGOBVWKFG5KxqMLn37n60VVfoaKZR//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A marked reduction in terminal hair density is present on the crown of the scalp.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Female pattern hair loss",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A marked reduction in terminal hair density is present on the crown of the scalp.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Female pattern hair loss",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 379px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A marked reduction in terminal hair density is present on the crown of the scalp.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_26_37290=[""].join("\n");
var outline_f36_26_37290=null;
var title_f36_26_37291="Symptoms of pulmonary AVM";
var content_f36_26_37291=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F79966&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F79966&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Signs and symptoms with pulmonary arteriovenous malformations",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Incidence range (%)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Average incidence (%)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Symptomatic, percent",
"       </td>",
"       <td>",
"        44 - 91 &nbsp;&nbsp;",
"       </td>",
"       <td>",
"        76",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Epistaxis, percent",
"       </td>",
"       <td>",
"        29 - 79",
"       </td>",
"       <td>",
"        55",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dyspnea, percent",
"       </td>",
"       <td>",
"        32 - 71",
"       </td>",
"       <td>",
"        53",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hemoptysis, percent",
"       </td>",
"       <td>",
"        5 - 15",
"       </td>",
"       <td>",
"        12",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Telangiectases, percent",
"       </td>",
"       <td>",
"        34 - 79",
"       </td>",
"       <td>",
"        53",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bruit, percent",
"       </td>",
"       <td>",
"        29 - 67",
"       </td>",
"       <td>",
"        43",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Clubbing, percent",
"       </td>",
"       <td>",
"        13 - 54",
"       </td>",
"       <td>",
"        27",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cyanosis, percent",
"       </td>",
"       <td>",
"        16 - 29",
"       </td>",
"       <td>",
"        24",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        HHT, percent",
"       </td>",
"       <td>",
"        47 - 88",
"       </td>",
"       <td>",
"        65",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    These data are based on the six largest consecutive case-series from the literature during the past 40 years.",
"    <div class=\"footnotes\">",
"     HHT: hereditary hemorrhagic telangiectasia.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_26_37291=[""].join("\n");
var outline_f36_26_37291=null;
var title_f36_26_37292="Amino acid composition GnRHa";
var content_f36_26_37292=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F73733&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=12\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F73733&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=12\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Amino acid composition of native GnRH and GnRH agonist analogues",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Amino acid position",
"       </td>",
"       <td class=\"subtitle1\">",
"        1",
"       </td>",
"       <td class=\"subtitle1\">",
"        2",
"       </td>",
"       <td class=\"subtitle1\">",
"        3",
"       </td>",
"       <td class=\"subtitle1\">",
"        4",
"       </td>",
"       <td class=\"subtitle1\">",
"        5",
"       </td>",
"       <td class=\"subtitle1\">",
"        6",
"       </td>",
"       <td class=\"subtitle1\">",
"        7",
"       </td>",
"       <td class=\"subtitle1\">",
"        8",
"       </td>",
"       <td class=\"subtitle1\">",
"        9",
"       </td>",
"       <td class=\"subtitle1\">",
"        10",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        GnRH Analogue",
"       </td>",
"       <td>",
"        pGlu",
"       </td>",
"       <td>",
"        His",
"       </td>",
"       <td>",
"        Trp",
"       </td>",
"       <td>",
"        Ser",
"       </td>",
"       <td>",
"        Tyr",
"       </td>",
"       <td>",
"        Gly",
"       </td>",
"       <td>",
"        Leu",
"       </td>",
"       <td>",
"        Arg",
"       </td>",
"       <td>",
"        Pro",
"       </td>",
"       <td>",
"        Gly-NH2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Leuprolide",
"       </td>",
"       <td>",
"        pGlu",
"       </td>",
"       <td>",
"        His",
"       </td>",
"       <td>",
"        Trp",
"       </td>",
"       <td>",
"        Ser",
"       </td>",
"       <td>",
"        Tyr",
"       </td>",
"       <td>",
"        D-Leu6",
"       </td>",
"       <td>",
"        Leu",
"       </td>",
"       <td>",
"        Arg",
"       </td>",
"       <td>",
"        N-ethyl Pro",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nafarelin",
"       </td>",
"       <td>",
"        pGlu",
"       </td>",
"       <td>",
"        His",
"       </td>",
"       <td>",
"        Trp",
"       </td>",
"       <td>",
"        Ser",
"       </td>",
"       <td>",
"        Tyr",
"       </td>",
"       <td>",
"        D-Nal(2)6",
"       </td>",
"       <td>",
"        Leu",
"       </td>",
"       <td>",
"        Arg",
"       </td>",
"       <td>",
"        Pro",
"       </td>",
"       <td>",
"        Gly-NH2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Goserelin",
"       </td>",
"       <td>",
"        pGlu",
"       </td>",
"       <td>",
"        His",
"       </td>",
"       <td>",
"        Trp",
"       </td>",
"       <td>",
"        Ser",
"       </td>",
"       <td>",
"        Tyr",
"       </td>",
"       <td>",
"        D-Ser(tBu)6",
"       </td>",
"       <td>",
"        Leu",
"       </td>",
"       <td>",
"        Arg",
"       </td>",
"       <td>",
"        Pro",
"       </td>",
"       <td>",
"        Aza-Gly-NH10",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Buserelin",
"       </td>",
"       <td>",
"        pGlu",
"       </td>",
"       <td>",
"        His",
"       </td>",
"       <td>",
"        Trp",
"       </td>",
"       <td>",
"        Ser",
"       </td>",
"       <td>",
"        Tyr",
"       </td>",
"       <td>",
"        D-Ser(tBu)6",
"       </td>",
"       <td>",
"        Leu",
"       </td>",
"       <td>",
"        Arg",
"       </td>",
"       <td>",
"        Pro",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Histrelin",
"       </td>",
"       <td>",
"        pGlu",
"       </td>",
"       <td>",
"        His",
"       </td>",
"       <td>",
"        Trp",
"       </td>",
"       <td>",
"        Ser",
"       </td>",
"       <td>",
"        Tyr",
"       </td>",
"       <td>",
"        Imbzl-D-His6",
"       </td>",
"       <td>",
"        Leu",
"       </td>",
"       <td>",
"        Arg",
"       </td>",
"       <td>",
"        Pro",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    All of the agonists have amino acid changes at positions 6 and most have changes at position 10.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Robert L Barbieri, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_26_37292=[""].join("\n");
var outline_f36_26_37292=null;
var title_f36_26_37293="Muscle innervation part A";
var content_f36_26_37293=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F73819&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F73819&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Function and peripheral and segmental innervation of muscles: part A",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Function",
"       </td>",
"       <td class=\"subtitle1\">",
"        Muscle",
"       </td>",
"       <td class=\"subtitle1\">",
"        Nerve",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\" rowspan=\"1\">",
"        Plexus cervicalis: C1-C4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\" rowspan=\"1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        Cervical nerves",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Flexion, extension, rotation and lateral bending of the back",
"       </td>",
"       <td>",
"        Colli profundi (+ sternocleidomastoideus + trapezius)",
"       </td>",
"       <td>",
"        C1-C4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Lifting of upper thorax; inspiration",
"       </td>",
"       <td>",
"        Scaleni",
"       </td>",
"       <td>",
"        C3-C5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\" rowspan=\"1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        Phrenic nerve",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Inspiration",
"       </td>",
"       <td>",
"        Diaphragm",
"       </td>",
"       <td>",
"        C3-C5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\" rowspan=\"1\">",
"        Plexus brachialis: C5-T1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\" rowspan=\"1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        Anterior thoracic nerve",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Adduction and internal rotation of arm and dorsoventral lowering of shoulder",
"       </td>",
"       <td>",
"        Pectoralis major and minor",
"       </td>",
"       <td>",
"        C5-T1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\" rowspan=\"1\">",
"        &nbsp;&nbsp;",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        Long thoracic nerve",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Fixation of scapula during lifting of arm (anterior movement of shoulder)",
"       </td>",
"       <td>",
"        Serratus anterior",
"       </td>",
"       <td>",
"        C5-C7",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\" rowspan=\"1\">",
"        &nbsp;&nbsp;",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        Dorsal scapular nerve",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Elevation and adduction of scapula toward spinal column",
"       </td>",
"       <td>",
"        <p>",
"         Levator scapulae",
"        </p>",
"        <p>",
"         Rhomboidei",
"        </p>",
"       </td>",
"       <td>",
"        C4-C5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\" rowspan=\"1\">",
"        &nbsp;&nbsp;",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        Suprascapular nerve",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Lifting and outward rotation of arm",
"       </td>",
"       <td>",
"        Supraspinatus",
"       </td>",
"       <td>",
"        C4-C6",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Outward rotation of arm in shoulder joint",
"       </td>",
"       <td>",
"        Infraspinatus",
"       </td>",
"       <td>",
"        C4-C6",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\" rowspan=\"1\">",
"        &nbsp;&nbsp;",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        Dorsal thoracic nerve",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Inward rotation of shoulder joint; adduction from ventral to dorsal; lowering of elevated arm",
"       </td>",
"       <td>",
"        <p>",
"         Latissimus dorsi",
"        </p>",
"        <p>",
"         Teres major",
"        </p>",
"        <p>",
"         Subscapularis",
"        </p>",
"       </td>",
"       <td>",
"        C5-C8 (from dorsal portion of plexus)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\" rowspan=\"1\">",
"        &nbsp;&nbsp;",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        Axillary nerve",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Lateral lifting (abduction) of arm up to the horizontal line",
"       </td>",
"       <td>",
"        Deltoideus",
"       </td>",
"       <td>",
"        C5-C6",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Outward rotation of arm",
"       </td>",
"       <td>",
"        Teres minor",
"       </td>",
"       <td>",
"        C4-C5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\" rowspan=\"1\">",
"        &nbsp;&nbsp;",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        Musculocutaneous nerve",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Flexion of upper and lower arm and supination of lower arm",
"       </td>",
"       <td>",
"        Biceps brachii",
"       </td>",
"       <td>",
"        C5-C6",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Elevation and adduction of arm",
"       </td>",
"       <td>",
"        Coracobrachialis",
"       </td>",
"       <td>",
"        C5-C7",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Flexion of lower arm",
"       </td>",
"       <td>",
"        Brachialis",
"       </td>",
"       <td>",
"        C5-C6",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\" rowspan=\"1\">",
"        &nbsp;&nbsp;",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        Median nerve",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Flexion and radial deviation of hand",
"       </td>",
"       <td>",
"        Flexor carpi radialis",
"       </td>",
"       <td>",
"        C6-C7",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Pronation of lower arm",
"       </td>",
"       <td>",
"        Pronator teres",
"       </td>",
"       <td>",
"        C6-C7",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Flexion of hand",
"       </td>",
"       <td>",
"        Palmaris longus",
"       </td>",
"       <td>",
"        C7-T1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Flexion of fingers II-V in middle phalanges",
"       </td>",
"       <td>",
"        Flexor digitorum superficialis",
"       </td>",
"       <td>",
"        C7-T1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Flexion of end phalanx of the thumb",
"       </td>",
"       <td>",
"        Flexor pollicis longus",
"       </td>",
"       <td>",
"        C6-C8",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Flexion of end phalanges of index and middle finger",
"       </td>",
"       <td>",
"        Flexor digitorum profundus (radial portion)",
"       </td>",
"       <td>",
"        C7-T1",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Duus, P. Topical Diagnosis in Neurology, 2nd ed. Thieme Medical Publishers,&nbsp;New York, 1989.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_26_37293=[""].join("\n");
var outline_f36_26_37293=null;
var title_f36_26_37294="Age adjusted death rates for CHD";
var content_f36_26_37294=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F83599&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F83599&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 590px\">",
"   <div class=\"ttl\">",
"    Age adjusted death rates for coronary heart disease by race/ethnicity and sex, US, 1999 to 2008",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 570px; height: 419px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Non-Hispanic.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: NHLBI Fact Book, 2011. National Heart Lung and Blood Institute. Available at: file://www.nhlbi.nih.gov/about/factbook/toc.htm.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_26_37294=[""].join("\n");
var outline_f36_26_37294=null;
var title_f36_26_37295="Higher BNP predicts death in non ST ACS";
var content_f36_26_37295=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F62159%7ECARD%2F72910&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F62159%7ECARD%2F72910&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 567px\">",
"   <div class=\"ttl\">",
"    Levels of brain natriuretic peptide predict mortality in patients with an acute coronary syndrome",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 547px; height: 322px; background-image: url(data:image/gif;base64,R0lGODlhIwJCAcQAAP////+ZMyBzOQAz/4CAgAAAAH9MGf8AABA5HIiIiBEREQAZf1VVVTMzM8zMzHd3d6qqqu7u7n8AAERERCIiIpmZmd3d3WZmZru7u8DAwEBAQD8mDAgcDj8AAAAMPwAAACH5BAAAAAAALAAAAAAjAkIBAAX/ICCOZGmeaKqubOu+cCzPdG3feK7vfO//wKBwSCwaj8ikcslsOp/QqHRKrVqv2Kx2y+16v+CweEwum8/otHrNbrvf8Lh8Tq/b7/i8fs/v+/+AgYKDhIWGh4iJiouMjY6PkJGSk5SVlpeYmZqbnJ2en6ChoqOkpaanqKmqq6ytrq+wsbKztLW2t7gwCQUJNA4FDCwNFBYyCQoRMRENCsW5z6G/BdMNDgAMBcgADQUO0tMT1iO7vTO/wSoPBRAzFOgquw8k59D1nr8NALvB2MDb3fgAYCiQbxwvX/5UKCgYA8I6FvFKYHNmr+KlgOSuFaBQoAI3bwQBRMhGImMFjv64/1UAMAFgywITLNCroGCaAhIDy41cuLHYrmwF5IlgQEGEwwbcJvzsFZFEhYMWo1L6RnAlNggKKHAEme/pO328Al7o6DAmTAAUkD29cG4nxRFPV4ok+TTcRrBCIygoV5ZlRwt3m474JVSq4UcB0RawgM3BT4DTpjFIZjDB42nyOI6FQJUgvbGSnXYUsRMAvn14Rexy5pDfutKCRRA+TLtRwAgcGXf7B5lhCXKJDd5F22xwQpE1KeYkTXLfwHxNKUwY0VojBNhBSzwtV7v7IaoUrO6WxhWFSZQH9UJ18BLYuW97SyxkrqDmhGTqCGYfyM6ov6vYRXaTRm95Z6BU6rBT2v8JLa10QVE10HPghIYNY8GCI3CDmQgKFCbDMsVRKOKIJJZo4okopqjiilrgNqAIHm3IIhYWtNRAgTMakt+L1eWYhYbD+ZhIfSO0xJECcgk5RU2RUaakIURyWEAEFkQJQAYEZKklARlogeWWYGbZ5TNAQvgklC/m9o84X26pAQFaENCBBHTWaWcHcD5TI0E4nhmIleokUKWZJ2QZpwQHJKroohLk6eejY+Q3TTn9hKOCoVkQgOiinDYK6ad4YIqFppx26igJI0X20AhXufBTMk+BI05JTPYH6q05iHoFqaUq6qkJqTpJQqssOFRTMhesVFcJgeLqrA66WsFrrwf8WkL/qjKqFlk+knInQpXHTCmahwDUx1E1z6Y7Q7RVTNurtSioNOxDEbVkK24XlCuuaTa9FdCy6gbsArtUuFsqvCc0y+pDrapT2GXTOPkLoYAVhaHAGKNA8BQGm3oCBOh8NO9K9a4qn7gTsDNQUa1yg4FXGcdc6KnSbkotwt+iFF4JDtTErU3eknAsAKDBZE2rewIjrMwybyxFx4zSfGKbYVZttZhMjyp1wXPa6TWeLBKwgQFkl2322WiXvcHWWUPhdBRUWz2migQYEMDdeOet9954G8B22068DbgQdfNt+OF+D17w34oHUfjhkOedeONRCP5E3FXPneLjkUc+OeVPWB64/wcLlG766R4wLiLnnSOuOuhFiN4EAQsMYPvtuC/w+oSst87357AzIbvwteNuvO5h2+2768EHvvvsxRt/O/Ip2ChSe0FLOo2t+i59wkngOOPiCf1ApUjvy0v+fPM/DL8E7dLn/vcDPpt23z8YnPCLNiMMrULFAIDZjshXDJctAn3puxvw2IcE9ykBfvGzHfVMQJOn+GYb/JOI+TSyoW6VQDPqSJKVTsAN7h0CgQlcIAON4MAkQDCCE8RJR4LTj3yZwCGEklIySsa9x1iKQy8ygZEYgcL0qXCFRGhhA6MXvxguTFW+wUaSMjSakyWjYdmRzVl2YaYRDuZIs0pEEZd3RP8kEm5972Oi9JzIs5AkwIYN6h5YLigln2THXiN4Dr+6+KKrSANdRFReAvVWRjMCQYlHeGETGRcQB6CnHMfCjclK0kGg/YZJMQGA9nrhR1UdBxFj9F0hDekDRLJQjcdDY3dC2bpRkpIHpowd6U5Hy9Qlb5B7c+UroaXKJGAuTJpDESs7p8td4iCWxiTBMD3Xy2TCAJnOBMAyIVfMaK6rmdYcwTSZl80eQFMIvwRTME+0TcNVs5sv+KbjOICAdrrznRzApmHK+Tt5onNmcUKAAPbJz34iwJ5RoWcuAXpPZRKUcPrsp0L/eUtcqq+gvMynQhfKtse8YyBfkY3OpihHFoz/TwRFmwxvmuQUlGRyEAIl5EEhqs5DJnSi+2QoBf0xll5oKKP6kEeVgtjRdNikSNaoKSV9A0CYoVSQDg3AOSF6qZW6FKb8lGkbO8SAEEnoBFWKYmTk4UETeJFok9zKBwtwgRASIqUPZeoNWtq+l8JUqhqUDGWuerIq9k9cPPRqEH/iG3Xg1IdhBARa++bUe7K1lG6dKFwr4xcb0tUEarrrFR/iML2aYBc21EuIjDMdLp4VqQ5dqlrxmanEUvQEmAWLY49zrAv0QpJvSU5q8CifAbHHjjbERmGuoseJfTaphB2tDQ7rTdP6k21FsyGQdnOsWG2Eoz/hqiVJsMkItEek/wPJYKvCBZM+9WGwCiwsOokLS+NGVby5AK9S0ZtN8u6AAOx8p3zj2VDgila4BvXS1bQ0ThOp9774FYF7kfhf9lpzwCsscICvueAUKLjBzzSwDsK5pf6W6MFM/ahpMOldAUs4V2NLG9nWVt+kAniFA1RNL/ri4A8fE7QqLXFoXcy0r1qwqXGCcVrppuMU0lhmXsSK+TD3phxT828YJQ325gLFS2aDo8RagYZFMBDKNtl+1LhsreyAYaaOEDRfIfKPazDGMt5UNvcz4MI81BeRLcyECfvpCCyQFit7SC8N8J4mN1iHLkPUSv0gF2lH1ePwpuCxGJRYkETQrIxoK8tdrf8tCRrAACxSwxpczBYQzxXYOPgZnZvkYGQ6rc0x06DMf6NrDSfNZ9Q4eij0uuMkgVikfEQ5gHdpWQHyp8WunKXPhSajqQ2J4Bcf+dCfhLVcjsKgaXBkiq3CoqCj1BmTlWYsK1EYAAB4MTl8WnEYcEa4EzlsGaAa2eh4owjiqBhb+c80FLigFGc763Lx1DrXYAfM2tyNiLjMqHT49uAaIJQH0NFx5Y7BuUmoKm88Ulu+GRqTLrC0noVkR9lTlbcsrbRH7ywiSRMpsIFraNBhgBnxZsbBD5nwZwb7xPMMtihbPiKHqApJ5I5TiEVM4hUJvG0RcG0E9HxG/e6XSzLGJcz/hVts9v0c6Al4gNSDVnQIm+DpWWtPSFhIc8BhXWYjaQAExs7r2HW9bV+XGcHfd/aspT1mD5L6A6iOcKtfXeatbDuFlrvy9um9aXgn5t8PhIEEjH3sObe7MgPPzOb9BAINsKHZFb94kq+3efGmAAQMnnjKS5Pxx4bdSCAPgQv0vZSDz9jbM0YB09NP8klMPcZWjzHnbjb2nhcw6LkZPAzMvcN+z/3nLb90XD1gOg5oAEer7nnaCyw+1zi9N2UvMOera/SMlj4sqR8w66sLKRWgCeyH0PTmeT9dtgf+9IV//nQ54PcN5L662u+sC4yf6+zfvTnlfxgGaD/4uUd/uHIM/3JHdyyXf8THfxVyZZMXgPpXT82DAYcHAWWHew6YgOxjAddxHZ1HeQJ4K48XeR2oeB8IKpm3ef8XURdIcsUHKqMndqY3gnZXgp/SegSnAPdXdytoXwooFekng1ZHg5/ie4ISfwjIgj3og/AHhBAmhI9SNApAage4gyaWhBUxEgwAATQxHfhHhTPWPGKXfUzYYE7oJxcwAVI3AWhogOvnhUpnhRWxXFlmgc33gAMVgRNIdg1YhxgofBoDh59Sht1UfsEjiMHDHs4GZ/nlhoPUgma0FYBxb4vIh0i4QiCjiDCADUpBVjjGiD62QlX2Q+YQGTsjAmJ2hDwoCXtyI4NAEf8RsHlsyAJpAQBC5gyn6IlGBIhUUCaD0ABKoQP1UQyRNWgeaIcxFglMEjGCABoKwAAVOAOQRw2Y6GGoWIWSwIutyF3Kt4fF2IeQsIrqhwcY8CDOtnXkp4uPYohKwg2tZw2OwY0kaIw7BjoJsHzwOIPyGFy9J27h+F7o6CfqKCRrp0kpmCv/eCYBOSMnlxVIMR9dSImpCDo2JyD2OIUQaY2iJ3REp4NvIHUUkpCCQGFHB0xY8AAWEHUFOIZmAAETUFYMEIsWAZKBIDYiVpNp03NV8IIMSIdtYHMwGZP5WHKiIJM0cB0SeHjPyHxswJIu+ZP2QJR/AJVhQIhL4JG8E5T/lzcKUhkDcteVTqmCF/mFWomVjugD2LKT51iNYjmUZMl/eaiHD9mNlTiW3ngF3GWOPBmPdQkKWykDWkEQzaiSAdaXe0CYLzASuxB0OMWRchmRbLmXVPCCD+B/golfhpkHl+kClJYfOWiRjYmRjzmXW2AZRoiLwkYKmdkC4yYQ/QiWn7mWoZCawlBwBXlMB/kksjlyolkFC5lyDnmPQdiWqCmcVzCRNlGRACgGIjmSFVYRuRlwxHkFQZcAQ+dCtylN8SVf2rmd8HSdevCccwCeKGB/bEcGBGBeUAVVi5Ve0Rmb7WkFlPlA13me6Vmfp/WU7/kJ4olaHTJ1lTkq6Gmf/8flnPnpCftpAnz3n7sSoAIaU96JmQXaCQdaAkcJl8DZBfTZoPW5nrgwoW7goSVAgdZpngzaoAjwJsx5dBbGCSDKBi26YdSwkahHohq6oTtnkziKk+4JmQYaoVKgFQ9wAYEZl2CQoTX6Vj66CS+qBi2KfQSpoNJSogKKAEmqCUuaBi/qDlpIaVDaLlJqn1TKoxJapZnwoo8RhV1aMF+6oWSKCVfqBMuZohrQpk5AhK3pmkW6pukZprtpCHHKnHMqpoIAX9xZqNvJAXSqBJvXlXOXphyjp+qZqIWZnYZaqYgqqDMJqUiKqU6gPXN4oVxgpEe6UJL6nZqqWKWKmadKqv+c2gR8lZJE+gWiOqpRlaqhsqr+ZKt3MKu0KgB86phWADIb8ZX+SKO9mqut6ge8Squ/CponhKu1mqxNEAGvUppisKyj2qywaQjYeqTa+obnA60xpatEYAFC2oxJmZZj0K01+q2N+KBJJK6+Sq59Jq/u+olXkB9IgRSdmZxTaa/0GnAAK618wK4aeq+5WJKehJfqeq0D26eFYLAmGrDh+bDAmpNDl7E6UGXTKE3zabHOyq0gu60RO7Lgegd0VhMdS5XFdazICrFnZbLvGq4uG60wGweUdmtX97E1O64EW5gyi6+gFLQJawcTYGsmc4sO27Pz+rOmyrQIe5piRLRSSwf/1dYfSvuvUEux3ka1M0ezPRu1X5sHOlsCLFteW+u0qpq2NzuoXpt3elC2k6i1Ycu1nva2gge2NSu2cMutPFu3anurbHuxJTu4ITuof7u3dgsHEjuli/sGjQumj7sGZ/teeNt4U2u4JBuzmnuyEZu4Lsu3eZu5gNu2mdq5M+u3xqq4gburlxt6Q4u6QntWoHusoou5sVu6hMu5unu4M5lwfzqSGvC6vPesslu0ucu6pvtdCUcAs0RL0Bu9qEO8+6e3oTu5bRC5bNq64dm8qBRB4DsAC0C9EEi6yru7KEW+d6i6LvS94dtE6nuMyXu93Fuvx1u1tPtA7vu+xxO/8yiy//c7tvNru9iLpd7Lv/w7vgHctwPcq7cLu8bbu5srWAeMwOGrwBLsuW0QvEc3vAs8ug3MrAWMBpWrSBa8Rv6rjx/6vNLbwtP7wbgbwefruxSsvycMvhg8wxNMwvt7wjlMv8tbBhy8Xx6cwan7uTZ8w/ALwxDsoj1swT9MwPUbJyzswi7sASkslPnbvkq8xEY8u07cxSjMxMUbxmKcO1mclUjMxWc8PWlcltLyxAgcxQ48wm4jxwn8xvDqmafUxm5MxtULuXj8vnQswlOcKYN8wXp8QhXsx4WcrXYcOomMw4ssyH4sQZW8xkt0yeKbydk7yTDkyWbsyKKMuElMyoBcvv8fCsperMMaPMpt/MjeGsllUMKsPMZfjLyfzMmy3K60DD28XMq/e8qxLMxYesv9m8rru8rBrMzyu8WbfMm9fLC/TDzNnMv4C8tnPM0Te8iQ28jF7Mz/S7nIjMbirMK7LM3GHJXgvM3rfAYmLMbc7LjevCvl/MfYLMDQnEj3jMnnrMXaLM/vbAbx3MXzLLn1nL3tLND/rMbpjMr5zMAPHc4RDcL73Mfq3NBw3C793Mkavcca09EHvb1BXJgLbdADvQRDfDUaINIpbZ4u/dGMTMzuLNPt0jVek9M6fScxXdExHNAobdOazM/X7MpHzDE2Qy1KzSg9bdRgTM5FDcToy87/NM3QPt3ElZPUS73UEtDUUk3DPBzVUlzS33nSSjzSe1rNCqfVW30zXj3WUw3Pb13HCe2iZn3DaB2pdQ0tbN3WBzPXhkzW1wrYkLzXTHrXPvzSLtTXfs3UYk3Xgj2VhD3Lhm3AVR3UV13GWd3YXD3ZvlzZN7DSVtPSjx3Ycc28l33Wit1AjM3Z1eLZ1Azaw4XTO13bPF3ahR3Zu4rYULzaidTanN3VuE3Zuh07wN3Ywp3RmR3IQ43REO3Uuvw0x+3Xyf3cX73DszPdbV3dFA3d2WzKbGzdcA3W2e3abj3cn13cSaTdW83dNb3cqnzRsQPb3aze5MfenY3esW3fhIPf/0rt3lbt3fqMUrw9x77NQv593sot4BIt3eb9LvRNz/ztbQWex0KN1A/+1/pd36f9PgkO4Rsu4R1u0qmN1wdu3BneKRGO0BN+SB+u4Qt+3a8M3tEs3pA94oud4o4d4+ON3cLz4ioe4iyO45hZ4YR84uut476y4iRN5L+t5IkC4JjN4BY9B9YVPp3oAqJdNaTN4zdO3j8O5a8t5E0O5h4u5lKu2hc+B510eu4jJ7Yd53XSAUye1rJNZkC+4zZu2mb+QHm+5GRu5y0OBhK3L8TIAlBj3mlu4mu+2VC+6Ind6G7z51Fe53o96F6wIP5DZCgqp7Qt5zvdAVVsxdLrAZRaqf+FygE3iqM1uQGdnqKwHuthogGfDuo5LeqkTuqmjuqoruqszuquLuvCPuy0buu2jeu5fsWnzuva6eu/bpPBPpIrSujisunDfu3Ynu3avu3c3u3e/u3gHu7iPu7kXu7m3pxowFsM64fsngNX3l3tHu/yPu/0Xu/2fu/4nu/6vu/83u/+/u8AH/CAI7dCI4kocOUGXwkE3z8JDywt0fCV0CNatJi08RPuuD1DcBUSL2nUkWyMJQNDs/FUYPH8Um89oPEeT2sdT/GvBgMhn/Jf0CrBsQKxQQIbj2juThKo8BOuYfI8sPAq3wIJMgPvlgU8z0EdmwNAb28vMPQgb+hnIPP/624eWXRDn4TzFQ8UT6GyrsYL7655WBYx5RMTO9ESQWcT60APY18MI0QP3NAPlrFVjwH2b5/27dEeDzATTBIMZZ8NUigEu1ATW78OXU+dLwH2iCj2kUH22WD2zJj2/7H4bB9Ebg8Mk/IYc0eK7FD3nHH3W6X3odH3aHoFUv8zE1ATwZB8o6Yq6hEaR5EUETATKJFRa//6BLFDaC8PRKIOp+8Pc5/0kBAP5wIg9TE+AJIWLtJp2ECdGhf5nPFJy8/0xhEMLpNd+GYQ0wEkEJAWszI07+FGQYEdFA/4QTH8r1H8s3j8yMD9JrD8Z4kanfQV0d/2KbFr1n9ru5D9kbH9/6MPAoBSRIBTMGcDJMUTFQqLArV947m+8z3AFCCmwupRSIgKjkahYms9cJQCBkIzJk4pIuDS1AET1glgcjxRZlGFDJt0PAtkH71uv+Pz+hy0VQEKAQGtkQAwtaw8TRW4wMgAuAFqsSy6iDzWTDI5OP4EAUCYMa5sDiXWjJRoQYESdVox7MnGPfgBeg4mlRxyKTI2xtREBk0mVK5hDsVudt6G/pIqmd6kKrNaNbzSzHLT3apAHhkqVUBHsIb/QsCqrf4yRvnCs2O1xLKyhSNtPo92/wMMCBCdJyEnGFkoGIGCgoUK4AyRAaWTmjLEUJyQaCmfDU1Kmn0agQFcKQAMIf8mSagF3MRg7ATaIfjtV0JADh1CzKiGIiszEFYGw5fMI6dgt0SSlGbyoY0RKjFyaSnjJcyALZCUu6BvHEomFVpobUEGEDszWaCeuqETCr0jGKJubCNuE9JeVe/ixSvz07hYACKIamBQFAkgRIBhMqOAyU8ahpkgU0uDmdFPLQ5Hy0n4HLxJFUYU0KrNb94de4X0rQF41OBfER4jtqGY8STYkTtO/lhZyGUmmTNtvvzAM2jRLreV5uaFkV83dH+JZkKCyeIgVqArA1ChEhIbttsiMXI4snMlve0mT68+IBMM69/Dj2+jvfz69u/jv2PGSf7+/ne8ldZ/AxJoQ4AFIpj/oIJ2SGfJgg9CGKGEE1JYoYUXYpihhhty2KGHH4IIE1UhcugGiSd2cxWKK/rHjjPI4WCBKBMkAMM74vhXzYVuVGMiHgTZsBwFLzTI3H+3sHiDinuAw1WST+rxImk4lBLKfEr9p6OGPeL4o4M2uCEjRD76hySUS+rRJJRrxqGVGRgE6A5rRPhWQlOhdXclSjeIR8N2RsoYQypGTDDCBUAw5cCMFmBTp2FfFrjfJWpc9egDhI4Qy2oFUCAEj0q8Y6cnE7zAZ5c3fMaIDIoyMkFCl43wQKNyXIbEa4x06ohiDlyGHoi9IqHinyhE4JQIaYBGQ7IQAAFHn+HJkSmbG6Jh/0EMCXhxViwvkmEWqu/M4aSNRGCD2wpe/CHOoOoWYEFWS0WQ1RgWIaElgmClisEUGKjIZb1K2MRQBJ/yCqkJlTSQ0FbjMOKIwvBmhYYa8+5nbRqAWNyJPQWhyMoUFlwFDrpYlJOnSVQ02WxPQRA8rYaHKHDBBB/X9gl4OTjwwL41lHTDpkf0Cs8IcKz7bwSwHATNzfYWWCwFMj/N6QxGb/XcLiyzW3A8OAzs7cI4LAfVOw1szJZjQXSSbMPHbcsXiY8yAsFVQbuARqEl9HlRIs3eYsSlc2HpsoUtxJwqGTU7cbNqE/DHhMI952AFBWpaJETRurDD0MNLt/ugYhVcMP9CsOwmVJ4DATfk9xtg4cBAd+gKcyrXTmluIFyyng0BSPz9xbYnvIfIehxnCSjKPXIUJLEnWlduuuAYWttE9EhM4sAIgl1x6gOBoeYkDr0Kph13SxBxeSrssMrczcItWE677sOhonCmbxq+BVMU+pF0oiZgmAJ5kikTv/ifCQgTC/FAxkVoC8atVDUaE1yvY+8oGFa40wppRIA6jPFEEJqVDgI673kiVM9b0jDCEEnqhCpc4QivQ4Q9sfBCDdpaDGtowxviMIc63CEPe+jDHwLRh2gKIn6GSMQjIrE/RrxDkyCXRDos0Q5NDNwTq2hFHUSxDpS7Yh2ySIctcjGMSQT/1tTEx5xidU4ByPpFLJblwWeFI39TEuIvRlfBMxpLjUkwkhulAUdMwUiMghyhx9oVMi6M7Aglu8G+UmYeS/ikZT8sJMjOgMgmkOxUjeyFyiCJtX/BcJCiZBPcgjC3Gw2HU3dLR9wcebpP+C2EPiyl3ICGSrs1hJV6qwHfYOkCWY4ymGcKjZIsWTwjiSV5UlveyiAATB4KrwaHPCYNkimJZXYyCpEEXCiF6c0TBY2CZmQEEq4DhwzGYIOGYZYfVQWtfVARmhMUlgXN+RcNfmKdb3Rn1eL5zX8CNKACHShBC2rQgyI0oQpdKEMb6tCHQjSiEp0oRStq0YtiNKMa3ShHRTvq0Y+CNKQiHSlJS2rSk6I0pSpdKUtb6tKXwjSmMp0pTWtq05viNKc63SlPe+rTnwI1qEIdKlGLatSjIjWpSl0qUykaAgA7);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    In a study of 2525 patients, the level of brain natriuretic peptide (BNP) predicts 10-month mortality in subgroups with an ST segment elevation and non-ST segment elevation myocardial infarction and unstable angina. P values are for the trend within each subgroup.",
"    <div class=\"footnotes\">",
"     * p = 0.02.",
"     <br>",
"      &bull; p &lt;0.001.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Data from de Lemos JA, Morrow DA, Bentley JH, et al. N Engl J Med 2001; 345:1014.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 563px\">",
"   <div class=\"ttl\">",
"    Levels of brain natriuretic peptide predict cardiac events in patients with an acute coronary syndrome",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 543px; height: 315px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    In a study of 2525 patients with a non-Q wave myocardial infarction or unstable angina, the incidence of death, new or progressive heart failure (HF), and new or recurrent myocardial infarction (MI) at 30 days and 10 months is higher in those with brain natriuretic peptide levels &gt;80 pg/mL (p &lt;0.005) compared to levels &le;80 pg/mL for each comparison.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from de Lemos JA, Morrow DA, Bently JH, et al. N Engl J Med 2001; 345:1014.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_26_37295=[""].join("\n");
var outline_f36_26_37295=null;
